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The purpose of this research was to measure the serum 25-hydroxyvitamin D
[25(OH)D] response to daily supplementation with 800 IU vitamin D3 during winter in
premenopausal women living in Maine, and to examine the effects of body composition
and hormonal contraceptive use on baseline serum 25(OH)D levels and the response to
supplementation.
One hundred twelve women (22.2±3.7 years old) received placebo from March
2005 until September 2005 when they were randomized to receive either placebo or 800
IU vitamin D3 through February 2006. Eighty-six women completed the study. Body
composition was measured by dual-energy x-ray absorptiometry. Actual vitamin D3
content of the supplements averaged 885 IU per capsule.
In February 2005 the mean±SD serum 25(OH)D was 62.0±23.4 nmol/L in all
subjects. Twenty-nine percent of subjects had optimal serum 25(OH)D levels (≥75
nmol/L). Serum 25(OH)D levels were significantly higher (p < 0.0005) in the 58

hormonal contraceptive users (68.6±24.0 nmol/L) than in the 28 non-users (48.3±14.8
nmol/L). The 25(OH)D concentration increased with estrogen dose. Subjects in the
highest tertile body fat (>33%) had significantly lower serum 25(OH)D levels (47.8±17.3
nmol/L) than subjects in the middle and lowest tertiles (69.4±23.8 and 69.0±22.2
nmol/L). Estrogen dose, percent body fat, and alcohol consumption were significant
predictors of February 2005 serum 25(OH)D levels.
Serum 25(OH)D levels increased by 35.3±23.2 nmol/L from February 2005 to
February 2006 in the treatment group, compared to 10.9±16.9 nmol/L in the placebo
group. Treatment group, magnitude of summer increase in 25(OH)D, estrogen dose, and
baseline serum 25(OH)D levels, but not body fat, were significant predictors of the oneyear change in 25(OH)D levels.
Daily supplementation with 800 IU vitamin D3 during winter achieved optimal
25(OH)D levels (≥75 nmol/L) in 80% of subjects, indicating that this dose is too low to
optimize vitamin D status in the population as a whole. Body fat does not appear to
influence the serum 25(OH)D response to supplementation with vitamin D3, except
through its influence on the baseline serum 25(OH)D level. Further research is needed to
determine whether there is a health benefit to the higher serum 25(OH)D levels in oral
contraceptive users.
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Chapter 1
INTRODUCTION
Serum 25-hydroxyvitamin D [25(OH)D] levels are used to measure the adequacy
of vitamin D status. The consensus among researchers is that 25(OH)D concentrations of
at least 75 nmol/L are optimal.1,2 Serum 25(OH)D levels reflect both dietary intake of
vitamin D and cutaneous synthesis of vitamin D after exposure to solar ultraviolet-B
radiation.3 An individual’s serum 25(OH)D concentration is usually less than optimal
after winter in Maine (44o53’N)4 due to insufficient sunlight from November through
February.5 Vitamin D insufficiency is widespread at northern latitudes such as Maine,
even in populations with dietary vitamin D intake equal to, or greater than, the current
Dietary Reference Intake of 200 IU daily for 19 to 50 year olds.4,6-8
Insufficient vitamin D levels are of concern because vitamin D insufficiency is
associated with suboptimal calcium absorption9,10 and increased parathyroid hormone
levels,11-15 which lead to increased bone resorption, accelerated corticol bone loss, and
increased risk of fracture.1 Currently, an estimated 10 million Americans have
osteoporosis, 8 million of whom are women.16 In addition to the effect on bone,
inadequate vitamin D may play a role in the development of type 1 diabetes,17 multiple
sclerosis,18 hypertension,19 and in the outcome of certain cancers.20 Since vitamin D
insufficiency is widespread, even in populations that meet the Dietary Reference Intake,
further research is needed to determine the intake required to achieve optimal serum
25(OH)D concentrations, and, once this is determined, strategies must be developed to
raise the population to optimal levels.

1

Research is needed to determine how much vitamin D3 intake is needed to
optimize serum 25(OH)D levels for different age groups. The purpose of this research
project was to evaluate the serum 25(OH)D response to supplementation with 800 IU
vitamin D3 during winter. The primary objective was to achieve optimal serum 25hydroxyvitamin D levels in premenopausal women living in Maine. The secondary
objective was to examine the effects of body mass index (BMI), body composition, and
oral contraceptive use on baseline serum 25-hydroxyvitamin D levels and the response to
oral vitamin D supplementation.

2

Chapter 2
LITERATURE REVIEW
Metabolism of Vitamin D
Vitamin D can be synthesized in the skin upon exposure to ultraviolet-B radiation
and is, therefore, not technically a vitamin, but rather a steroid hormone. There are two
forms of vitamin D: vitamin D2, ergocalciferol, which is found in plants, and vitamin D3,
cholecalciferol, which is synthesized in the skin of animals and humans upon exposure to
sunlight. Vitamin D written without a subscript may refer to either vitamin D2 or vitamin
D3.21
Skin synthesis is the primary source of vitamin D3 and provides 90 to 100% of the
vitamin D requirement for most people.3 In the skin of humans, 7-dehydrocholesterol
(provitamin D3), which is produced in relatively large quantities, absorbs ultraviolet-B
radiation (290-315 nm wavelengths) upon exposure to sunlight. Absorption of the
radiation causes transformation of 7-dehydrocholesterol to previtamin D3. Previtamin D3
is thermodynamically unstable and is isomerized to form the more stable vitamin D3 in
one to three days. Vitamin D3 diffuses from the skin into the extracellular space and is
picked up by vitamin D-binding protein (DBP) in the dermal capillary bed. DBP carries
vitamin D3 primarily to the liver. However, some (approximately 12%) vitamin D is
deposited in adipose tissue for storage along the way.22-24
Vitamin D-binding protein is the primary transport protein for 25(OH)D,
1,25(OH)2D, and vitamin D3. Less than 5% of the binding sites on DBP are occupied by
vitamin D sterols.25,26 DBP is produced in the liver and has a high affinity for 25(OH)D;
88% of 25(OH)D is bound to DBP; 12% is bound to albumin, and less than 1% is in the
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free (unbound) form.25 Other vitamin D metabolites are bound to DBP with less affinity.
The regulation of DBP is unclear. Lower levels are found in nephrotic syndrome (due to
urinary losses) and severe liver disease (due to poor production),25 but this does not seem
to affect the binding capacity of DBP because binding sites are largely unoccupied under
normal conditions.27 Estrogen increases hepatic production of DBP, resulting in higher
concentrations during pregnancy and oral contraceptive use.25 The concentration of DBP
is not affected by vitamin D deficiency or excess.27
When individuals are exposed to higher doses of ultraviolet radiation, the serum
25(OH)D response does not increase proportionately resulting in vitamin D
intoxication.28 Instead, previtamin D3 and vitamin D3 absorb sunlight and are converted
to other photoproducts, including lumisterol, tachysterol, suprasterols, and toxisterols,
which are sloughed off with the skin rather than continuing on the pathway to 25(OH)D
production.3,29 Therefore, the skin cannot generate excessive quantities of vitamin D3 to
cause vitamin D intoxication upon exposure to sunlight.29
Vitamin D is slowly released from adipose tissue during times of vitamin D
deprivation.3,22,29,30 The mechanism for the release of vitamin D from adipose tissue is
unknown.
About 50% of the vitamin D consumed from the diet is incorporated into micelles
and absorbed by passive diffusion into intestinal cells.23 Within the intestinal cell,
vitamin D is incorporated into chylomicrons and excreted into the lymphatic system for
transport to the blood. In the blood, some vitamin D is transferred from the chylomicrons
to DBP for delivery to extrahepatic tissues for storage.31 After chylomicrons enter the
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blood, they undergo conversion to chylomicron remnants that contain the vitamin D and
are taken up by the liver via hepatic receptors.23
Vitamin D3 synthesized in the skin after exposure to ultraviolet-B (UVB)
radiation is transported mainly via DBP, whereas vitamin D ingested from the diet is
transported primarily by chylomicrons in the bloodstream.23,25,32 Upon reaching the liver,
delivered either by chylomicron remnants or DBP, vitamin D is hydroxylated by a 25hydroxylase enzyme, forming 25(OH)D, the major circulating form of vitamin D.
Although 25-hydroxylase is less efficient when vitamin D is in abundance, 25hydroxylase is poorly regulated. Therefore, the serum 25(OH)D concentration reflects
overall vitamin D status.23 A membrane receptor on the hepatocyte quickly picks up
chylomicron remnants, resulting in a quicker increase in serum 25(OH)D concentration
after oral vitamin D consumption compared to cutaneous production.31,32 In contrast,
vitamin D from the skin diffuses into the blood more slowly and enters the liver more
gradually, allowing for prolonged production of 25(OH)D.32 Serum 25(OH)D levels
have been found to be sustained for a longer period following cutaneous vitamin D
synthesis than after oral consumption of vitamin D.32,33
From the liver, 25(OH)D is released back into the bloodstream where it is
transported bound to DBP to the kidney and other tissues. In the kidney and other
tissues, 25(OH)D is further hydroxylated by a 1-α-hydroxylase enzyme, producing the
active form of vitamin D, 1,25-dihydroxyvitamin D [1,25(OH)2D], which interacts with
nuclear vitamin D receptors (VDR) in the cells to influence gene transcription.23
The primary function of 1,25(OH)2D is to maintain serum calcium levels within a
normal range so as to support cellular activities and neuromuscular function.29 A
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decrease in serum calcium concentration stimulates the parathyroid gland to secrete
parathyroid hormone (PTH), which goes to the kidney to stimulate production of
1,25(OH)2D from 25(OH)D. DBP carries 1,25(OH)2D to the intestines where it acts via
the vitamin D receptor in the intestines to increase active calcium absorption. If there is
inadequate dietary calcium to maintain serum calcium concentrations, 1,25(OH)2D and
PTH work together to stimulate reabsorption of calcium from the renal tubules and
mobilize calcium from the skeleton to maintain normal serum calcium levels.29,34 The
steroid hormone, 1,25(OH)2D, is only made in the kidneys as needed, and production is
tightly regulated by PTH and calcium.20
High concentrations of 1,25(OH)2D inhibit 1-α-hydroxylase activity, and increase
24-hydroxylase enzyme activity, which acts to degrade 1,25(OH)2D to calcitroic acid for
excretion.35 The 24-hydroxylase enzyme produces 24,25-dihydroxyvitamin D and
1,24,25-trihydroxyvitamin D, intermediates in the degradation of 1,25(OH)2D to
calcitroic acid.36 Calcitroic acid is excreted via bile in feces.37 Twenty-fivehydroxyvitamin D is also broken down via this pathway.36 High serum 1,25(OH)2D
levels decrease the half-life of 25(OH)D,38 most likely by increasing metabolic clearance
as noted by increased fecal, urinary, and biliary excretion of catabolic products.39-41 An
increase in 1,25(OH)2D due to inadequate serum calcium and vitamin D can accelerate
the depletion of 25(OH)D stores.42
Serum concentrations of 1,25(OH)2D are only about 1/100 of serum
concentrations of 25(OH)D and the half-life of 1,25(OH)2D is only four to six hours,
compared to three to four weeks for 25(OH)D.42
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Recently, vitamin D receptors and 1-α-hydroxylase were found in many tissues
outside the kidney; these tissues produce 1,25(OH)2D, which acts locally to regulate cell
growth. This 1,25(OH)2D does not enter circulation and is therefore not measured as part
of the serum concentration. Extrarenal production of 1,25(OH)2D is dependent on an
adequate supply of 25(OH)D reaching the tissues.20
In summary, vitamin D, whether consumed orally or synthesized cutaneously
upon exposure to UVB radiation, is transported to the liver where it is hydroxylated to
25(OH)D. Then, 25(OH)D is carried by DBP from the liver to the kidney and extrarenal
tissues where it is further hydroxylated to the biologically active 1,25(OH)2D.
Functions of Vitamin D
The primary function of vitamin D is to maintain serum calcium levels within a
normal range so as to support cellular activities and neuromuscular function.29 Vitamin
D is necessary for calcium absorption, for bone mineralization, and in the prevention of
rickets, osteomalacia, and osteoporosis. In addition to the calcemic roles, vitamin D also
appears to have important non-calcemic, non-skeletal-related functions including:
reducing the risk of developing autoimmune diseases such as type 1 diabetes, rheumatoid
arthritis, and multiple sclerosis; improving immune function; and improving the outcome
of certain cancers.
The functions of vitamin D are carried out through the actions of the active form,
1,25(OH)2D, which interacts with nuclear vitamin D receptors (VDRs). VDRs act
through vitamin D-responsive elements (VDREs) to either initiate or suppress gene
transcription.34,43

7

Calcemic Functions
Calcium Absorption
Vitamin D is necessary for active transport of calcium across the intestinal cell
mucosa. When serum calcium levels start to decrease, the parathyroid gland is stimulated
to secrete PTH, which then increases renal 1,25(OH)2D production. The 1,25(OH)2D
interacts with nuclear vitamin D receptors (VDRs) in the intestinal cells activating genes
for calcium binding protein (calbindin) and other proteins involved in calcium and
phosphorus transport across the cell membranes, through the cells, and into circulation to
maintain serum calcium levels.43
If there is inadequate dietary calcium to maintain serum calcium concentrations,
1,25(OH)2D and PTH work together to stimulate reabsorption of calcium from the renal
tubules and mobilize calcium from the skeleton to maintain normal serum calcium
levels.29,34
Without vitamin D the intestine only absorbs 10% to 15% of dietary calcium via
passive diffusion. Calcium absorption increases to 30% with adequate vitamin D and up
to 80% during growth, lactation, and pregnancy.44 Postmenopausal women with mean
serum 25(OH)D levels of 86.5 nmol/L absorbed 45% to 65% more calcium than did
women with mean serum 25(OH)D levels of 50.1 nmol/L.9 In another study, after
adjusting for age, calcium intake, and 1,25-dihydroxyvitamin D concentration, serum
25(OH)D level was the most significant determinant of calcium absorption in elderly
women.45
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Bone Mineralization and Fracture Risk
Vitamin D is essential for the prevention of rickets (poor mineralization resulting
in softening of the bones) in children and osteomalacia (defective bone mineralization)
and osteoporosis (porous, thinned bones) in adults. Rickets causes deformity and
increased risk of fracture in children. Osteomalacia results in pain, weakness, and
fragility of bones in adults. Rickets, osteomalacia, and osteoporosis increase fracture
risk.20
When there is inadequate 25(OH)D, calcium absorption decreases and serum
calcium drops, which stimulates secretion of PTH by the parathyroid gland, resulting in
secondary hyperparathyroidism. Parathyroid hormone alone, and in cooperation with
1,25(OH)2D, induces maturation of osteoclasts in the bone, which release hydrochloric
acid and enzymes to destroy the bone matrix, releasing calcium and other minerals into
the circulation.34,44 Over time, the withdrawal of mineral from the bone and destruction
of the matrix results in osteoporosis.29 Secondary hyperparathyroidism also increases
renal tubular absorption of calcium and loss of phosphorus in the urine resulting in an
inadequate calcium-phosphate product to promote mineralization of the bone, which
leads to osteomalacia and rickets.44
Accumulation of peak bone mass during childhood and adolescence and the rate
of bone loss during aging are two of the main factors contributing to osteoporosis.46,47
Although accumulation of bone mass is most rapid during late childhood and early
adolescence, bone mass can continue to accumulate until women are in their late
twenties47 and bone loss typically begins after age 30. Vitamin D intake is positively
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correlated with bone mineral density (BMD) in young adult women.47,48 Similarly, serum
25(OH)D levels and BMD are positively correlated in adolescent girls.46,49
In the elderly, men and women receiving 700 IU vitamin D3 and 500 mg calcium
daily over three years experienced a significant reduction in bone loss and a 54%
reduction in non-vertebral fractures.50 Researchers have found that supplementation with
vitamin D significantly reduces bone loss in elderly subjects50-52 and fracture risk.50-56
The decrease in fracture risk is likely due to both the improvements in bone density and
in muscle strength.57
Skeletalmuscular Comfort
In osteomalacia, it is believed that the osteoblasts deposit collagen matrix on the
endosteal and periosteal surfaces of the skeleton, but without adequate calcium phosphate
product, the matrix is rubbery and is not strong enough to support the weight of the
skeleton. Instead, the rubbery matrix expands under the periosteal covering, putting
pressure on the covering, which is innervated with sensory pain fibers, resulting in the
deep bone aching and pain associated with osteomalacia.58 Muscle pain and weakness
probably precede bone disease and can occur in patients without signs of osteomalacia.59
However, the mechanism for this muscle pain is not yet known.
Osteomalacia, which causes generalized aching in the bones, and muscle pain and
weakness, is common in vitamin D deficiency60,61 and can be misdiagnosed as
fibromyalgia.58,59,62 But, unlike in fibromyalgia, correction of the vitamin D deficiency
can provide nearly complete pain relief.59,63 In Minnesota, more than 90% of hospital
inpatients with nonspecific muscle aches and bone pain had severe vitamin D
deficiency.62 In Denmark, 88% of Arab women with muscle weakness and bone pain
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were severely vitamin D deficient.60 In the Arab women, treatment with vitamin D,
which increased serum 25(OH)D levels by over 400% (from 6.7 ± 0.6 to 34.4 ± 2.0
nmol/L) significantly reduced subjective complaints of muscle and bone discomfort, in
most cases within one and a half months. Vitamin D supplementation also significantly
improved objective measures of muscle power (maximal voluntary quadricep contraction,
single twitch stimulation, maximal production rate, and maximal relaxation rate) in the
same women.59 Middle-aged men and women experienced a 24.8 ± 8.0% improvement
in overall muscle power when mean serum 25(OH)D levels increased from 7.0 ± 0.7 to
48.3 ± 8.3 nmol/L.59
In the elderly, low serum 25(OH)D levels are associated with decreased muscle
strength and increased risk of falling.64-66 Improvement in the function of type-II muscle
fibers after supplementation with vitamin D may explain the reduced risk of falling seen
in some supplementation studies.64
Non-Skeletal Functions
In the United States and worldwide, people who live at higher latitudes, and
therefore have limited access to sunlight, have increased risk of prostate, colon, breast,
ovarian, and esophageal cancers and non-Hodgkins lymphoma,67-70 multiple sclerosis,71
type 1 diabetes,72 rheumatoid arthritis,73 and hypertension.74,75
Adequate amounts of the active form of vitamin D, 1,25(OH)2D, are necessary in
cancer prevention and other diseases. In the kidneys, low calcium levels promote the
production of 1,25-dihydroxyvitamin D; however, this is not the case in the extra-renal
tissues where adequate supply of the substrate, 25(OH)D, is necessary for 1,25(OH)2D
production.20
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Most of the studies relating vitamin D status to disease rates are based on
associations and are, therefore, not necessarily causal. Thus, the role of vitamin D in
cancer and autoimmune disease is still somewhat controversial.
Cancer
The active form of vitamin D, 1,25(OH)2D, plays an important role in the
proliferation and differentiation of cells. Normal tissue and some cancer cells (including
prostate, colon, breast, and lung cancer cells) have 1-α-hydroxylase and are able to
convert 25(OH)D into 1,25(OH)2D, which interacts with the vitamin D receptor (VDR) in
these cells, decreasing their differentiation and promoting their maturation, to regulate
cell growth and possibly prevent malignancy.20,29
Studies show that serum 25(OH)D levels of at least 50 nmol/L decrease the risk of
developing and dying of colon, prostate, and breast cancer by 30% to 50%.30,67,68,70 In a
review of 18 observational studies looking at 25(OH)D levels or oral vitamin D intake
and colon cancer, Gorham et al76 found that colorectal cancer risk can be decreased by
50% with serum 25(OH)D levels above 80 nmol/L compared with 29 nmol/L or with oral
intake of at least 1000 IU vitamin D3 daily compared with 100 IU daily.
In a study designed to look at fracture risk, women in rural Nebraska receiving
1400 to 1500 mg calcium and 1100 IU vitamin D3 daily for four years had a 0.402
relative risk (RR) for all cancers compared to women receiving placebo.77 The RR
dropped to 0.232 when only cancers diagnosed after the first year were included (cancers
diagnosed during the first year might have been present, but undiagnosed, at the start of
the study). Subjects receiving 1400 to 1500 mg calcium, but no vitamin D, daily for four
years had a RR of 0.532 for all cancers compared to placebo. Their RR did not change
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when only cancers diagnosed after the first year were included. Over the four-year
period, out of 1180 women, there were 50 non-skin cancer diagnoses occurring in the
breast (19), colon (3), lung (7), lymph/leukemia/myeloma (10), uterus (3), and other (8).
Baseline serum 25(OH)D levels and treatment were significant predictors of cancer risk
using linear regression analysis. The RR for the calcium-only group suggests a protective
effect of calcium, or, the researchers suggest, it could be a chance occurrence since, with
the exception of colon cancer, no other studies have ever shown an association between
calcium and cancer. High calcium intake may reduce 1,25(OH)2D concentration, which
would result in slower consumption and degradation of 25(OH)D.42 This would act like a
higher dose of vitamin D and could explain the protective effect of calcium.
Autoimmune Diseases
Development of type 1 diabetes, multiple sclerosis, and rheumatoid arthritis has
been prevented in mice prone to these diseases after treatment with 1,25(OH)2D at an
early age.73,78-82 The likely mechanism of action is that 1,25(OH)2D interacts with Thelper lymphocytes, which suppresses the inflammatory responses of T-helper type 1
lymphocytes.34
The risk of developing type 1 diabetes was reduced by 80% in non-obese diabetic
mice, prone to type 1 diabetes, who received 1,25(OH)2D throughout their lives.78,81
In humans, children in Finland who received the recommended dose of 2000 IU
vitamin D daily during their first year of life in 1966 were 80% less likely to develop type
1 diabetes over the next 30 years.17 Additionally, children who had been diagnosed with
rickets during childhood were three times more likely to develop type 1 diabetes.17
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Experimental autoimmune encephalomyelitis (EAE) is the animal model for
multiple sclerosis (MS). Administration of adequate 1,25(OH)2D to animals can
eliminate or suppress EAE at any stage of development.79 However, this therapy caused
hypercalcemia in the animals.
Munger and colleagues,18 analyzing serum samples of white military personnel,
found an inverse relationship between serum 25(OH)D levels before age 20 and risk of
developing multiple sclerosis. For the Hispanics and African Americans no significant
relationship was seen, probably due to the smaller sample size and, in blacks, lower
serum 25(OH)D levels. Among whites, the odds ratio of developing MS was 0.38 in the
highest quintile of serum 25(OH)D (>99.1 nmol/L) compared to the lowest quintile of
25(OH)D (<63.3 nmol/L). Having serum 25(OH)D concentrations above 100 nmol/L
reduced the risk of multiple sclerosis by 51% compared with serum concentrations less
than 75 nmol/L.18
In mice, supplementation with 1,25(OH)2D decreased symptoms and arrested the
progression of arthritis in animals inflicted with an animal version of rheumatoid arthritis
(RA). Supplementation with 1,25(OH)2D prevented the development of arthritis in
mice.73
Immunity
Researchers believe that 1,25(OH)2D stimulates the innate immune response.
Vitamin D prevents macrophages from releasing too many cytokines and chemokines83
and enhances macrophage ability to function.84,85 The active form of vitamin D,
1,25(OH)2D, activates the gene for production of the antimicrobial peptide (AMP),
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cathelicidin.86-88 Antimicrobial peptides act like antibiotics to destroy invading
microorganisms, and accelerate wound healing.87
In human studies, there is evidence that adequate vitamin D status benefits
immunity. When serum from African Americans with low 25(OH)D levels was
inoculated with Mycobacterium tuberculosis, macrophages produced 63% less
cathelicidin than did macrophages in serum from white Americans with higher 25(OH)D
levels.88 Addition of 25(OH)2D to the African American serum increased cathelicidin
production to that seen in the white serum.
When Wayse and colleagues89 compared 80 children with lower respiratory
infections to healthy controls, 80% of the ill children had serum 25(OH)D levels less than
25 nmol/L, compared to only 31% of the controls. Some researchers suggest adequate
vitamin D levels may protect against influenza.90 In a psychiatric hospital in California,
none of the men receiving high doses of vitamin D for treatment of deficiency became ill
during an influenza outbreak that affected over 100 men at the facility.91 In 756 young
Finnish men serving in the military, Laaksi and colleagues92 found that men who had
serum 25(OH)D levels less than 40 nmol/L in July missed significantly more days of
military duty due to respiratory infection over the following six months. The men with
vitamin D deficiency missed a median of four days compared to two days missed by the
control group.92
Hypertension
Adequate vitamin D may help prevent hypertension by preventing
overstimulation of the renin angiotensin system (RAS). The proposed mechanism for the
effect of vitamin D on hypertension, as demonstrated in mice, is that 1,25(OH)2D down-
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regulates renin gene transcription through a mechanism involving the VDR.93 VDR
knock-out mice had increased renin expression and increased angiotensin II production
resulting in hypertension, which was corrected with an angiotensin converting enzyme
(ACE) inhibitor.93 Further research is needed to examine the molecular mechanism for
vitamin D regulation of renin expression.
Hypertensive patients exposed to UVB radiation for three months experienced a
162% mean increase in serum 25(OH)D levels and a 6 mmHg mean drop in diastolic and
systolic blood pressure; there was no change in a group exposed to UVA radiation.19
This change in blood pressure upon exposure to UVB is similar to that obtained from
medications.19 Data from the Health Professionals’ Follow Up Study and the Nurses’
Health Study revealed the pooled relative risk of incident hypertension was 3.18 for men
and women with serum 25(OH)D levels less than 37.5 nmol/L compared with those with
levels greater than 75 nmol/L.75
Inflammation
Likely through its role in enhancing the immune system, decreasing cytokine
production83 and enhancing macrophage function,84,85 vitamin D also plays a role in
decreasing inflammation.94 Studies have reported an inverse relationship between Creactive protein and serum 25(OH)D levels.94,95 Van den Berghe and colleagues94 saw a
decrease in C-reactive protein and interleukin-6 (IL-6) concentrations in critically ill
patients receiving 500 IU vitamin D3 in parenteral nutrition daily. Timms and
colleagues95 gave 47 vitamin D deficient adults (25(OH)D levels less than 27 nmol/L)
either 500 or 50,000 IU vitamin D3 intramuscularly every three months for one year.
Serum 25(OH)D levels increased to 37.5 nmol/L in the high dose group, and 32.9 nmol/L
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in the low dose group. The researchers reported difficulty in accurately measuring 500
IU vitamin D3 to be given intramuscularly and speculated that subjects received
injections containing more than 500 IU which might explain the lack of a difference in
final serum 25(OH)D levels between the two dosage groups. Overall, C-reactive protein
levels decreased by 23% in the subjects receiving vitamin D3; there was no placebo
group.95
In men and women over 50 years old participating in NHANES III, serum
25(OH)D concentrations were inversely associated with periodontal attachment loss.96
Periodontal attachment loss is the loss of periodontal ligament and alveolar bone, which
is characteristic of periodontal disease.96 Men in the lowest quintile lost 0.39 mm more
attachment than those in the highest quintile of serum 25(OH)D concentration; women in
the lowest quintile of serum 25(OH)D lost 0.26 mm more periodontal attachment. BMD
and attachment loss were not significantly associated. The researchers credit the antiinflammatory effects of vitamin D for the inverse association with periodontal disease.96
Possibly, vitamin D inhibits the release of proinflammatory cytokines in response to
bacteria in the dental plaque. Without sufficient vitamin D, the cytokines stimulate bone
resorption in the affected teeth.96 The same researchers looked at the association between
gingivitis and serum 25(OH)D levels in NHANES III participants.97 Gingivitis is a better
tool for examining the effect of vitamin D on inflammation because, unlike periodontal
disease, its development is completely unrelated to bone. The highest quintile of serum
25(OH)D (median 99.6 nmol/L) had 20% lower odds of bleeding than the lowest quintile
(median 32.4 nmol/L). There was a significant inverse association between serum
25(OH)D levels and bleeding of the gums on probing (a measure of gingivitis). This
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association did not reach a threshold at a point where gingival inflammation leveled off,
suggesting that serum 25(OH)D concentrations higher than 90-100 nmol/L may be
needed to reduce inflammation.
Summary
Vitamin D is essential for maintaining skeletal strength throughout the lifecycle98
and may also play important roles in the prevention and treatment of several cancers,
hypertension, and autoimmune diseases.20,30
The actions of vitamin D are carried out by the active hormonal form,
1,25(OH)2D, interacting with a vitamin D receptor in the cell nucleus to enhance or
suppress gene transcription. Adequate serum 25(OH)D is critical to provide adequate
substrate for hydroxylation to 1,25(OH)2D. Because 1,25(OH)2D produced outside the
kidneys does not enter into circulation, measurement of the active form of vitamin D does
not reflect adequacy of vitamin D status. Instead, assessment of serum 25(OH)D
concentration is the appropriate indicator of vitamin D status.
Optimal Levels of Serum 25(OH)D
Serum 25-hydroxyvitamin D concentration is the best measure of vitamin D status
because it reflects both cutaneous synthesis of vitamin D and absorption of vitamin D
from the diet. The enzyme that converts vitamin D into 25(OH)D, 25-hydroxylase, is
poorly regulated. Therefore, 25(OH)D concentration reflects overall vitamin D status. In
the past, optimal levels of 25(OH)D were the levels that prevented osteomalacia and
rickets.2
Most laboratories use 37.5 to 50 nmol/L (15 to 20 ng/mL) as the lower limit of
normal for 25(OH)D. To obtain the normal range, a diverse population of asymptomatic
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subjects was sampled. However, this “normal” population could include individuals with
inadequate sun exposure and suboptimal serum 25(OH)D levels.9 Hollis and colleagues99
suggest the “normal” population should be redefined as sun-replete individuals such as
lifeguards, surfers, and farmers from locations where vitamin D is synthesized yearround. In 93 surfers and skateboarders in Honolulu, Hawaii (21oN) with self-reported
sun exposure of three or more hours on five or more days per week for the previous three
months, serum 25(OH)D levels ranged from 28 to 178 nmol/L.99 Similarly, the median
serum 25(OH)D levels of 30 sun-replete healthy men who spent long hours outdoors
during the summer in Nebraska (landscaping, construction, farming, or recreation) was
122 nmol/L (interquartile range: 100 to 154 nmol/L) in late summer.10
The optimal level of 25(OH)D is the concentration associated with the maximum
suppression of PTH, maximum calcium absorption, maximum bone mineral density and
reduced rate of bone loss, reduced rate of falling and improved muscle strength, and
reduced risk of fractures.1 During a round table discussion at the 5th International
Symposium on the Nutritional Aspects of Osteoporosis, held in Lausanne, Switzerland in
May 2003, five of the six leading vitamin D researchers agreed that, based on the
evidence available, the optimal concentration of serum 25(OH)D is at least 70 to 80
nmol/L.1 Further research is needed to determine the optimal concentration of serum
25(OH)D required for the non-calcemic functions of vitamin D; however, preliminary
evidence suggests levels of at least 75 nmol/L are desirable.2,100
Maximum Suppression of PTH
Many studies have found an inverse relationship between serum 25(OH)D levels
and PTH levels.8,11-15,101 Researchers have found that serum PTH levels increase when
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serum 25(OH)D levels drop below 37 nmol/L,11,15 50 nmol/L,12 78 nmol/L,13 95
nmol/L,101 and 110 nmol/L.14 Possible explanations for the wide range of estimated
threshold levels include variations in ethnicity, age, and calcium intake of the subjects,
renal insufficiency, and the use of unstandardized assays for serum 25(OH)D levels.102,103
Maximum Calcium Absorption
In a study of postmenopausal women, calcium absorption increased with serum
25(OH)D levels up to 80 nmol/L, at which point fractional calcium absorption plateaued.
Women with mean serum 25(OH)D levels of 86.5 nmol/L absorbed 45% to 65% more
calcium than did women with mean serum 25(OH)D levels of 50.1 nmol/L.9 In healthy
men, calcium absorption did not change significantly when serum 25(OH)D levels
dropped from 122 nmol/L at the end of summer to 74 nmol/L at the end of winter.10
These studies suggest that the threshold for maximum calcium absorption is at serum
25(OH)D levels of at least 75 nmol/L.
Reduced Rate of Falling / Improved Muscle Strength
Low serum 25(OH)D levels are associated with decreased muscle strength and
increased risk of falling in the elderly. Increasing serum 25(OH)D levels from 30 to 65
nmol/L significantly increased muscle strength (measured by the “timed up&go” test,
knee flexor strength, knee extensor strength, and grip strength) and reduced the number
of falls in older men and women.64 In another study, elderly men and women with serum
25(OH)D levels between 50 and 74 nmol/L were twice as likely to experience loss of grip
strength (an indicator of muscle strength that is positively correlated with both lower- and
upper-extremity strength) compared to subjects with serum 25(OH)D levels above 75
nmol/L.65
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Reduced Risk of Fractures
A meta-analysis of vitamin D supplementation and fracture risk revealed that
fractures were prevented at serum 25(OH)D levels of at least 74 nmol/L, and optimal
fracture prevention was achieved when serum 25(OH)D levels reached at least 100
nmol/L.57 In one study, overall fracture risk was decreased by 22% in communitydwelling men and women with a mean serum 25(OH)D level of 74.3 nmol/L, compared
to those with a mean of 53.4 nmol/L.55 Other vitamin D supplementation studies that
failed to achieve serum 25(OH)D levels greater than 75 nmol/L did not find a significant
reduction in fracture risk.104-106
Maximum Bone Mineral Density and Reduced Rate of Bone Loss
In an analysis of NHANES III data, Bischoff-Ferrari and colleagues107 found a
positive correlation between serum 25(OH)D levels and BMD, which continued as serum
25(OH)D levels increased above 100 nmol/L.
In another study, when serum 25(OH)D levels were maintained above 90 nmol/L
in 100 postmenopausal women, wintertime bone loss was decreased compared to the
control group, resulting in a slight gain in BMD of the spine over one year.108 Similarly,
postmenopausal women with a mean serum 25(OH)D level of 100 nmol/L experienced
significantly less femoral bone loss over one year than subjects with a mean serum
25(OH)D level of 66.3 nmol/L.109 These studies suggest that levels even greater than 75
nmol/L may be optimal to prevent bone loss in postmenopausal women.
Conclusion
The above evidence suggests that optimal serum 25(OH)D levels are at least 75
nmol/L, and possibly higher. Based on the recent editorial by Dawson-Hughes and
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colleagues,1 which reports an informal consensus among prominent vitamin D
researchers to establish 75 nmol/L as the lower end of the optimal serum 25(OH)D range,
this level was selected as the cut-off for determining optimal concentrations of serum
25(OH)D in this research study. Increasing serum 25(OH)D levels in the US to at least
75 nmol/L would result in an expected 4% to 5% increase in BMD; a 4% to 6% increase
in lower extremity function in older adults; and a 25% reduction in hip or non-vertebral
fractures.103
Factors Influencing Serum 25(OH)D Levels
Dietary Vitamin D Intake
Recommended Dietary Intake Levels of Vitamin D
The recommended Adequate Intake set by the Food and Nutrition Board of the
Institute of Medicine for Vitamin D, in the absence of sunlight, is 200 IU for children and
adults up to 50 years old; 400 IU for adults 51 through 70 years old; and 600 IU for
adults over 70 years old.21 However, the data used to set this intake recommendation in
1997 are now obsolete and most researchers agree that at least 800 to 1000 IU daily is
needed for optimal vitamin D status in the absence of sunlight.1
Sources of Vitamin D
Most people rely on food to meet their vitamin D requirement during times of
inadequate sunlight. Few foods, primarily oily fish such as salmon, mackerel, and
sardines; cod liver oil; and organ meats, are natural sources of vitamin D. Oily fish is not
consumed daily by most individuals in the United States; therefore, the US population
must rely on fortified foods for vitamin D.110 In fact, 65 to 87% of dietary vitamin D
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intake comes from fortified foods in the US.111 A list of foods that contain vitamin D can
be found in Appendix A.
In the early 1930’s the United States began fortifying milk with 100 IU vitamin
D2 or D3 per eight ounce cup in an effort to prevent rickets in children.112 However, the
actual amount of vitamin D in milk has been found to vary considerably.112,113 In
addition to milk, some orange juice, some cereals and breads, some yogurts, and some
margarines are fortified with vitamin D in the US (see Appendix A). Despite fortified
food, women 19 to 50 years old only consumed an average of 168 IU vitamin D daily
from fortified and naturally occurring food sources111 leading some researchers to argue
for higher levels of fortification in a larger variety of foods.110,114 However, even with
more fortification, supplemental vitamin D may still be necessary for individuals with
inadequate sun exposure,114 including those living at high latitudes.
Sunlight, in the form of ultraviolet-B (UVB) radiation, is the primary source of
vitamin D, providing 90 to 100% of the requirement for most people who are exposed to
adequate sunlight.3 The amount of vitamin D3 produced by whole-body exposure to one
minimal erythemal dose (MED) of sunlight (the amount needed to cause a light pinkness
to the skin) is equivalent to the consumption of 10,000 to 25,000 IU oral vitamin D2.115
However, the exact amount of vitamin D produced in response to sunlight will vary by
age and skin type,116 and is highly variable between individuals, with some individuals
having low serum 25(OH)D levels despite abundant sun exposure.117
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Factors that Influence Cutaneous Synthesis of Vitamin D
Anything that reduces the number of UVB photons absorbed by the skin or
decreases the amount of 7-dehydrocholesterol in the skin will decrease or eliminate
vitamin D synthesis.
Latitude, Time of Day, and Season
The position of the sun in the sky varies daily and seasonally. When the sun is
low on the horizon, UV radiation must travel farther, is more easily scattered, and is more
absorbed by ozone than when the sun is directly overhead, resulting in fewer UVB
photons reaching the earth’s surface.5 Because of the tilt of the earth on its axis, UV
radiation must travel farther to reach areas closer to the north or south poles than to reach
areas nearer the equator. Therefore, the ability of the skin to synthesize vitamin D is
affected by latitude, season, and time of day.5
Above 35oN latitude, no previtamin D3 is produced in the skin for four to six
months during winter.20 In Boston (42oN) human skin samples synthesized the greatest
amount of previtamin D3 in June and July and did not synthesize any previtamin D3 on
cloudless days from November through February.5 In Edmonton, Canada (52oN), no
previtamin D3 was synthesized from October through March.5 In Orono, Maine (44oN),
no vitamin D3 synthesis occurred in human skin samples on a sunny day at the end of
February.118 Below 35o latitude (Los Angeles and Puerto Rico), however, previtamin D3
was formed year-round.5 Similar results were found in the southern hemisphere; in
Argentina previtamin D3 synthesis was negligible in Ushuaia (55oS), but adequate in
Buenos Aires (34oS) during winter.119 The period when there is insufficient UVB for
vitamin D synthesis is known as “Vitamin D Winter”.120
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In North America (30oN to 43oN), serum 25(OH)D levels are reported to be at
their lowest point at the end of the Vitamin D Winter in February, rapidly increase after
March, reach their peak in August, and then slowly decline after September.6,121,122
Time of day also affects the zenith angle of the UVB rays, and, therefore, affects
vitamin D synthesis. In Boston in July, vitamin D synthesis can occur as early as 0700
EST and continue as late as 1700 EST, with peak synthesis between 1000 and 1400.123 In
August in Orono, Maine, significant vitamin D3 synthesis only occurred between 1000
and 1600.118 During spring and autumn in Boston, vitamin D synthesis only occurs
between 1000 EST and 1500 EST.115
In summary, season, latitude, and time of day affect the amount of UVB radiation
reaching the earth’s surface and, therefore, affect cutaneous vitamin D synthesis.
Maximum vitamin D synthesis occurs at the equator at midday during summer. No
vitamin D is synthesized during winter at high latitudes at any time of day.
Pollution
Aerosols in the atmosphere deflect UVB photons, thus decreasing the amount of
UVB radiation reaching the earth’s surface.120 High ozone levels in the troposphere
absorb UVB photons and reduce cutaneous synthesis of vitamin D.115 Extremely high
atmospheric ozone levels can extend the duration of “Vitamin D Winter” by two months
and increase the latitude for “Vitamin D Winter” by approximately ten degrees.120
Individuals living in locations with high levels of pollutants in the air may have lower
serum 25(OH)D levels than in areas with low pollution rates.
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Cloud Cover
Ultraviolet-B radiation at the earth’s surface can be reduced by as much as 45%
on a cloudy day.124 Sullivan and colleagues118 compared in vitro previtamin D3
production on a cloudy summer day with a sunny summer day in Maine and found
previtamin D3 production was reduced by 50% when cloudy.
Sunscreen
Sunscreens, although beneficial in the prevention of skin cancer, prevent vitamin
D synthesis in the skin. Sunscreen with a sun protection factor (SPF) of eight or greater
reduces vitamin D production by more than 95% if applied and reapplied according to
package instructions.125 In fact, twenty white individuals who used sunscreen on sunexposed areas for more than one year had serum 25(OH)D levels 55% lower than
matched controls (40.2 versus 91.3 nmol/L) during summer.126 Two (10%) of the
sunscreen users had vitamin D deficiency (serum 25(OH)D levels less than 20
nmol/L).126
On the other hand, Wolpowitz and Gilchrest127 argue that most individuals do not
apply sufficient amounts of sunscreen, reapply it as directed, or cover all sun-exposed
body surfaces and, therefore, are not receiving enough sun protection to prevent vitamin
D synthesis. They also argue that, even if properly applied, sunscreens with SPF-15
permit 1/15 (6%) of UVB photons to penetrate the skin and, therefore, vitamin D
deficiency due to sunscreen use is highly unlikely.127
In Australia, Marks and colleagues128 gave 113 people either sunscreen with SPF17 or a placebo cream. All subjects were instructed to apply the cream daily, and to
reapply if they were likely to have sweated, washed, or rubbed it off during the day. All
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subjects were advised to avoid sun exposure at midday, and to wear hats and clothing for
sun protection since they could be in the placebo group and getting no other sun
protection. The researchers found no significant difference in serum 25(OH)D levels
between the sunscreen users and the control group. However, there were some
weaknesses in this study, which may explain why Marks and colleagues failed to find any
difference in serum 25(OH)D levels. Subjects were only instructed to apply cream to
their head, neck, forearms and dorsum of each hand, which left their legs, and upper arms
exposed to sunlight and could explain why sunscreen users synthesized vitamin D. All
subjects were encouraged to protect themselves from sun by avoiding midday sun and
wearing protective hats and clothing; therefore, subjects in the placebo group likely had
decreased vitamin D synthesis. Overall, serum 25(OH)D levels increased only 12.3
nmol/L, which was less than the seasonal differences of 20.1 nmol/L4 and 31 nmol/L129
seen in other studies between winter and summer.
Thus, sunscreen, if applied to all exposed skin, and reapplied frequently, can
prevent vitamin D synthesis. In reality, however, most individuals do not apply and
reapply sunscreen to all sun-exposed areas regularly enough to cause vitamin D
deficiency.
Clothing
Clothing absorbs UVB radiation, preventing vitamin D synthesis. When subjects
wearing black or white clothes made from cotton, polyester, or wool fabric were exposed
to six MEDs of ultraviolet radiation, they did not produce any vitamin D.130 Vitamin D
deficiency is common in sunny countries such as Saudi Arabia, Jordan, and the United
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Arab Emirates, where, due to cultural clothing customs, women rarely expose their skin
to sunlight.131-133
Aging
In general, compared to younger people, older people are more likely to stay
inside during the peak period for vitamin D production, wear more clothing, and use
more sunscreen than younger people, putting them at risk for lower serum 25(OH)D
levels.134 In addition, the amount of 7-dehydrocholesterol in the skin may decrease by
more than 50% by age 70,135 possibly due to decreased skin thickness and skin mass.136
Despite the decrease in 7-dehydrocholesterol, the elderly are still able to make vitamin
D3, it just takes longer to make the same amount as a younger person.137 Elderly stroke
patients in Japan who were exposed to 15 minutes of sunlight on their hands and faces
every pleasant weather day for one year increased their mean serum 25(OH)D levels
from 18 to 52 nmol/L. In contrast, in a similar group of patients who were not regularly
exposed to sunlight, mean serum 25(OH)D levels dropped from 17 to 13 nmol/L.137
Older individuals may have lower baseline serum 25(OH)D levels than younger people
due to decreased sun exposure and a decreased ability to synthesize vitamin D in the skin.
Melanin
The skin pigment melanin acts as natural sunscreen.115 People with dark skin do
not make vitamin D3 as efficiently as people with white skin.5,138,139 Dark-skinned
individuals with Fitzpatrick skin types V or VI (dark brown or black) require ten to fifty
times more sun exposure to produce the same amount of vitamin D3 as lighter skinned
individuals with skin types II or III (fair or slightly beige skin).138 In fact, in Boston in
June, a black skin sample (type V) had negligible conversion of 7-dehydrocholesterol to
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vitamin D3 after 20 to 30 minutes of UVB exposure, whereas a white skin sample (type
II) exhibited significant vitamin D3 production after just five to ten minutes.140
Analysis of data from NHANES III found that mean serum 25(OH)D levels in
non-Hispanic whites were 1.2 to 1.7 times higher than levels in Mexican Americans or
non-Hispanic blacks.121 In Boston, 20 to 40 year old white women had serum 25(OH)D
levels more than twice those of black women in summer and in winter.141
Tanning Beds
Tanning beds that provide an artificial source of UVB radiation promote vitamin
D3 synthesis. At the end of winter in Boston, the serum 25(OH)D levels of adults who
had used a tanning bed in the previous six months were 90% higher than adults who did
not use a tanning bed.142 The tanners, who had tanned an average of 6.2 years, had
significantly lower PTH levels and higher total hip BMD than non-tanners.
Skin pigmentation also affects vitamin D production from artificial UVB
radiation. After 12 weeks of artificial UVB radiation with 0.75 MED in each tanning
session, serum 25(OH)D levels increased 210% in subjects with skin type II (fair), 187%
in subjects with skin type III (medium), 125% in subjects with skin type IV (olive or light
brown), and 40% in subjects with skin type V (brown).140
Other Factors that Influence Serum 25(OH)D Levels
Obesity
There is an inverse relationship between serum 25(OH)D levels and body mass
index (BMI) or body fat14,129,139,143-149 As DBP transports vitamin D to the liver for
hydroxylation, some vitamin D is deposited in the adipose tissue for storage.22,23,24,146
Obese individuals with large amounts of adipose tissue pick up and store more vitamin D,
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resulting in lower serum 25(OH)D levels.146 It is believed that once the adipose tissue
has been saturated, the vitamin D remains in the serum and is delivered to the liver for
hydroxylation, but there are no long term data on vitamin D supplementation in obese
adults.34
Wortsman and colleagues146 found that obese individuals had a 57% lower serum
25(OH)D response to UV radiation compared to normal weight peers. However, the
amount of 7-dehydrocholesterol converted to vitamin D3 was not different between the
two groups. Therefore, the researchers concluded that obesity does not affect the ability
of the skin to make vitamin D3, but affects the release from skin into the circulation.146
Arunabh and colleagues129 found a significant difference in serum 25(OH)D
levels between women with the lowest and highest quartiles of total body fat (<31% body
fat and 56.6 nmol/L compared with >42% body fat and 44.2 nmol/L). There was a
significant inverse correlation between fat quartile and the likelihood of achieving serum
25(OH)D levels of at least 80 nmol/L. Because total body fat correlated with serum
25(OH)D levels more strongly than either BMI or weight, researchers concluded that
adiposity, rather than body mass, impacts serum 25(OH)D levels.129,148 Similarly,
Bolland and colleagues150 found lower serum 25(OH)D levels at the end of summer in
post-menopausal women and older men in the highest quartile of fat mass compared to
those in the lowest quartile; however, they did not find a significant difference in serum
25(OH)D levels at the end of winter.
NHANES III data demonstrated that white women with a healthy BMI (18.5 to
25) had higher 25(OH)D levels than white obese women (BMI ≥30).139 No relationship
was seen in African American women possibly due to the higher proportion of lean body
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mass or to the lower serum 25(OH)D levels in African Americans.139 Eighty-nine
percent of morbidly obese adults undergoing gastric bypass surgery in Bangor, Maine
had serum 25(OH)D levels less than 80 nmol/L before surgery.151
Vitamin D stored in adipose tissue is slowly released during times of vitamin D
deprivation.3,22,29,30 However, in the obese, vitamin D is presumed to be sequestered deep
in the body fat, so it is less bioavailable than in normal weight individuals.43
Bell and colleagues143 suggested an alternative hypothesis to explain the lower
serum 25(OH)D levels associated with obesity. They suggested that the elevated
1,25(OH)2D levels seen in obese individuals exert negative feedback on 25(OH)D
production in the liver.143 However, the findings of Wortsman and colleagues146
contradict this theory as they found no difference in 25(OH)D production in obese
subjects receiving oral vitamin D.
In research, BMI or, preferably, body fat, should be accounted for when
evaluating vitamin D status. Clinically, obese individuals should be assessed for vitamin
D deficiency.
Estrogen
Oral contraceptives are prescribed most often for preventing pregnancy, but are
sometimes used to control acne, or moderate menses. Oral contraceptive pills must be
taken daily and may contain either progestin only, or a combination of estrogen (ethinyl
estradiol) and progestin. Depending on the prescription, the active pills may provide 15,
20, 25, 30, or more than 35 μg estrogen per day. The active pills may be monophasic,
biphasic, or triphasic and are taken for the first 21 days of the menstrual cycle followed
by 7 days of inactive pills (placebo) or no pill. Monophasic oral contraceptives provide
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the same amount of estrogen and progestin every day for the first 21 days. Biphasic pills
provide the same amount of estrogen for the first 21 days, but the progestin dose is lower
in the second half of the cycle. Triphasic pills have the same or varying doses of
estrogen, and varying doses of progestin throughout the cycle. In addition to the oral
contraceptive pill, hormonal contraception is available as a skin patch, vaginal ring,
injection, or implant. The vaginal ring and skin patch provide a steady low dose of
estrogen equivalent to less than 15 μg per day.
Serum 25(OH)D levels are 15 to 25 nmol/L higher in oral contraceptive users
than in non-users.139,152,153 In rural Iowa during summer, mean serum 25(OH)D levels
were 25% (15 nmol/L) higher in 20-34 year old white women on oral contraceptives
compared to those not on oral contraceptives.152 In Boston during winter, Harris and
Dawson-Hughes153 found that oral contraceptive users had serum 25(OH)D levels 41%
(24.1 nmol/L) higher than non-users. Analysis of NHANES III data collected in summer
and winter found mean serum 25(OH)D levels 24.3% (24.8 nmol/L) higher in white oral
contraceptive users compared to non-users.139
The mechanism for the increased serum 25(OH)D levels in oral contraceptive
users is uncertain. In male rats, estrogen administration increases mitochondrial 25hydroxylase activity in the liver, which increases serum 25(OH)D levels.154 In rabbits
and cattle, vitamin D-binding protein stimulates 25-hydroxylase activity .155 Since
estrogen stimulates hepatic production of DBP in humans, DBP levels are increased in
oral contraceptive users.25 However, in humans, there is no evidence that the increase in
serum 25(OH)D levels in oral contraceptive users is due to increased 25-hydroxylation in
the liver.
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Oral contraceptives are believed to increase serum 25(OH)D levels due to the
increase in DBP causing increased circulating concentrations of serum vitamin D
sterols.25 Estrogen delivered transcutaneously or via skin patch does not increase serum
DBP concentrations.156 Approximately one month following pregnancy, or after oral
contraceptives are discontinued, DBP concentrations return to normal.25
Although the DBP and total 25(OH)D concentrations are increased, the
percentage of sterol in the free form is decreased, and the concentration of free 25(OH)D
remains unchanged.25,157 Likewise, studies have shown an increase in DBP and total
1,25(OH)2D concentrations after three months of oral estrogen use, but there was no
increase in the concentration of free 1,25(OH)2D.156,158
According to the free hormone hypothesis, the biologic activity of a hormone is
affected by its free (unbound) concentration, not by its bound concentration.159
Therefore, since total serum 25(OH)D levels are increased in oral contraceptive users due
to increased DBP concentration, but the concentration of free 25(OH)D remains similar
to those not using oral contraceptives, one could presume there should not be a
physiologic advantage to oral contraceptive use in terms of serum 25(OH)D status.
However, evidence of the effect of elevated serum 25(OH)D in oral contraceptive users
on health is lacking.
The change in endogenous estrogen levels during the menstrual cycle is not
associated with any detectable change in 25(OH)D levels.160,161 The phases of change in
estrogen levels may be too short to detect changes in 25(OH)D levels.161 Hormone
replacement therapy with one to two mg estradiol daily in postmenopausal women
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increased plasma levels of vitamin D-binding protein,162 but did not affect serum
25(OH)D levels.162,163
Gender
Serum 25(OH)D concentrations were generally 20% higher in elderly men than in
elderly women living in Boston in summer and fall, but not from February to May.14 The
difference in serum 25(OH)D levels may have been due to a difference in sun exposure
as the men reported spending more time outdoors.14 Dietary intake of vitamin D was
similar between the men and women.14 Elderly women have decreased estrogen levels,
which may also lower their serum 25(OH)D levels.14
NHANES III data showed the rate of vitamin D insufficiency was two times
higher in females than males of the same age.121 Another study of older women and men
in the Netherlands found that women had lower 25(OH)D levels than men, but this
difference disappeared after adjustment for body fat.149
The differences in serum 25(OH)D concentration seen between men and women
may be explained by differences in sun exposure and body fat. Therefore, it is not clear
whether there is a gender difference in serum 25(OH)D levels.
Calcium Intake
In healthy men fed their normal diets (estimated to contain 800 mg calcium) plus
2000 mg calcium for six to seven weeks during winter, serum 25(OH)D levels increased
significantly more than in a control group.164 Serum 1,25(OH)2D levels decreased
significantly in the group receiving calcium. The authors hypothesized the increase in
serum 25(OH)D and decrease in serum 1,25(OH)2D could be due to one of the following:
a) increased calcium intake decreases PTH secretion, which decreases 1,25(OH)2D and
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causes an increase in 25(OH)D due to a released negative feedback inhibition of 25hydroxylase enzyme; or b) increased calcium intake stimulates 25-hydroxylation of
vitamin D; or c) increased calcium intake, or the resulting decrease in 1,25(OH)2D, may
decrease the metabolism of 25(OH)D.164
The findings of Bell and colleagues,165 that 1,25(OH)2D may inhibit the formation
of 25(OH)D from vitamin D3 support the first hypothesis. In addition, in hypocalcemic,
vitamin D-deficient rats, Haddad and colleagues166 found that dietary calcium stimulated
hepatic microsomal 25-hydroxylase activity. In support of the second hypothesis,
researchers found decreased 25-hydroxylase activity166 and decreased 25(OH)D
production40 in calcium deficient rats.
There is also much research supporting the third hypothesis that increased
calcium, or the resulting decrease in 1,25(OH)2D, may decrease 25(OH)D catabolism.
High serum 1,25(OH)2D levels decrease the half-life of 25(OH)D,38 most likely by
increasing metabolic clearance.39-41 In rats fed a calcium free diet, the resulting
secondary hyperparathyroidism caused an increase in 1,25(OH)2D, which increased the
metabolic clearance rate of 25(OH)D.39,40 Bolt and colleagues40 found the clearance rate
of 25(OH)D was similar to the increased production rate of 1,25(OH)2D found in other
studies of rats deprived of calcium, leading the researchers to conclude that the increased
turnover of 25(OH)D was due to increased production of 1,25(OH)2D.
Therefore, the decreased 25(OH)D levels in calcium deficient rats are likely due
to both increased metabolic clearance of 25(OH)D for the production of 1,25(OH)2D, and
decreased production of 25(OH)D from vitamin D.40 Similarly, in humans, infusion with

35

1,25(OH)2D stimulated the excretion of 25(OH)D catabolic products, resulting in a
shorter half-life of 25(OH)D.42
Calcium intake may affect baseline serum 25(OH)D levels in individuals with
very low calcium intakes by stimulating serum 1,25(OH)2D production thereby lowering
serum 25(OH)D levels, and decreasing 25-hydroxylation of vitamin D.
Alcohol Consumption
Moderate alcohol consumption increases estrogen levels in postmenopausal
women,167 which may reduce bone loss168 and increase serum 25(OH)D levels. In elderly
women, some researchers have found a positive association between moderate alcohol
consumption and serum 25(OH)D levels,169,170 while others have found no association
with serum 25(OH)D levels.168 Lamberg-Allardt and colleagues171 found a positive
association between alcohol and serum 25(OH)D levels in healthy adult men and women
(30 to 42 years). Moderate alcohol consumption may influence serum 25(OH)D levels
and, therefore, should be considered when evaluating vitamin D status.
Smoking
Some studies have shown a negative association between smoking and serum
25(OH)D levels in healthy adult men and/or women,92,171-173 elderly women,147,170 and
adult patients with Crohn’s Disease.174 Other studies, however, have failed to find any
relationship between smoking and vitamin D status.129,149,169 Another study found a
relationship between smoking and 25(OH)D levels in adult women, but not in men.173
Some of the studies129,169,175 may have failed to find a relationship between smoking and
serum 25(OH)D levels due to a low percentage of participants who were smokers.

36

The mechanism for the relationship between smoking and serum 25(OH)D levels
is uncertain, but may be due to changes in sex hormones.172,175,176 Some researchers have
found that, in postmenopausal women receiving hormone replacement therapy, estrogen
levels are lower in smokers than in non-smokers177,178 presumably due to increased
hepatic clearance of estrogen.177 Lower estrogen levels could result in lower serum
25(OH)D levels. However, Ortego-Centeno and colleagues179 found higher levels of
serum estradiol and serum hormone binding globulin (SHBG) in premenopausal smokers
than in non-smokers. SHBG increases with estrogen and thyroid hormones.176 Other
researchers found that SHBG levels were significantly reduced after smoking cessation in
postmenopausal women176 and in men and women with a mean age of 32.2 years.175
Thus, serum 25(OH)D levels may be lower in smokers, but the mechanism for this
possible decrease is uncertain.
Assay Methods
Because serum 25(OH)D is highly hydrophobic and exists in two forms,
25(OH)D2 and 25(OH)D3, it is very difficult to assay.180 Furthermore, assay results vary
by 33% or more between labs.181,182 Therefore, it is difficult to compare results between
supplementation studies.
High performance liquid chromatography (HPLC), DiaSorin Radioimmunoassay
(RIA), Nichols Advantage Competitive Binding Protein Assay, and Immunodiagnostic
Systems (IDS) RIA are the assays that have been most commonly used for determining
25(OH)D levels in research over the past few years.180 Recently, however, it was
discovered that the very popular Nichols Advantage assay and the IDS RIA did not detect
25(OH)D2 well and are, therefore, no longer used.180 The DiaSorin RIA, when used by
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experienced personnel, was able to accurately measure both 25(OH)D2 and 25(OH)D3.180
Measuring 25(OH)D by HPLC is considered the gold standard. However, this slow and
expensive method is only accurate if it is performed by a highly experienced
individual.180 Until a method to standardize assays is developed, caution must be used
when comparing results from different research studies.183
Diseases and Medications
Diseases characterized by intestinal malabsorption, liver disease, and kidney
disease as well as some medications such as corticosteroids, anticonvulsants, some
weight loss medications, and medications for treatment of high cholesterol affect serum
25(OH)D levels. Higher rates of vitamin D insufficiency have been documented in
patients with malabsorptive diseases such as cystic fibrosis,184-186 celiac disease,187 and
inflammatory bowel disease (Crohn’s disease and ulcerative colitis)174 than in healthy
controls, often despite oral vitamin D supplementation. Vitamin D insufficiency is
common in liver disease due to fat malabsorption and also due to poor hydroxylation.188
Patients with nephrotic syndrome have low serum 25(OH)D levels due to a
combination of urinary excretion of vitamin D-binding protein, and long-term
glucocorticoid use.189 Weng and colleagues189 found 90% of children with nephrotic
syndrome had serum 25(OH)D levels less than 75 nmol/L.
Corticosteroids decrease calcium absorption,190 which increases PTH, stimulating
renal 1,25(OH)2D, and leading to a decrease in serum 25(OH)D levels.42 Orlistat, a
pancreas lipase inhibitor prescribed for weight loss, may cause malabsorption of vitamin
D and/or calcium.191
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The impact of the hypolipidemic drug cholestyramine on serum 25(OH)D levels
was mixed. Knodel and colleagues192 reported impairment of vitamin D absorption in
people taking large doses of cholestyramine (more than 32 grams daily). Two other
studies, however, showed no deleterious effects of cholestyramine therapy (24 gm daily)
on serum 25(OH)D levels.193,194
Serum 25(OH)D levels are lower in individuals taking anticonvulsant
medications, including, but not limited to, phenobarbitol, phenytoin, carbamazapine,
oxycarbazepine and valproate.195,196 Although research results are mixed, anticonvulsant
medications are believed to induce 24-hydroxylase enzymes which promotes the
degradation of 25(OH)D. 195,196
Factors that Influence Response to Supplementation
Baseline Serum 25(OH)D Levels
Studies have shown that subjects with lower serum 25(OH)D levels have a larger
increase in serum 25(OH)D levels due to supplementation (hereafter referred to as
response to supplementation) than individuals with higher serum 25(OH)D
levels.28,145,197-199 Barger-Lux and colleagues145 believe that this difference in response to
supplementation depending on baseline levels suggests that hepatic 25-hydroxylation is a
saturable process.
When Trang and colleagues197 gave adults 4000 IU vitamin D3 daily for 14 days,
the serum 25(OH)D levels of subjects in the lowest tertile of baseline serum levels (10 to
34 nmol/L) increased 30.6 ± 16.2 nmol/L, compared to a 13.3 ± 13.9 nmol/L increase in
the highest tertile (50 to 86 nmol/L).197 In another study of young and old men living in
the Boston area, there was a significant inverse correlation between baseline serum
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25(OH)D levels and response to supplementation with 800 IU vitamin D3 daily during
winter.198 Baseline serum 25(OH)D levels (but not BMI or vitamin D intake) were
predictive of response to supplementation in the young men, but not in the old men.198
In Ireland, DeLappe and colleagues199 supplemented elderly women with 800 IU
vitamin D3 and 1000 mg calcium for three months. The 36 women who had baseline
serum 25(OH)D levels less than 50 nmol/L increased mean serum 25(OH)D
concentrations significantly from 28.9 to 52.5 nmol/L; the 15 women who had baseline
levels greater than 50 nmol/L increased their serum levels from 73.9 nmol/L to 76.1
nmol/L, an insignificant change. In nursing home residents in Brazil, serum response to
7000 IU vitamin D3 per week was significantly influenced by baseline serum 25(OH)D
levels, but not body fat.200 Residents with baseline levels less than 50 nmol/L increased
serum levels by 25 nmol/L compared to a 13 nmol/L increase in residents with baseline
serum 25(OH)D levels greater than 50 nmol/L. On the other hand, Orwoll and
colleagues201 did not see any effect of baseline serum 25(OH)D levels on response to
supplementation with 1000 IU vitamin D3 in 30 to 82 year old men. However, with a
mean of 60 nmol/L, there may not have been enough low serum 25(OH)D levels to see
an effect.
One study also observed a stronger response to ultraviolet radiation in subjects
with low baseline serum 25(OH)D levels. In 13 German men and women, 20 to 57 years
old, when exposed to a high dose of ultraviolet radiation over 21 days (total of 36 J/cm2),
serum 25(OH)D levels increased twice as much in subjects with baseline serum 25(OH)D
levels less than 25 nmol/L compared to those with baseline serum levels greater than 50
nmol/L.28
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Obesity
The effect of body fat on response to supplementation is uncertain. Wortsman
and colleagues146 found no difference between obese and normal weight subjects in their
response to oral supplementation with a one-time dose of 50,000 IU vitamin D2.
Likewise, elderly subjects in Brazil, given 7000 IU vitamin D3 weekly, had a similar
25(OH)D response to supplementation, regardless of tertile of body fat.200 In another
study, however, when given three different doses of vitamin D3, heavier men had less of a
response to supplementation.145 The researchers calculated that men weighing 85 kg had
approximately 65% of the response to supplementation as did 55 kg men.145
Calcium Intake
A high calcium diet may increase the serum 25(OH)D response to oral vitamin D
supplementation by increasing serum calcium levels slightly, which will decrease PTH
secretion, thereby decreasing production of 1,25(OH)2D. Decreasing 1,25(OH)2D will
slow the depletion of 25(OH)D stores42 because less 25(OH)D will be used as substrate
for 1,25(OH)2D production. In one study, serum 25(OH)D levels increased significantly
less in eight normal subjects taking 100,000 IU vitamin D2 with 2000 mg calcium for
four days than when taking the same amount of vitamin D2 alone.202 In another study
however, Goussous and colleagues,203 using intakes of calcium and vitamin D within the
range that are usually recommended, found that daily calcium intakes of 500 or 1500 mg
did not affect the serum 25(OH)D response to supplementation with 800 IU vitamin D3
for three months during winter.
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Cholecalciferol (Vitamin D3) versus Ergocalciferol (Vitamin D2
Until recently, vitamin D2 and vitamin D3 were believed to be equally effective at
increasing serum 25(OH)D levels. However, recent studies show that D3 is the more
effective form of supplemental vitamin D.197,204,205
Tjellesen and colleagues204 gave 19 premenopausal women either 4000 IU
vitamin D2 or vitamin D3 for eight weeks. In the vitamin D2 group, 25(OH)D2 increased
68 nmol/L, but 25(OH)D3 decreased by 51.5 nmol/L (more than would be expected due
to season), so the total 25(OH)D remained unchanged. In the vitamin D3 group,
25(OH)D3 and total 25(OH)D increased 32 nmol/L. The researchers suggested the
decrease in vitamin D3 in the vitamin D2 group may have been due to either competition
for hydroxylase or up-regulated catabolism.204
A few years later, Trang and colleagues197 gave volunteers either 4000 IU vitamin
D2 or vitamin D3 or nothing for 14 days. Total 25(OH)D increased 23.3 nmol/L in the
vitamin D3 group versus only 13.7 nmol/L in the vitamin D2 group, and 3.0 nmol/L in the
untreated group.197 The researchers attributed this difference to the findings of Holmberg
and colleagues206 that, in hepatic mitochondria, the hydroxylation rate of vitamin D3 is
five times that of vitamin D2. In the same study, no hydroxylation of vitamin D2 and very
little hydroxylation of vitamin D3 was detected in the microsomes.
Armas and colleagues205 gave 30 men either 50,000 IU vitamin D2 or vitamin D3
or nothing daily for 28 days. Serum 25(OH)D2 and 25(OH)D3 increased the same
amount in the first three days, suggesting they were absorbed and hydroxylated the same.
However, by the end of the study, total 25(OH)D was 22 nmol/L higher in the vitamin D3
group than in the vitamin D2 group.205 Since DBP has a higher affinity for D3 than D225
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the researchers concluded that vitamin D3 is metabolized more slowly and vitamin D2 is
cleared more quickly, resulting in a lower response to supplementation.205 In work by
Guo and colleagues,207 it appears that vitamin D2 is preferentially 24-hydroxylated and is
therefore degraded more quickly. Vitamin D3, however, is preferentially 25hydroxylated.
Dose of Vitamin D3
Higher doses of vitamin D3 increased serum 25(OH)D levels less per unit of
vitamin D consumed than did lower doses of vitamin D3.208,209 When Vieth and
colleagues210 gave subjects either 1000 or 4000 IU vitamin D3 for three months during
late winter, the increases in serum 25(OH)D levels per microgram of vitamin D3 input
were 1.02 and 0.59 nmol/L, respectively. In another study, subjects were given either
5000 or 10,000 IU vitamin D3 daily and serum 25(OH)D levels increased 0.736 and
0.636 nmol/L per microgram of vitamin D3 intake, respectively.209
Aging
Aging does not appear to affect response to supplementation with oral vitamin
D3.198,211 Harris and colleagues198 found no significant difference between 18 to 35 year
old men and 62 to 79 year old men in their response to supplementation with 800 IU
vitamin D3. Vieth and colleagues211 found that adults less than 50 years old and adults
more than 70 years old consuming similar amounts of vitamin D had no difference in
serum 25(OH)D levels. However, the researchers did find that older adults needed a
higher 25(OH)D concentration to maximally suppress PTH and, therefore, may need a
higher recommended intake than younger adults.211
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Absorption
Diseases characterized by intestinal malabsorption can affect serum response to
oral supplementation with vitamin D3. Some medications, such as some weight loss
medications, and some medications for the treatment of high cholesterol induce fat
malabsorption and may, therefore, also affect serum 25(OH)D levels.
Despite vitamin D supplementation, higher rates of vitamin D insufficiency have
been documented in patients with malabsorptive diseases such as cystic fibrosis,184-186
celiac disease,187 and inflammatory bowel disease (Crohn’s disease and ulcerative
colitis)174 than in healthy controls, suggesting a reduced response to supplementation in
these disorders.
Orlistat, a pancreas lipase inhibitor prescribed for weight loss, may cause
malabsorption of vitamin D and/or calcium191 and would, therefore, reduce response to
supplementation. Large doses of cholestyramine induce fat malabsorption and
impairment of vitamin D absorption.192 Two other studies, however, showed no
deleterious effect of cholestyramine therapy on serum 25(OH)D levels.193,194
Gender
In Brazilian nursing home patients, Canto-Costa and colleagues200 saw no
difference in response to supplementation between men and women given 7000 IU
vitamin D3 weekly for twelve weeks.
Other
Estrogen, alcohol consumption, and smoking influence baseline serum 25(OH)D
levels, but their impact on the response to supplementation has yet to be determined.
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Summary
The typical American diet provides little vitamin D and, therefore, has a minimal
effect on serum 25(OH)D levels. The majority of vitamin D for most people comes from
cutaneous synthesis upon exposure to sunlight. Winter at high latitudes, pollution, and
cloudy skies scatter UVB photons reducing cutaneous synthesis of vitamin D and
lowering serum 25(OH)D levels. Sunscreen, clothing, and dark skin pigmentation block
UVB rays from reaching the skin, thereby decreasing synthesis of vitamin D and serum
25(OH)D levels. Increased body fat, elevated 1,25(OH)2D levels, smoking, and some
medical conditions and medications cause decreased serum 25(OH)D levels. On the
other hand, hormonal contraceptives and moderate alcohol consumption result in
increased serum 25(OH)D levels. These factors must be considered when assessing
serum 25(OH)D levels in individuals and populations. In addition, 25(OH)D assays are
not standardized, which makes comparisons between studies difficult.
Baseline serum 25(OH)D levels are known to be inversely associated with
response to oral vitamin D supplementation. Medical conditions characterized by
malabsorption and medications inducing fat malabsorption are believed to hinder
response to supplementation. However, the effects of obesity, calcium intake, estrogen,
gender, alcohol, and smoking on serum 25(OH)D response to supplementation are
uncertain at this time.
Prevalence of Vitamin D Insufficiency
Many studies have documented high rates of vitamin D deficiency in
premenopausal women in North America, particularly at the end of winter and in
northern latitudes (Table 1). When comparing these studies, it is important to remember

45

the many factors that influence serum 25(OH)D levels, including the type of assay used,
the latitude and season in which serum 25(OH)D levels were drawn, and the age and race
of the subjects. The cut-off values for 25(OH)D indicating insufficiency vary among the
studies; they are all higher than the 27.5 nmol/L used to set the DRI in 1997,21 but most
are lower than the optimal level of 75 nmol/L.
Analysis of NHANES III data for non-Hispanic white, non-Hispanic black, and
Mexican American women between the ages of 20 and 39 years, living in the US at lower
latitudes (median latitude 32ºN) in winter, found 40% of subjects with serum 25(OH)D
levels less than 50 nmol/L and 55% with levels less than 62.5 nmol/L.121 Because of the
unpredictable weather at higher latitudes during winter, the NHANES III data was
collected at 25oN to 47oN (median 39oN) during summer. Eighteen percent of 20 to 39
year old non-Hispanic white, non-Hispanic black, and Mexican American women living
in the north were found to have serum 25(OH)D levels less than 50 nmol/L and 30% had
levels less than 62.5 nmol/L during summer.121
In Omaha (41oN), Kinyamu and colleagues212 found a much lower incidence of
vitamin D insufficiency than other researchers. They compared institutionalized and
free-living elderly women with younger women and found only 6% of 25 to 35 year old
women had serum 25(OH)D levels less than 30 nmol/L between November and May.
Eight percent of the institutionalized women, and 1.6% of the free- living elderly women
had serum 25(OH)D levels below 30 nmol/L.212 More recently in Omaha, Armas and
colleagues116 found a much higher incidence of vitamin D deficiency with 58% of young
men and women (19 to 49 years old) having levels below 80 nmol/L at the end of
summer and 96% at the end of winter. The same researchers observed that although
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Table 1. Prevalence of vitamin D insufficiency in North America.

Study

Looker et al.
2002121

Assay
Used*

RIA

Latitude

Season

median
32oN
Southern
US

Winter

median
39oN
Northern
US

Summer

Gender

Age

Race

20 – 39

White, Black,
Mexican
American

Mean
25(OH)D
(nmol/L)
62.7

F

% Below 50 % Below 75
nmol/L
nmol/L

40%
-

81.6

18%

Kinyamu et al.
1997212

CPB

41oN
Omaha

Winter

F

25 – 35

n/a

70.6 ± 26.3

6%
(30 nmol/L)

-

Rucker et al.
20027

RIA

51oN
Calgary

Winter

M, F

27 – 89

98% White

57.3 ± 21.3

39%

86%
(80 nmol/L)

Sullivan et al.
20054

CPB

44oN
Bangor

Winter

F

9 – 11

White

55.9 ± 16.5

48%

-

Tangpricha et
al. 20028

CPB

42oN
Boston

March

M, F

18 – 29

60% White

70 ± 25

36%

-

Vieth et al.
20016

RIA

43oN
Toronto

Winter

F

18 – 35

White

58 ± 24

21%
(40 nmol/L)

-

Weng et al.
2007213

RIA

40oN
Philadelphia

Winter

M, F

6 – 21

White

~75

-

51%

Black

~ 45

-

94%

*RIA = Radioimmunoassay, CPB = Competitive Protein Binding
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subjects who reported just casual summer sun exposure (i.e. walking to and from the car)
had a seasonal fluctuation in serum 25(OH)D levels, their summer sun exposure was not
sufficient to increase serum 25(OH)D levels above 80 nmol/L.116 In a study of healthy
young men and women (18 to 29 years) in Boston (42ºN), Tangpricha and colleagues8
found that 36% had serum 25(OH)D levels less than 50 nmol/L in March.
In 18 to 35 year old women living in Canada (43ºN), where milk is fortified with
vitamin D at the same level as in the US, 21% of white women, some of whom were
taking multivitamin supplements, had 25(OH)D levels less than 40 nmol/L in winter.6 In
Calgary, Canada (51oN), 20% of 27 to 89 year old men and women had serum 25(OH)D
levels less than 40 nmol/L; 39% had levels less than 50 nmol/L; and 86% had levels less
than 80 nmol/L during winter.7
Similar rates of vitamin D insufficiency were seen in children and adolescents in
the US. In Bangor, Maine (44oN), over a three-year period, 48% of healthy white
adolescent girls (9 to 11 years) were found to have at least one serum 25(OH)D level less
than 50 nmol/L at the end of winter4 and all subjects were found to have at least one
serum 25(OH)D level less than 75 nmol/L at the end of winter.214 Likewise, 51% of
white 6 to 21 year olds in the Philadelphia area (40oN) had serum 25(OH)D levels less
than 75 nmol/L during winter.213 The researchers found a much higher prevalence of
vitamin D insufficiency in black children with 94% presenting with serum levels less
than 75 nmol/L during winter.213
As mentioned previously, serum 25(OH)D levels fluctuate seasonally. Sullivan
and colleagues4 saw a 28% (20.1 nmol/L) drop in mean serum 25(OH)D levels from
summer to winter in adolescent girls. Arunabh and colleagues129 found a 37% drop (from
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84 to 53 nmol/L) in mean serum 25(OH)D levels from summer to winter in white
women. In 24 to 70 year old women, serum 25(OH)D levels increased 18.0 nmol/L
(36%) from winter to summer in London.215 In white women in Toronto, Canada, serum
25(OH)D levels measured in summer were 31% higher than those measured in winter.6
Although serum 25(OH)D levels are higher in summer than in winter, there are
still cases of vitamin D deficiency at the end of summer. Seventeen percent of adolescent
girls in Bangor, Maine had serum 25(OH)D levels less than 50 nmol/L at the end of
summer.4 Nationally, NHANES III data revealed 18% of women living between 25 and
47oN latitude had serum 25(OH)D levels less than 50 nmol/L at the end of summer.121
NHANES III data also showed that the rate of vitamin D insufficiency was two times
higher in females than males of the same age.121
Although less common, vitamin D deficiency is present at the end of summer in
some individuals, and vitamin D deficiency rates are much higher at the end of winter,
affecting up to 94% of some populations. It is not known whether there is a cumulative
negative effect of repeated cycles of insufficient wintertime serum 25(OH)D levels
during adolescence and young adulthood on the ability to achieve peak bone mass.121
However, given the many important functions of vitamin D, optimizing levels of serum
25(OH)D year-round is a logical goal.
Supplementation Studies
Previous Supplementation Trials
The general consensus among vitamin D researchers is that the optimal
concentration for serum 25(OH)D is at least 75nmol/L.1 Many people do not reach these
levels in winter. The amount of vitamin D needed to optimize levels for various groups
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needs to be determined. Once this amount is ascertained, strategies must be developed to
raise the entire population to optimal levels. A number of vitamin D supplementation
trials have been completed. When comparing these studies, one must consider the many
factors that may affect response to supplementation, including season and exposure to
UVB radiation (whether through natural or artificial means), body fat, baseline serum
25(OH)D levels, the form of vitamin D used (vitamin D2 or vitamin D3), the type of assay
used, and, in women, exogenous estrogen use. In addition, it is important to consider
whether the supplementation period was long enough for the serum 25(OH)D to reach an
equilibrium concentration. The half-life of serum 25(OH)D levels is approximately three
to four weeks42 and the concentration equilibrium is reached approximately four weeks
after supplementation begins.216 When comparing studies, one must also keep in mind
that many studies do not measure the actual vitamin D content of the supplement. Some
manufacturers may put more vitamin D in the supplement than the label states in order to
compensate for storage losses,216 so the response to supplementation may be exaggerated
in some studies if the actual vitamin D content is not measured.
In the US, no supplementation studies have focused on the vitamin D needs of
premenopausal women. In the few studies worldwide that have supplemented
premenopausal women with vitamin D3, they have either failed to consider hormonal
contraceptive use, had a small sample size, included men in the sample, or did not
account for changing serum 25(OH)D levels due to season. Rarely were the supplements
evaluated for actual vitamin D3 content.
Van der Klis and colleagues217 gave 800 IU vitamin D3 to six Dutch
premenopausal women, five of whom were on oral contraceptives, for four weeks during
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March. Serum 25(OH)D levels increased from 46.2 nmol/L to approximately 82 nmol/L,
a 1.8 nmol/L increase per microgram of vitamin D3. There was no placebo group to
control for the decreasing serum 25(OH)D levels that would be expected during March in
the Netherlands (52oN).217
Barnes and colleagues218 administered a chewable supplement containing either
600 IU vitamin D3 and 1500 mg calcium or just 1500 mg calcium daily to 27 men and
women aged 18 to 27 years for eight weeks, from January to March, in Northern Ireland
(55oN). Use of oral contraceptives was not mentioned. Serum 25(OH)D levels
increased 38.6 nmol/L from a baseline level of 47.9 nmol/L in the group receiving
vitamin D, and decreased 7.2 nmol/L in the control group. After adjusting for the change
in the control group, serum 25(OH)D levels increased 2.1 nmol/L per microgram of
vitamin D3 in the treatment group.218
In another study, 14 men and women, aged 22 to 60 years, drank one cup of
orange juice fortified with 1000 IU vitamin D3 and 350 mg calcium daily; another 12
subjects drank one cup of orange juice fortified with calcium only every day for 12
weeks, from March until May, in Boston (42oN).219 Serum 25(OH)D levels increased
from 37.0 to 94.0 nmol/L in the group receiving vitamin D fortified orange juice. In the
control group, serum 25(OH)D levels increased from 50.0 to 73.0 nmol/L due to the
spring season. After accounting for the change in the control group, serum 25(OH)D
levels increased 1.4 nmol/L per microgram of vitamin D3. Information on oral
contraceptive use and menopausal stage was not provided.
In Denmark (56oN), 19 healthy premenopausal women, 5 of whom were taking
oral contraceptives, were given either 4000 IU vitamin D2 or vitamin D3 and 500 mg
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calcium for eight weeks from September to November.204 The capsules were analyzed
for actual vitamin D content and were found to contain 4400 IU vitamin D3. There was
no placebo group to describe the seasonal decrease in serum 25(OH)D levels that would
be expected between September and November. In the vitamin D3 group, serum
25(OH)D levels increased from 77.5 nmol/L to 113.4 nmol/L, a change of 0.33 nmol/L
per microgram of vitamin D3. After adjusting for a 51.5 nmol/L drop in the serum
25(OH)D concentration in the group supplemented with vitamin D2, the change per
microgram of vitamin D3 increased to 0.79 nmol/L. The researchers suggested the drop
in serum 25(OH)D levels in the vitamin D2 group was too large to be due to the seasonal
change in vitamin D3 production alone and suggested competition between vitamin D2
and vitamin D3 for hydroxylation as the cause.204
Vieth and colleagues210 gave 61 men, and pre-and postmenopausal women either
1000 or 4000 IU vitamin D3 for three months, starting in January and February in
Toronto, Canada (43oN). In the group receiving 1000 IU, serum 25(OH)D levels
increased from 43.3 nmol/L to 68.7 nmol/L, a 1.02 nmol/L increase per microgram of
vitamin D3. In the group receiving 4000 IU, serum 25(OH)D levels increased from 37.9
to 96.4 nmol/L, an increase of 0.59 nmol/L per microgram of vitamin D3.210
In a frequently cited attempt to help determine the dose-response relationship for
vitamin D3 and serum 25(OH)D levels, Heaney and colleagues209 studied 67 healthy
young men (age 38.7 ± 11.2 years, BMI 26.2 ± 2.4) with daily dietary vitamin D intakes
less than 200 IU during winter in Omaha, Nebraska (41oN). Subjects consumed either
placebo or 1000, 5000, or 10,000 IU vitamin D3 tablets daily for five months. Serum
25(OH)D levels decreased 11 nmol/L in the placebo group, and increased 12, 92, 159
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nmol/L in the 1000, 5000, 10,000 IU groups, respectively. Using the dose-response
curves from this data, the researchers determined that serum 25(OH)D levels increase by
0.7 nmol/L for every microgram (40 IU) of vitamin D3 input.209
In the supplementation studies involving young women described above, the
increase in serum 25(OH)D levels per microgram of vitamin D3 intake ranged from 0.59
to 2.1 nmol/L, which bracket the value obtained by Heaney and colleagues.209 In the
studies in which baseline serum 25(OH)D levels were lowest, the change in serum
25(OH)D levels in response to supplementation was the greatest.210,219
Theoretical Dose Required
Previous studies of 18 to 35 year old men and women in North American (41o to
43oN) have found serum 25(OH)D levels at the end of winter in the range of
approximately 58 nmol/L6 to 70 nmol/L.8,212 Using the 0.7 nmol/L increase in 25(OH)D
levels per microgram of vitamin D3 intake suggested by Heaney and colleagues,209 a dose
of 285 to 970 IU vitamin D3 would be required to optimize the mean vitamin D status of
these populations. Furthermore, in a recent editorial by Dawson-Hughes and colleagues,1
researchers suggested at least 800 to 1000 IU vitamin D3 would be necessary to achieve a
mean serum 25(OH)D concentration of 75 nmol/L.
Risk and Safety Monitoring
Vitamin D toxicity is not subtle. It causes soft tissue calcification, hypercalcemia,
and dehydration. Hypercalcemia is characterized by fatigue, muscle weakness, nausea
and vomiting, thirst, and loss of appetite. Development of hypercalciuria (increased ratio
of urinary calcium to urinary creatinine) precedes hypercalcemia in vitamin D
intoxication220 and is, therefore, a useful and convenient monitor of vitamin D tolerance.
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However, hypercalciuria can be caused by many factors unrelated to hypercalcemia and
vitamin D intoxication, and should not be considered an adverse effect of vitamin D
supplementation if serum calcium levels remain normal.216
Based on a serum 25(OH)D response to supplementation of approximately 1.0
nmol/L per microgram of vitamin D3 intake, the current Adequate Intakes for vitamin D,
200 IU for 1 to 50 year olds; 400 IU for 51 to 70 year olds; and 600 IU for those older
than 70, would only increase serum 25(OH)D levels by 4, 8, and 12 nmol/L, respectively.
The current tolerable upper limit (2000 IU) would increase serum 25(OH)D levels by 35
nmol/L. Vitamin D intoxication occurs when serum 25(OH)D levels exceed 220
nmol/L221 to 375 nmol/L,216,222,223 or more.224 Using NHANES data, Nesby-O’Dell and
colleagues139 found the mean serum 25(OH)D levels of white women in the US to be
82.5 ± 1.5 nmol/L. In summer in Toronto (43oN), 95% of white women had serum
25(OH)D levels no higher than 90 nmol/L.6 The highest serum 25(OH)D levels of sunreplete individuals in the US were 154 to 178 nmol/L.10,99 The current tolerable upper
limit, if consumed daily, would be unlikely to cause vitamin D intoxication, even in sunreplete individuals in the US.
Vitamin D toxicity has only occurred in individuals taking more than 10,000 IU
daily. Mawer and colleagues221 reported vitamin D intoxication in eight patients who had
been taking 50,000 to 200,000 IU vitamin D2 daily for six or more years. Koutkia and
colleagues223 reported a patient who presented to the hospital with hypercalcemia after
taking an over-the-counter vitamin D3 supplement for two years. When analyzed, the
supplement contained 26 to 430 times the labeled amount of vitamin D3. The patient had
been taking 156,000 to 2,604,000 IU vitamin D3 for an unknown length of time.223
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Serum calcium levels usually normalize within one to four months of discontinuing
vitamin D supplements,220 but it may take years for serum 25(OH)D levels to drop below
115 nmol/L after reaching toxic levels, even without exposure to UVB radiation.223
Although the body protects itself from vitamin D intoxication upon exposure to
excessive sunlight, in theory, adults receiving profuse amounts of sunshine may be more
susceptible to vitamin D toxicity when taking supplements because of the cumulative
effect of sun and supplements.225 In addition, patients with granulomatous diseases such
as sarcoidosis and tuberculosis should avoid vitamin D supplements and sunshine
because granulomas cause hypercalcemia due to unregulated production of calcitriol.226
Summary
The documented cases of vitamin D intoxication have occurred at intake levels far
exceeding the upper limit of 2000 IU. Although vitamin D intoxication is rare, and is
highly unlikely to occur in individuals supplemented with 800 IU vitamin D3, safety
monitoring of serum calcium and urinary calcium to creatinine ratio may detect changes
in calcium excretion related to vitamin D intoxication. At “safe” supplementation levels,
the existing literature on supplementation in adult men and women indicates a response
to supplementation of approximately 1.0 nmol/L per microgram of vitamin D3 intake.
However, most studies have included men in the sample, and failed to consider the effect
of exogenous hormones, body composition, and season on the response to
supplementation. A supplementation study of premenopausal women in the United
States, that takes into consideration oral contraceptive use, seasonal fluctuations in serum
25(OH)D levels, and body composition, is needed to help determine how much vitamin
D3 is needed to optimize serum 25(OH)D levels in this population.
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Rationale for Research Project
Vitamin D has many skeletal and non-skeletal purposes. There is a high
prevalence of vitamin D insufficiency in Maine and other areas above 35oN latitude due
to inadequate UVB radiation for synthesis of vitamin D during winter. Many factors
influence an individual’s vitamin D status, including sun exposure, skin color, body
composition, and oral contraceptive use. Researchers speculate that approximately 800
to 1000 IU vitamin D3 is required to raise serum 25(OH)D levels to at least 75 nmol/L in
the absence of sunlight. Further research is needed to determine how much vitamin D3 is
required to optimize serum 25(OH)D levels for different age groups, while taking into
consideration sun exposure, skin color, body composition, and hormonal status. There
have been no studies looking at the serum 25(OH)D response to supplementation with
800 IU vitamin D3 in premenopausal women in the United States that takes into
consideration the use of hormonal contraceptives and body composition.
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Chapter 3
METHODS AND MATERIALS
Study Design
In February 2005, 112 women aged 19 to 35 years enrolled in the study to receive
six months of placebo daily followed by five months of either an 800 IU oral vitamin D3
supplement or a matching placebo daily. The goal was to achieve a serum 25(OH)D
level of at least 75 nmol/L in the treatment group during winter.
The project took place over 16 months (Figure 1):
•

November 2004 – February 2005: Four-month recruitment period

•

February 2005: Measurement of baseline serum 25(OH)D levels

•

March – September 2005: Six-month run-in period

•

September 2005 – February 2006: Five-month placebo-controlled, doubleblind vitamin D supplementation period

Blood samples were drawn in February 2005, September 2005, and February
2006 for analysis of serum 25(OH)D, PTH, and calcium levels. Urine samples were
obtained in February 2005, September 2005, and February 2006 for analysis of urinary
calcium and creatinine levels.
Each participant had a total body scan using dual energy x-ray absorptiometry
(DXA) in March 2005 and again in March 2006 for determination of percent body fat and
bone mineral density. Height was measured in March 2005 and March 2006; weight in
light clothing without shoes was measured in March 2005, September 2005, and March
2006.
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THE VITAMIN D STUDY TIMELINE

Vitamin D3
Nov ’04
thru
Feb ‘05

Recruit,
Screen
and
Consent

Sept ‘05

June ‘05

25(OH)D
PTH
Calcium
Lifestyle
Questionnaire
DEXA #1

Lifestyle
Questionnaire

25(OH)D
PTH
Calcium
Lifestyle and
Skin Type
Questionnaire

Food Record

March

Dec ‘05

Lifestyle
Questionnaire

25(OH)D
PTH
Calcium
Lifestyle
Questionnaire
DEXA #2

Food Record

Figure 1. The Vitamin D Study timeline.
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Upon enrollment, subjects completed a Health History Questionnaire (Appendix
B), which was then reviewed with them to determine eligibility for the study. Every
three months thereafter, participants completed a brief lifestyle questionnaire (Appendix
B) to update their health history and provide information about sun exposure, oral
contraceptive use, and so on. In addition, three-day food records were collected upon
enrollment and during the following winter.
Subjects and Recruitment
One hundred twelve women, aged 19 to 35 years, living in the Bangor, ME area,
were recruited from a pool of roughly 6000 female students at the University of Maine
and 15,000 women in this age range in Penobscot County, Maine. Enrollment was open
to any ethnic or racial group. Premenopausal women were chosen as a homogeneous
group in which to assess vitamin D intake requirements.
During the fall semester of 2004, students were recruited at the University of
Maine through mailings to all female freshman, sophomores, and juniors (see Appendix
C), and through e-mail folders and bulletin boards. Women within the community were
recruited through fliers on public bulletin boards (see Appendix D) and through a local
television station.
To be eligible for participation in the study, subjects were required to have a body
mass index between 18.5 and 40 kg/m2, and be free of any disease or condition that
influences calcium, or vitamin D metabolism, such as hyper- and hypothyroidism,
primary hyperparathyroidism, diabetes, celiac disease, cystic fibrosis, liver disease,
kidney disease, or inflammatory bowel disease. Women who were pregnant or planned
to become pregnant during the study period were excluded, as were those taking any
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medications that affect calcium or vitamin D metabolism, including corticosteroids and
anti-convulsant medications. Subjects were asked not to travel to a southern latitude
between September and March, and to refrain from using tanning booths. Subjects had
not regularly consumed any calcium or vitamin D-containing supplement within the
previous four months and agreed not to take any calcium, vitamin D, or multivitamin
supplements other than those provided during the study period. Subjects with baseline
serum 25(OH)D levels less than 22.5 or greater than 175 nmol/L were excluded.
Subjects were recruited in November and December 2004. In January 2005
informational meetings were held for women interested in participating in the study.
Interested individuals completed a brief, confidential Health History Questionnaire (see
Appendix B), which was then reviewed with them to screen for eligibility.
Written informed consent was obtained from each subject. This study was
approved by the University of Maine Human Subjects Committee and St. Joseph
Hospital’s Institutional Review Board. The consent form is found in Appendix E.
January 2005
Interested individuals attended informational meetings to learn more about the
study and to be screened for eligibility. At this time, written informed consent was
obtained from each subject. Appointments were scheduled to have blood drawn at the
University of Maine Cutler Health Center in February and to have dual energy x-ray
absorptiometry (DXA) scans for assessment of body composition at the Maine Center for
Osteoporosis Research and Education (MECORE) in March. Subjects were given
instructions for completing a three-day food record to include two weekdays and one
weekend day.
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Baseline - February / March 2005
In February 2005, prior to the University of Maine spring break, participants
reported to Cutler Health Center to have their blood drawn for measurement of baseline
serum 25(OH)D, PTH, and calcium levels. A random urine sample was obtained from
each subject for measurement of urinary calcium and creatinine. Participants answered a
brief lifestyle questionnaire to update their health history and provide information about
nutritional supplement use, contraceptives, and sun exposure, including winter vacation
locations and use of tanning booths. In March 2005, participants reported to the Maine
Center for Osteoporosis Research and Education (MECORE) for DXA scan and
measurement of height and weight.
At MECORE, subjects received their first three-month supply of placebo
capsules, which were manufactured by Tishcon, Corporation (Westbury, NY). During
the run-in period from March to September 2005, all subjects took a placebo for six
months. Subjects with less than 75 percent compliance with placebo, as determined by
pill counts every three months, were to be dismissed from the trial.
June 2005
In June 2005, subjects who were in the Bangor area for the summer reported to
the Vitamin D Research Room (123 Hitchner Hall, University of Maine) to return unused
capsules for assessment of compliance and to pick-up a new supply of placebo. At this
time, subjects completed a lifestyle questionnaire to update their health history (see
Appendix B). Because estrogen-containing medications affect serum 25(OH)D levels,
the lifestyle questionnaire given every three months included questions to detect changes
in use or non-use of prescription contraceptives.
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A new supply of placebo was mailed to subjects who were not in the Bangor area
during the summer. Subjects were instructed to finish the pills in their current pill bottle
before starting the new bottle. All unused capsules were to be returned for counting in
September. The lifestyle questionnaire was mailed to these subjects along with an
addressed and stamped envelope for ease of return.
September 2005
Subjects were contacted via email in late August 2005 to schedule appointments
for phlebotomy at Cutler Health Center in September. In September, subjects reported to
Cutler Health Center again to provide blood and urine samples, and to have their weights
measured. Participants returned unused placebo capsules.
In August, individuals were randomly assigned to either the treatment group or
the control group using Research Randomizer (version 3.0) software. The random
number generator assigned subjects to either the treatment group or the placebo group.
One-third of the subjects (36/103) were randomized to the placebo group; two-thirds
(67/103) to the treatment group. At the time of randomization, t-tests were conducted
and no significant differences were seen between the two groups regarding baseline
serum 25(OH)D levels, percent body fat, or age. An investigator not directly involved
with the subjects transmitted the list of subjects in the treatment group and the placebo
group to the pharmacist at Cutler Health Center to be packaged in child-resistant vials
labeled with each subject’s name and identification number. The researchers and
subjects remained blinded to the content of the capsule taken by the subjects. In
September, subjects picked up a three-month supply of either placebo or 800 IU vitamin
D3 and completed another lifestyle questionnaire (see Appendix B), which included a
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skin type questionnaire that was used to categorize them according to Fitzpatrick skin
type (I-VI).227
December 2005
In December 2005 subjects reported to the Vitamin D Research Room to return
unused capsules for assessment of compliance and to pick-up a new supply of capsules.
Returned capsules were counted to measure percent compliance. Subjects completed
another lifestyle questionnaire to update their health histories (see Appendix B).
Instructions for recording three-day food records were reviewed with subjects and they
were asked to again record intake on two weekdays and one weekend day.
February / March 2006
In February 2006, prior to the University of Maine spring break, participants
reported to Cutler Health Center to provide blood and urine samples. Participants
answered a final brief lifestyle questionnaire to update their health history (see Appendix
B) and returned unused capsules, which were counted to measure percent compliance.
The compliance rates were calculated for September to December and December to
February, and the mean percent compliance was used in data analysis. In March 2006,
participants reported to the Maine Center for Osteoporosis Research and Education
(MECORE) for the final DXA scan and measurement of height and weight.
Vitamin D3 Supplements
The supplements and matching placebo were manufactured by Tishcon
Corporation (Westbury, NY). The capsules were analyzed for actual vitamin D3 content
using high performance liquid chromatography (HPLC) on three separate occasions. At
the time of manufacture (February 2005), Tishcon Corporation measured 869 IU vitamin
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D3 per capsule. At the beginning and end of the supplementation period, an independent
laboratory (Analytical Laboratories of Anaheim, Inc) measured 956 IU vitamin D3
(September 2005) and 832 IU vitamin D3 (April 2006). The average vitamin D3 content
of the capsules was 885 IU vitamin D3. No vitamin D3 was detected in the placebo
capsules by either the manufacturer or the independent laboratory.
Qualified medical personnel at Cutler Health Center packaged the capsules in
child-resistant vials labeled with each subject’s name and identification number. The
placebo capsules contained maltrin and magnesium stearate; the vitamin D capsules
contained maltrin, magnesium stearate, and vitamin D3.
Analysis of Serum and Urine Samples
Non-fasting serum samples were obtained by skilled phlebotomists from Cutler
Health Center in February 2005, September 2005, and February 2006. Samples from all
subjects were drawn within a two-week time period. Ten milliliter blood specimens were
centrifuged within two hours of being drawn, and the serum was removed and frozen in
one milliliter aliquots at -70oC until analysis. Serum samples were shipped on dry ice to
the Medical University of South Carolina, Charleston for analysis of 25(OH)D and PTH
by Dr. Bruce Hollis. Serum 25(OH)D was measured by radioimmunoassay.228 The
intraassay and interassay coefficients of variation were less than 10%. Intact PTH was
measured by radioimmunoassay (DiaSorin Inc., Corp., Stillwater, MN). The intraassay
and interassay coefficients of variation were less than 10%. Serum samples were assayed
for baseline 25(OH)D levels in March 2005 to determine eligibility for the study and to
assure that mean baseline 25(OH)D levels were not significantly different between
groups at randomization. Serum samples from all three points in time were batch-
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analyzed at the conclusion of the study to avoid inter-assay variation. Serum samples
were protected from ultraviolet light during processing.
Serum 25(OH)D levels were measured in September and February when levels
are at their highest and lowest points of the year, respectively.122 Five months elapsed
from the start of vitamin D3 supplementation to the next measurement of serum 25(OH)D
to allow ample time for equilibration at the new level of intake before levels were
reassessed.
Serum calcium was measured by a colorimetric assay using the clinical analyzer
(Beckman-Coulter CX-4 PRO) in the Clinical Nutrition Laboratory at the University of
Maine. A random urine sample was collected from each subject in February 2005,
September 2005, and February 2006 for measurement of calcium and creatinine content.
Urinary calcium and creatinine were measured by a colorimetric assay using the clinical
analyzer (Beckman-Coulter CX-4 PRO) in the Clinical Nutrition Laboratory at the
University of Maine, and the urinary calcium to creatinine ratio was calculated. The
calcium to creatinine ratio was used to monitor tolerance to the supplementation.
Anthropometric Measurements
Height was measured in March 2005 and March 2006 using a calibrated
stadiometer. Weight in light clothing, without shoes, was measured using an electronic
standing scale in March and September 2005 and March 2006.
Body fat content was measured using dual energy x-ray absorptiometry (DXA) on
a Hologic QDR 2000 (Hologic Inc., Waltham, MA, USA) by a single DXA technician in
March 2005 and March 2006 at the Maine Center for Osteoporosis Research and
Education. DXA is a valid measure of body composition and body fat.229 The DXA
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machine was calibrated against a phantom daily. The coefficient of variation (CV) was
0.6%. Urine pregnancy tests were confirmed negative prior to DXA scans.
Questionnaires
Every three months between February 2005 and February 2006, participants
answered a brief lifestyle questionnaire to update their health history and provide
information about nutritional supplement use, intake of alcoholic beverages, hormonal
contraceptive use, and sun exposure, including winter vacation locations and use of
tanning booths. Specific brand names of hormonal contraceptives were obtained and a
daily average intake of estradiol was calculated. Subjects also completed a skin type
questionnaire to categorize them according to Fitzpatrick skin type (I-VI).
Dietary Intake Assessment
Subjects completed three-day food records in February 2005 and again in
February 2006.230 Instructions for recording three-day food records (two weekdays and
one weekend day) were reviewed with subjects prior to keeping each food record.
Subjects were instructed to record intake immediately after consumption and to include
as much information as possible including brand names, package sizes, and recipes when
possible. Serving sizes were either measured with measuring cups when possible, or
estimated using common household items (i.e. ¼ cup is approximately the size of a golf
ball). Food records were analyzed using Nutritionist Pro software, version 2.5 (Axxya
Systems, Stafford, TX) for calories, protein, calcium, sodium, and vitamin D intake.
Sun Exposure Questionnaire
The February 2005 and September 2005 Lifestyle Questionnaires (see Appendix
B) included a series of questions used for calculating sun exposure.118 Subjects were
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asked the approximate number of days worked per week, the number of days off per
week, and the number of days spent on vacation. In addition, they were asked how many
hours they spent outside between 1000 EST and 1500 EST while at work, on their days
off, or on vacation. Based on a 16-week summer (May through August), the average
number of hours spent outside per week was calculated. An example showing the
calculation of the average weekly number of hours of sun exposure can be found in
Appendix F.
Statistical Analysis
All data from subject records were entered into a Microsoft Excel spreadsheet.
The statistical analysis was performed using SPSS, Student Version 13.0.
Vitamin D intake, sun exposure, body fat, BMI, and oral contraceptive use are
known to affect serum 25(OH)D levels. Both multiple and logistic regression were used
to measure the effects of these variables on serum 25(OH)D levels, the serum 25(OH)D
response to supplementation with 800 IU vitamin D3, and the seasonal increase in serum
25(OH)D levels. Additionally, age, years of oral contraceptive use, tanning during
winter, BMI, sun exposure during the previous summer, skin type, the summer increase
in serum 25(OH)D levels, smoking, day of the menstrual cycle on which blood was
drawn, and dietary calcium and vitamin D intake were included as independent variables
in the logistic regression analysis of baseline serum 25(OH)D levels. The cut-off for
baseline serum 25(OH)D levels in the binary logistic regression was 75 nmol/L (the
optimal serum 25(OH)D level). In the analysis of the one-year change in serum
25(OH)D levels, estrogen dose, the magnitude of the summer increase in serum 25(OH)D
levels, baseline 25(OH)D levels, the randomization group, mean body fat, change in
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serum calcium levels, smoking, one-year change in calcium and vitamin D intake,
alcohol consumption, the one-year change in calcium to creatinine ratio, one-year change
in sun exposure, tanning bed use during winter, and the number of days with a cold were
included as independent variables. The cut-off for one-year change in serum 25(OH)D
levels in the binary logistic regression was 40 nmol/L (0.25 standard deviation above the
mean).
In the logistic regression analyses, the Wald statistic was used to test the
significance of the regression coefficients for each independent variable.231 Nagelkerke’s
R2 was used to approximate the percent of variance explained by the model.232 The
Hosmer and Lemeshow test, a chi-square test of goodness of fit, was used to determine
whether the regression model fit the data at an acceptable level.233
Student’s t-test was used to compare means between two variables, and one-way
analysis of variance was used to compare means between multiple variables.
Assumptions were tested by examining normal probability plots of residuals and scatter
diagrams of residuals versus predicted residuals. No violations of normality, linearity, or
homogeneity of variance were detected.
Statistical significance was set at 0.05.
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Chapter 4
RESULTS
Subject Characteristics
In February 2005, 112 subjects enrolled in the study, 98 of whom completed the
study in February 2006 (a retention rate of 88%). Ten subjects chose to withdraw from
the study and four subjects were excluded from the study because their baseline
(February 2005) serum 25(OH)D levels were outside the range (22.5 to 175 nmol/L)
established for inclusion criteria (two were above and two were below the acceptable
range). Reasons cited for withdrawing from the study included moving out of the area
(5/10), desiring to take a multivitamin (2/10), and personal reasons (3/10). Twelve
subjects who either started or quit using hormonal contraceptives during the study were
excluded from analysis, leaving a total of 86 participants (Figure 2, flowchart).
The baseline (February 2005) characteristics are summarized in Tables 2a and 2b
for the 103 subjects who were randomized to receive either placebo or 800 IU vitamin
D3. Independent samples t-tests revealed no significant differences between the groups.
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Table 2a. Comparison of baseline characteristics between the treatment and
placebo groups in the 103 subjects who were randomized.
Treatment Group
Placebo Group
p
n
Mean ± SD
n
Mean ± SD
Age (y)
67
22.0 ± 2.9
36
22.3 ± 4.3
NS
2
BMI (kg/m )
67
25.8 ± 4.9
36
26.4 ± 5.4
NS
Total body fat (%)
67
30.0 ± 7.4
36
30.7 ± 7.6
NS
Height (cm)
67
164.8 ± 6.2
36
163.3 ± 7.3
NS
Weight (kg)
67
70.1 ± 14.6
36
70.0 ± 13.3
NS
2004 Summer sun exposure
67
16.0 ± 9.4
36
18.1 ± 8.6
NS
(h/wk)
Serum 25(OH)D (nmol/L)
67
61.9 ± 25.1
36
60.3 ± 22.1
NS
Serum PTH (pg/mL)
67
30.7 ± 9.7
36
34.0 ± 14.0
0.21
Serum calcium (mg/dL)
67
9.7 ± 0.27
36
9.7 ± 0.24
NS
Urine calcium:creatinine
67
0.14 ± 0.08
36
0.13 ± 0.08
NS
Years of contraceptive use*
43
2.67 ± 2.1
25
3.2 ± 3.8
NS
*Only includes subjects using hormonal contraceptives
Treatment and placebo groups were compared with use of independent samples t-tests.
Table 2b. Comparison of the daily nutrient intake at baseline (February 2005)
between the treatment and placebo groups in the 103 subjects who were
randomized.
Treatment Group
Placebo Group
p
n
Mean ± SD
n
Mean ± SD
Calories (kcal/d)
67
1759 ± 455
36
1749 ± 418
NS
Protein (g/d)
67
67.4 ± 19.8
36
67.1 ± 18.6
NS
Sodium (mg/d)
67
2980 ± 1007
36
2905 ± 996
NS
Calcium (mg/d)
67
890 ± 403
36
903 ± 357
NS
Vitamin D (IU/d)
67
143 ± 120
36
139 ± 101
NS
Treatment and placebo groups were compared with use of independent samples t-tests.
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116 Subjects
Recruited

February 2005
4 No-shows for blood draw
(n = 112)

March – June 2005
4 excluded for baseline 25(OH)D
levels outside range
3 w/d for personal reasons
2 w/d to take vitamins
(n = 103)

__________RANDOMIZATION__________

June – Sept 2005
5 moved away
(n = 98)

12 excluded for
changing oral
contraceptive use
(n = 86)

Vitamin D
Group
55
Subjects

Placebo Group
31 Subjects

Figure 2. Flowchart of participation.
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Characteristics of Subjects Who Did Not Complete the Study
Serum PTH levels were significantly higher in the 26 individuals who did not
complete the study compared to the 86 subjects who completed the study, but there were
no other significant differences at baseline (Table 3).
Table 3. Comparison of baseline characteristics of subjects who completed the
study and those who did not.
Did Not Complete
Completed the
the Study
Study
p
n
Mean ± SD
n
Mean ± SD
Age (y)
26
21.7 ± 2.1
86
22.2 ± 3.7
NS
2
BMI (kg/m )
26
25.9 ± 4.9
86
25.9 ± 5.1
NS
Serum 25(OH)D
26
58.2 ± 32.6
86
62.0 ± 23.4
NS
(nmol/L)
Serum PTH (pg/mL)
26
36.6 ± 13.5
86
30.9 ± 11.3
0.034
2004 Summer sun
26
17.0 ± 8.6
86
16.3 ± 9.2
NS
exposure (h/wk)
Calorie intake (kcal/d)
25
1745 ± 426
86
1747 ± 444
NS
Protein intake (g/d)
25
69.5 ± 24.3
86
67.4 ± 19.1
NS
Sodium intake (mg/d)
25
3089 ± 1039
86
2924 ± 975
NS
Calcium intake (mg/d)
25
847 ± 453
86
908 ± 375
NS
Vitamin D intake (IU/d) 25
149 ± 86
86
139 ± 117
NS
Subject groups were compared with use of independent samples t-tests.
Baseline Characteristics of Subjects Who Completed the Study
The baseline (February 2005) characteristics are summarized in Tables 4a and 4b
for the 86 subjects who completed the study. Independent samples t-tests revealed no
significant differences between the treatment and placebo groups.
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Table 4a. Comparison of treatment and placebo groups at baseline (February 2005)
in the 86 subjects who completed the study.
Treatment Group
Placebo Group
p
n
Mean ± SD
n
Mean ± SD
Age (y)
55
22.3 ± 3.1
31
23.2 ± 4.6
NS
2
BMI (kg/m )
55
25.5 ± 4.8
31
26.5 ± 5.7
NS
Total body fat (%)
55
29.8 ± 7.3
31
30.6 ± 7.9
NS
Height (cm)
55
164.7 ± 6.2
31
163.3 ± 7.7
NS
Weight (kg)
55
69.3 ± 14.1
31
70.4 ± 13.8
NS
2004 Summer sun exposure
55
15.4 ± 9.3
31
18.1 ± 8.9
NS
(h/wk)
Serum 25(OH)D (nmol/L)
55
62.1 ± 24.0
31
61.9 ± 22.6
NS
Serum PTH (pg/mL)
55
29.7 ± 9.1
31
32.9 ± 14.4
NS
Serum calcium (mg/dL)
55
9.8 ± 0.27
31
9.7 ± 0.25
NS
Urine calcium:creatinine
55
0.149 ± .0.80
31
0.127 ± 0.086
NS
Oral contraceptive use (y)
55
1.8 ± 2.0
31
2.5 ± 3.7
NS
Compliance (%)
55
97.5 ± 11.4
31
96.1 ± 13.6
NS
Treatment and placebo groups were compared with use of independent samples t-tests.
Table 4b. Comparison of the daily intake from food at baseline (February 2005)
between the treatment and placebo groups in the 86 subjects who completed the
study.
Treatment Group
Placebo Group
p
n
Mean ± SD
n
Mean ± SD
Calories (kcal/d)
55
1729 ± 451
31
1778 ± 438
NS
Protein (g/d)
55
67.0 ± 19.2
31
68.1 ± 19.3
NS
Sodium (mg/d)
55
2899 ± 941
31
2970 ± 1048
NS
Calcium (mg/d)
55
892 ± 385
31
937 ± 360
NS
Vitamin D (IU/d)
55
138 ± 125
31
140 ± 104
NS
Treatment and placebo groups were compared with use of independent samples t-tests.
Baseline Serum 25(OH)D Levels
Thirty-eight percent of the subjects were vitamin D deficient (serum 25(OH)D
levels less than 50 nmol/L), 33% were vitamin D insufficient (serum 25(OH)D 50 to 74
nmol/L), and 29% had optimal vitamin D levels (serum 25(OH)D levels at least 75
nmol/L). Pearson’s chi-square revealed no significant differences in the percent of
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subjects in the treatment and placebo groups with optimal, insufficient, or deficient serum
25(OH)D levels at baseline (Figure 3). Independent samples t-tests showed no
significant differences in mean serum 25(OH)D levels between the groups (Table 5).

Randomization

Percent of Subjects in Each Group

50.0%

Placebo
Vitamin D
40.0%

30.0%

20.0%

10.0%

0.0%
< 50 nmol/L

50 - 74.9 nmol/L

>=75 nmol/L

Category of Baseline 25(OH)D

Figure 3. Frequency of vitamin D sufficiency, insufficiency, and deficiency at
baseline (February 2005) in the 86 subjects who completed the study.
Table 5. Comparison of mean serum 25(OH)D levels in the placebo and treatment
groups by level of baseline serum 25(OH)D levels.
Placebo Group
Treatment Group
Baseline Serum 25(OH)D
Mean Serum
Mean Serum
Category
25(OH)D ± SD
25(OH)D ± SD
n
(nmol/L)
n
(nmol/L)
<50 nmol/L
14 40.8 ± 5.0
19 37.7 ± 8.6
50 – 74 nmol/L
7 65.1 ± 7.1
21 62.3 ± 8.1
≥75 nmol/L
10 89.0 ± 11.0
15 92.7 ± 14.9
Mean 25(OH)D levels were compared with use of independent sample t-tests.
Percent of subjects in treatment versus placebo groups were compared using Pearson’s
chi-square test, with no significant differences.
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Hormonal Contraceptives
Thirty-four subjects (62%) in the treatment group and 24 (77%) in the placebo
group used hormonal contraceptives. Pearson chi-square analysis indicated there was no
significant difference in the percent of subjects using hormonal contraceptives in the
treatment group compared to the placebo group. Baseline serum 25(OH)D levels were
not significantly different between the placebo and treatment groups for the subjects not
on hormonal contraceptives, on the low or high estrogen doses, or for the hormonal
contraceptive users overall (Table 6a). However, serum 25(OH)D levels were
significantly higher in the subjects in the medium estrogen dose group who were in the
treatment group compared to the placebo group (Table 6a). Serum 25(OH)D levels were
significantly higher in hormonal contraceptive users than in non-users, and analysis of
variance showed that serum 25(OH)D levels increased as exogenous estrogen dose
increased (Table 6b). Serum 25(OH)D levels and exogenous estrogen dose were
positively correlated (r = 0.463, p < 0.0005). Ninety-seven percent of non-hormonal
contraceptive users compared to 51% of hormonal contraceptive users had serum
25(OH)D levels less than 75 nmol/L at baseline (February 2005).

75

Table 6a. Comparison of baseline (February 2005) serum 25(OH)D levels between
the treatment and placebo groups among levels of exogenous estrogen exposure in
the 86 subjects who completed the study.
Treatment Group
Placebo Group
Mean 25(OH)D ± SD
Mean 25(OH)D ± SD
p
n
(nmol/L)
n
(nmol/L)
Non-hormonal
21
49.0 ± 16.0
7
46.1 ± 11.1
NS
contraceptive users
Hormonal
34
70.2 ± 24.8
24
66.5 ± 23.2
NS
contraceptive users
Non-hormonal
21
49.0 ± 16.0
7
46.1 ± 11.1
NS
contraceptive users
Low exogenous
6
46.5 ± 7.6
3
55.6 ± 17.7
NS
estrogen (15 μg/d)
Medium exogenous
9
80.2 ± 22.6
6
52.0 ± 16.0
0.021
estrogen (20-25 μg/d)
High exogenous
19
72.9 ± 25.2
15
74.4 ± 23.7
NS
estrogen (>25 μg/d)
Treatment and placebo groups were compared with use of independent samples t-tests.
Table 6b. Baseline (February 2005) serum 25(OH)D levels among levels of
exogenous estrogen exposure in the 86 subjects who completed the study.
Mean 25(OH)D ± SD
n
(nmol/L)
p
Non-hormonal contraceptive users
28
48.3 ± 14.8
<0.0005
Hormonal contraceptive users
58
68.6 ± 24.0
A Non-hormonal contraceptive users
28
48.3 ± 14.8
B Low exogenous estrogen (15 μg/d)
9
49.5 ± 11.6
<0.0005
C Medium exogenous estrogen (20-25 μg/d)
15
68.9 ± 24.2
D High exogenous estrogen (>25 μg/d)
34
73.6 ± 24.2
Mean 25(OH)D levels were compared among estrogen doses with use of ANOVA.
Tukey’s post-hoc analysis: A,C (p = 0.012); A,D (p < 0.0005); B,D (p = 0.013); B,C (p =
0.121)
Body Mass Index
Pearson chi-square analysis shows no significant differences in the percent of
subjects in the treatment group compared to the placebo group who were of healthy
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weight, overweight, or obese according to their BMI (Figure 4). Serum 25(OH)D levels
did not differ between treatment and control groups among the three BMI categories
(Table 7a). There was a significant inverse correlation between baseline serum 25(OH)D
levels and BMI (r = -0.383, p < 0.0005), and serum 25(OH)D levels are significantly
lower in the obese subjects compared to the healthy-weight subjects (Table 7b).
Randomization

60.0%

Placebo
Vitamin D

Percent of Subjects

50.0%

40.0%

30.0%

20.0%

10.0%

0.0%
<25

25-30

>30

Baseline BMI

Figure 4. Percent of subjects of healthy weight, overweight, and obese at baseline
(February 2005) in the 86 subjects who completed the study.
Table 7a. Comparison of baseline (February 2005) serum 25(OH)D levels between
the treatment and placebo groups among BMI categories in the 86 subjects who
completed the study.
Treatment Group
Placebo Group
Mean 25(OH)D ± SD
Mean 25(OH)D ± SD
BMI
p
n
(nmol/L)
n
(nmol/L)
<25 kg/m2
29
68.8 ± 24.6
17
70.0 ± 21.3
NS
2
25 – 30 kg/m
18
61.6 ± 21.2
7
54.7 ± 25.4
NS
2
>30 kg/m
8
39.1 ± 11.9
7
49.1 ± 16.3
0.191
Treatment and placebo groups were compared with use of independent samples t-tests.
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Table 7b. Baseline (February 2005) serum 25(OH)D levels among BMI categories in
the 86 subjects who completed the study.
Mean 25(OH)D ± SD
BMI
n
(nmol/L)
p
2
A
<25 kg/m
46
69.2 ± 23.2
2
0.001
B
25 – 30 kg/m
25
59.7 ± 22.1
C
>30 kg/m2
15
43.8 ± 14.6
Mean 25(OH)D levels were compared among levels of BMI with use of ANOVA.
Tukey’s post-hoc analysis: A,C (p < 0.0005); B,C (p = 0.069); A,B (p = 0.184).
Percent Body Fat
There was no significant difference in serum 25(OH)D levels (Table 8a) in the
treatment group compared to the placebo group among tertiles of percent body fat. There
was a significant inverse correlation between baseline serum 25(OH)D levels and percent
body fat (r = -0.405, p < 0.0005) and serum 25(OH)D levels were significantly lower in
subjects in the highest tertile of body fat compared to those in the lower tertiles (Table
8b).
Table 8a. Comparison of baseline (February 2005) serum 25(OH)D levels between
treatment and placebo groups among tertiles of body fat in the 86 subjects who
completed the study.
Treatment Group
Placebo Group
Percent Body Fat
Mean 25(OH)D ± SD
Mean 25(OH)D ± SD
Tertile
p
n
(nmol/L)
n
(nmol/L)
<26%
19
69.8 ± 22.7
9
67.5 ± 22.4
NS
26 – 33%
17
68.3 ± 25.4
12
71.1 ± 22.4
NS
>33%
19
48.9 ± 18.9
10
45.8 ± 14.6
NS
Treatment and placebo groups were compared with use of independent samples t-tests.
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Table 8b. Baseline (February 2005) serum 25(OH)D levels among tertiles of body
fat in the 86 subjects who completed the study.
Percent Body Fat
Mean 25(OH)D ± SD
Tertile
n
(nmol/L)
p
A
<26%
28
69.0 ± 22.2
<0.0005
B
26 – 33%
29
69.4 ± 23.8
C
>33%
29
47.8 ± 17.3
Mean 25(OH)D levels were compared among tertiles of body fat with use of ANOVA.
Significant differences (Tukey’s post-hoc analysis): A,C (p = 0.001); B,C (p = 0.001).
Weight
There was no significant difference in baseline serum 25(OH)D levels between
the treatment and placebo group among the tertiles of body weight (Table 9a). Weight
was inversely correlated with serum 25(OH)D levels (r = -0.302, p = 0.005). However,
serum 25(OH)D levels did not differ among the tertiles of body weight (Table 9b).
Table 9a. Comparison of baseline (February 2005) serum 25(OH)D levels between
treatment and placebo groups among tertiles of body weight in the 86 subjects who
completed the study.
Treatment Group
Placebo Group
Baseline Body
Mean 25(OH)D ± SD
Mean 25(OH)D ± SD
p
Weight Tertile
n
(nmol/L)
n
(nmol/L)
<62.5 kg
21
65.1 ± 22.0
8
69.3 ± 22.4
NS
62.5 – 71 kg
16
62.5 ± 27.3
14
66.2 ± 22.2
NS
>71 kg
18
58.2 ± 24.0
9
48.5 ± 19.9
NS
Treatment and placebo groups were compared with use of independent samples t-tests.
Table 9b. Baseline (February 2005) serum 25(OH)D levels among tertiles of body
weight in the 86 subjects who completed the study.
Mean 25(OH)D ± SD
Baseline Body Weight Tertile
n
(nmol/L)
p
<62.5 kg
29
66.3 ± 21.8
0.170
62.5 – 71 kg
30
64.2 ± 24.7
>71 kg
27
55.0 ± 22.8
Mean 25(OH)D levels were compared among tertiles of weight with use of ANOVA.
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Skin Type
Skin types II and III made up 76% of the overall group (Figure 5). There were no
significant differences in the frequency of each skin type between the treatment and
placebo groups. Within each skin type there was no difference in serum 25(OH)D level
between the treatment and placebo groups (Table 10a). Skin type was not significantly
correlated with serum 25(OH)D levels in February 2005 (r = 0.181, p = 0.095), nor was
there a significant difference in serum 25(OH)D levels among skin types (Table 10b).

1
1% 4
5%

16
18%

Skin Type
1 Ext Fair
2 Fair
3 Medium

23
27%

4 Olive / L
Brown
5 Brown

42
49%

Figure 5. Frequency of skin type at baseline (February 2005) in the 86 subjects who
completed the study.
Table 10a. Comparison of baseline (February 2005) serum 25(OH)D levels between
the treatment and placebo groups among skin types in the 86 subjects who
completed the study.
Treatment Group
Placebo Group
Skin Type
Mean 25(OH)D ±
Mean 25(OH)D ± SD
p
n
SD (nmol/L)
n
(nmol/L)
I Extremely fair
2
28.8 ± 16.6
2
65.6 ± 43.0
NS
II Fair
13
60.7 ± 23.5
10
58.2 ± 22.2
NS
III Medium
29
62.6 ± 24.2
13
59.1 ± 23.8
NS
IV Olive or Light brown 10
70.8 ± 22.7
6
72.8 ± 16.0
NS
V Brown
1
46.3
Treatment and placebo groups were compared with use of independent samples t-tests.
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Table 10b. Baseline (February 2005) serum 25(OH)D levels among skin types in the
86 subjects who completed the study.
Mean 25(OH)D ± SD
Skin Type
n
(nmol/L)
p
I Extremely fair
4
47.2 ± 34.1
II Fair
23
59.6 ± 22.5
NS
III Medium
42
61.5 ± 23.8
IV Olive or Light brown
16
71.5 ± 19.9
V Brown
1
46.3
Mean 25(OH)D levels were compared among skin type with use of ANOVA.
Tanning Bed Use
Seven (13%) subjects in the treatment group and four (13%) subjects in the
placebo group used a tanning salon prior to having their blood drawn in February 2005.
There was no significant difference in mean 25(OH)D levels between the treatment and
placebo groups (Table 11a). Although subjects who used a tanning salon had higher
serum 25(OH)D levels than did those who did not use a tanning salon, independent
samples t-tests revealed this difference was not significant (Table 11b).
Table 11a. Baseline (February 2005) serum 25(OH)D levels between the treatment
and placebo groups among users and non-users of tanning beds during winter 20042005 in the 86 subjects who completed the study.
Treatment Group
Placebo Group
Mean 25(OH)D ± SD
Mean 25(OH)D ± SD
p
n
(nmol/L)
n
(nmol/L)
No tanning bed use –
48
59.4 ± 22.6
27
61.5 ± 23.1
NS
Winter 2004-2005
Tanning bed use –
7
80.2 ± 27.3
4
64.1 ± 21.6
NS
Winter 2004-2005
Treatment and placebo groups were compared with use of independent samples t-tests.
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Table 11b. Baseline (February 2005) serum 25(OH)D levels among users and nonusers of tanning beds during winter 2004-2005 in the 86 subjects who completed the
study.
Mean 25(OH)D ± SD
n
(nmol/L)
p
No tanning bed use –
75
60.2 ± 22.7
Winter 2004-2005
0.061
Tanning bed use –
11
74.3 ± 25.6
Winter 2004-2005
Subject groups were compared with use of independent samples t-tests.
Summer Sun Exposure
There were no significant differences in serum 25(OH)D levels between the
treatment and placebo groups in any tertile of summer sun exposure (Table 12a).
Summer sun exposure and serum 25(OH)D levels were positively correlated (r = 0.229,
p = 0.034). However, analysis of variance showed that the increase in serum 25(OH)D
levels among tertiles of sun exposure was not significant (Table 12b).
Table 12a. Comparison of baseline (February 2005) serum 25(OH)D levels between
the treatment and placebo groups among tertiles of weekly sun exposure during
summer 2004 in the 86 subjects who completed the study.
Treatment Group
Placebo Group
Summer Sun
Mean 25(OH)D ± SD
Mean 25(OH)D ± SD
Exposure
p
n
(nmol/L)
n
(nmol/L)
<11 h/wk
22
57.9 ± 22.6
7
58.75 ± 24.6
NS
11 – 20 h/wk
17
60.6 ± 19.8
12
63.9 ± 23.5
NS
>20 h/wk
16
69.5 ± 29.2
12
61.6 ± 22.4
NS
Treatment and placebo groups were compared with use of independent samples t-tests.
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Table 12b. Baseline (February 2005) serum 25(OH)D levels among tertiles of
weekly sun exposure during summer 2004 in the 86 subjects who completed the
study.
Mean 25(OH)D ± SD
Summer Sun Exposure
n
(nmol/L)
p
<11 h/wk
29
58.11 ± 22.7
NS
11 – 20 h/wk
29
62.0 ± 21.1
>20 h/wk
28
66.1 ± 26.4
Mean 25(OH)D levels were compared among tertiles of sun exposure with use of
ANOVA.
Dietary Vitamin D Intake
There was no significant difference in serum 25(OH)D levels between the
treatment and placebo groups in any tertile of dietary vitamin D intake (Table 13a).
There was no correlation between serum 25(OH)D and vitamin D intake, nor did serum
25(OH)D levels differ significantly among tertiles of vitamin D intake (Table 13b).
Table 13a. Comparison of baseline (February 2005) serum 25(OH)D levels between
the treatment and placebo groups among tertiles of dietary vitamin D intake in the
86 subjects who completed the study.
Treatment Group
Placebo Group
Dietary Vitamin D
Mean 25(OH)D ± SD
Mean 25(OH)D ± SD
Tertile
p
n
(nmol/L)
n
(nmol/L)
<73 IU/d
20
60.7 ± 28.0
8
56.3 ± 26.2
NS
73 – 159 IU/d
17
65.7 ± 26.7
13
60.6 ± 22.9
NS
>159 IU/d
18
60.3 ± 16.4
10
68.0 ± 20.0
NS
Treatment and placebo groups were compared with use of independent samples t-tests.
Table 13b. Baseline (February 2005) serum 25(OH)D levels among tertiles of
dietary vitamin D intake in the 86 subjects who completed the study.
Mean 25(OH)D ± SD
Dietary Vitamin D Tertile
n
(nmol/L)
p
<73 IU/d
28
59.4 ± 27.1
NS
73 – 159 IU/d
30
63.5 ± 24.8
>159 IU/d
28
63.0 ± 17.8
Mean 25(OH)D levels were compared among tertiles of vitamin D intake with use of
ANOVA.
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Dietary Calcium Intake
There was no significant difference in serum 25(OH)D levels between the
treatment and placebo groups in any tertile of dietary calcium intake (Table 14a). There
was no correlation between serum 25(OH)D and calcium intake, nor did serum 25(OH)D
levels differ significantly among tertiles of calcium intake (Table 14b).
Table 14a. Comparison of baseline (February 2005) serum 25(OH)D levels between
the treatment and placebo groups among tertiles of dietary calcium intake in the 86
subjects who completed the study.
Treatment Group
Placebo Group
Dietary Calcium
Mean 25(OH)D ± SD
Mean 25(OH)D ± SD
Intake
p
n
(nmol/L)
n
(nmol/L)
<703 mg/d
20
63.3 ± 28.5
9
59.8 ± 28.4
NS
703 – 983 mg/d
19
65.1 ± 23.8
11
57.1 ± 20.1
NS
>983 mg/d
16
57.1 ± 18.0
11
68.3 ± 20.4
NS
Treatment and placebo groups were compared with use of independent samples t-tests.
Table 14b. Baseline (February 2005) serum 25(OH)D levels among tertiles of
dietary calcium intake in the 86 subjects who completed the study.
Mean 25(OH)D ± SD
Dietary Calcium Intake
n
(nmol/L)
p
<703 mg/d
29
62.1 ± 28.0
NS
703 – 983 mg/d
30
62.2 ± 22.5
>983 mg/d
27
61.7 ± 19.4
Mean 25(OH)D levels were compared among tertiles of calcium intake with use of
ANOVA.
Alcohol Consumption
Alcohol consumption was positively associated with serum 25(OH)D levels (r =
0.221, p = 0.040). Among tertiles of alcohol consumption, serum 25(OH)D levels did not
differ significantly between the treatment and placebo groups (Table 15a). Analysis of
variance revealed significant differences in serum 25(OH)D levels between the lowest
and highest tertiles of alcohol consumption (Table 15b).
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Table 15a. Comparison of baseline (February 2005) serum 25(OH)D levels between
the treatment and placebo groups among tertiles of alcohol consumption in the 86
subjects who completed the study.
Treatment Group
Placebo Group
Mean 25(OH)D ± SD
Mean 25(OH)D ± SD
p
n
(nmol/L)
n
(nmol/L)
0 drinks/wk
18
51.1 ± 20.0
12
58.1 ± 22.5
NS
0.5 - 3 servings/wk 20
59.1 ± 18.5
11
65.4 ± 20.7
NS
>3 servings/wk
17
77.3 ± 26.9
8
62.7 ± 27.2
NS
Treatment and placebo groups were compared with use of independent samples t-tests.
Table 15b. Baseline (February 2005) serum 25(OH)D levels among tertiles of
alcohol consumption in the 86 subjects who completed the study.
Mean 25(OH)D ± SD
Alcohol Intake
n
(nmol/L)
p
0 drinks/wk
30
53.9 ± 20.9*
0.011
0.5 - 3 servings/wk
31
61.3 ± 19.2
>3 servings/wk
25
72.6 ± 27.3*
Mean 25(OH)D levels were compared among tertiles of alcohol consumption with use of
ANOVA.
*Tukey’s post-hoc analysis: p = 0.008
Smoking
Ninety-three percent (51/55) of the treatment group and 97% (30/31) of the
placebo group did not smoke cigarettes. Four subjects (3 in the treatment group and 1 in
the placebo group) smoked less than half a pack of cigarettes per day. One subject in the
treatment group smoked more than one pack of cigarettes per day. Serum 25(OH)D
levels were not significantly different between the placebo and treatment groups among
smokers and non-smokers (Table 16a). There was a trend toward an inverse relationship
between smoking and serum 25(OH)D levels (r = -0.180, p = 0.097). Serum 25(OH)D
levels, however, were not significantly different between smokers and non-smokers
(Table 16b).
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Table 16a. Comparison of baseline (February 2005) serum 25(OH)D levels between
the treatment and placebo groups among smokers and non-smokers in the 86
subjects who completed the study.
Treatment Group
Placebo Group
Mean 25(OH)D ± SD
Mean 25(OH)D ± SD
p
n
(nmol/L)
n
(nmol/L)
Non-smokers
51
63.0 ± 24.3
30
62.9 ± 22.3
NS
Smokers
4
50.0 ± 17.4
1
32.0
NS
Treatment and placebo groups were compared with use of independent samples t-tests.
Table 16b. Baseline (February 2005) serum 25(OH)D levels among smokers and
non-smokers in the 86 subjects who completed the study.
Mean 25(OH)D ± SD
n
(nmol/L)
p
Non-smokers
81
63.0 ± 23.5
0.125
Smokers
5
46.4 ± 17.1
Subject groups were compared with use of independent samples t-tests.
Serum PTH
There were no significant differences in serum PTH levels between the treatment
and placebo groups among tertiles of serum 25(OH)D levels (Table 17a). There was no
significant correlation between baseline serum PTH levels and serum 25(OH)D levels,
nor were there any significant differences in serum PTH levels among tertiles of serum
25(OH)D at baseline (Table 17b).
Table 17a. Comparison of baseline (February 2005) serum PTH levels between the
treatment and placebo groups among tertiles of serum 25(OH)D levels in the 86
subjects who completed the study.
Treatment Group
Placebo Group
Baseline Serum
Mean PTH ± SD
Mean PTH ± SD
25(OH)D Tertiles
p
n
(pg/mL)
n
(pg/mL)
Lowest tertile
16
32.6 ± 7.2
12
33.5 ± 16.1
NS
(<47 nmol/L)
Middle tertile
20
27.6 10.2
9
32.0 ± 15.9
NS
(47 – 72.4 nmol/L)
Highest tertile
19
29.5 ± 9.1
10
33.1 ± 12.0
NS
(≥72.5 nmol/L)
Treatment and placebo groups were compared with use of independent samples t-tests.
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Table 17b. Baseline (February 2005) serum PTH levels among tertiles of serum
25(OH)D in the 86 subjects who completed the study.
Baseline Serum 25(OH)D Tertiles
Mean PTH ± SD
n
(pg/mL)
p
A Lowest tertile (<47 nmol/L)
28
33.0 ± 11.6
NS
B Middle tertile (47 – 72.4 nmol/L)
29
29.0 ± 12.2
C Highest tertile (≥72.5 nmol/L)
29
30.7 ± 10.1
Mean PTH levels were compared among tertiles of baseline 25(OH)D levels with use of
ANOVA.
Menstrual Cycle
Serum 25(OH)D levels did not differ between treatment and placebo groups
during any phase of the menstrual cycle (Table 18a), nor did serum 25(OH)D levels
differ among menstrual cycle phases (Table 18b). However, there was a positive
correlation between day of menstrual cycle and serum 25(OH)D levels (r = 0.319, p =
0.003).
Table 18a. Comparison of baseline (February 2005) serum 25(OH)D levels between
the treatment and placebo groups among three menstrual cycle phases in the 86
subjects who completed the study.
Treatment Group
Placebo Group
Mean 25(OH)D ± SD
Mean 25(OH)D ± SD
p
n
(nmol/L)
n
(nmol/L)
Days* 0 – 10
19
59.2 ± 22.2
7
73.7 ± 23.5
0.160
Days* 11 – 20
20
64.1 ± 23.6
12
64.5 ± 26.1
NS
Days* 21 - 35
11
63.7 ± 21.7
9
50.8 ± 14.4
0.143
*Day of menstrual cycle on which blood was drawn for 25(OH)D analysis.
Treatment and placebo groups were compared with use of independent samples t-tests.
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Table 18b. Baseline (February 2005) serum 25(OH)D levels among three menstrual
cycle phases in the 86 subjects who completed the study.
Mean 25(OH)D ± SD
n
(nmol/L)
p
Days* 0 – 10
26
63.1 ± 23.0
NS
Days* 11 – 20
32
64.2 ± 24.2
Days* 21 – 35
20
57.9 ± 19.5
*Day of menstrual cycle on which blood was drawn for 25(OH)D analysis.
Mean 25(OH)D levels were compared among menstrual cycle phase with use of
ANOVA.
Number of Days with a Cold
The number of days with a cold is being used as a rough estimate of subjects’
immune status. Eighty-five out of 86 subjects completed this question on the
questionnaire. Serum 25(OH)D levels differed significantly between treatment and
placebo groups in the highest tertile of the number of days with a cold, but were not
significantly different in the lower two tertiles (Table 19a). Serum 25(OH)D levels did
not differ among tertiles of the number of cold days (Table 19b). There was no
correlation between the number of cold days and serum 25(OH)D levels.
Table 19a. Comparison of baseline (February 2005) serum 25(OH)D levels between
the treatment and placebo groups among tertiles of number of days with a cold in 85
of the 86 subjects who completed the study.
Treatment Group
Placebo Group
Mean 25(OH)D ± SD
Mean 25(OH)D ± SD
p
n
(nmol/L)
n
(nmol/L)
0 to 0.66 days
18
67.2 ± 23.9
10
58.5 ± 21.0
NS
0.67 to 7 days
19
64.3 ± 28.7
11
54.8 ± 23.5
NS
>7 days
17
53.7 ± 17.2
10
73.0 ± 21.0
0.015
Treatment and placebo groups were compared with use of independent samples t-tests.
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Table 19b. Baseline (February 2005) serum 25(OH)D levels among tertiles of
number of days with a cold in 85 of the 86 subjects who completed the study.
Mean 25(OH)D ± SD
n
(nmol/L)
p
0 to 0.66 d
28
64.1 ± 22.9
NS
0.67 to 7 d
30
60.8 ± 26.9
>7 d
27
60.8 ± 20.6
Mean 25(OH)D levels were compared among tertiles of days wit a cold with use of
ANOVA.
Variables Affecting Baseline Serum 25(OH)D Levels
Linear and logistic regression analyses were performed to determine which
factors influenced baseline serum 25(OH)D levels. Both methods identified estrogen
dose, percent body fat, and alcohol consumption to be significant predictors of baseline
serum 25(OH)D levels. In addition, logistic regression found the number of days with a
cold during winter 2004-2005 to be significant.
The advantage of using logistic regression is that the dependent variable, serum
25(OH)D level, can be categorized into optimal (≥75 nmol/L) and suboptimal (<75
nmol/L) levels, and one can determine which parameters predict optimal serum 25(OH)D
levels, which is especially useful to a clinician. The logistic regression results are
described below.
Logisitic regression analysis was used to predict the probability that the baseline
serum 25(OH)D levels would be greater than 75 nmol/L. A backward stepwise approach
was used for this analysis. In the backward stepwise model, all of the variables start in
the model and, in a stepwise fashion, one variable is eliminated at each step. Estrogen
dose, percent body fat, number of days with a cold, and alcohol consumption were the
predictors included in the final model.
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A test of the full model versus a model with constant only was statistically
significant, X2 (df = 4) = 42.661, p < 0.0005. Table 20a shows the logistic regression
coefficient, Wald test, and odds ratio for estrogen dose, percent body fat, number of days
with a cold, and alcohol consumption. Table 20b shows the logistic regression
coefficient and Wald test for the variables eliminated from the final model.
The model was able to correctly classify 86% of the subjects with serum
25(OH)D levels less than 75 nmol/L and 72% of those with levels greater than 75
nmol/L, with an overall success rate of 81% (Table 20c). Nagelkerke R2 was 0.577 and
-2 Log likelihood was 57.456. Fifty-eight percent of the variation in baseline serum
25(OH)D levels can be explained by the logistic regression model.
A Hosmer and Lemeshow Test was performed, X2 (df = 8) = 2.429, p < 0.965.
Therefore we did not reject the null hypothesis that the observed and predicted values are
the same and concluded that the model fits the data reasonably well.
Table 20a. Logistic regression predicting baseline serum 25(OH)D levels from
estrogen dose, percent body fat, number of days with a cold, and alcohol
consumption.
Variable
Beta
S.E.
Wald
p
Odds Ratio
Estrogen dose
0.164
0.043 14.503 <0.0005
1.179
Percent body fat
-0.103 0.057
3.304
0.069
0.902
Number of days with a cold
-0.141 0.060
5.460
0.019
0.869
Alcohol
0.240
0.109
4.866
0.027
1.272
Constant
-1.519 1.806
0.707
0.400
0.219
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Table 20b. Variables eliminated from the backward stepwise logistic regression
model predicting baseline serum 25(OH)D levels.
Step
Variable Eliminated
Beta coefficient Wald Coefficient P Value
1
Smoking
-59.815
0.000
0.999
2
Years of oral contraceptive use
-0.005
0.000
0.984
3
Sun exposure summer 2004
-0.003
0.007
0.933
4
Tanning bed use
-0.107
0.010
0.920
5
BMI
-0.015
0.008
0.929
6
Summer 25(OH)D increase
0.004
0.095
0.758
7
Age
0.040
0.103
0.748
8
Vitamin D from diet
-0.001
0.406
0.524
9
Calcium from diet
-0.001
0.406
0.524
10
Skin type
0.352
0.630
0.428
11
Day of menstrual cycle
0.035
0.962
0.327
Table 20c. Classification table.
Predicted
Observed

<75 nmol/L
48
7

<75 nmol/L
≥75 nmol/L

≥75 nmol/L
8
18

Sensitivity = 48/56 = 86%
Specificity = 18/25 = 72%
Positive Predictive Value = 48/55 = 87%
Negative Predictive Value = 18/26 = 69%
Total Correct = 66/81 = 81%
September 2005 Serum 25(OH)D Levels and the Seasonal Increase in Levels
In September 2005, the mean serum 25(OH)D level was 103.0 ± 33.2 nmol/L.
The mean seasonal summer increase was 41.0 ± 26.1 nmol/L. Seventy-seven percent of
subjects had optimal serum 25(OH)D levels (≥75 nmol/L); 22% had insufficient levels
(50 – 74 nmol/L); and no subjects had deficient levels (<50 nmol/L) at the end of the
summer.
There was no significant difference in September serum 25(OH)D levels or the
seasonal increase in serum 25(OH)D levels between the treatment and placebo groups
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(Table 21a). There was also no significant difference between treatment and placebo
groups regarding September serum 25(OH)D levels and the seasonal change when these
groups were further divided into hormonal contraceptive users (OCP+) and non-users
(OCP-; Table 21a). Hormonal contraceptive users had significantly higher September
serum 25(OH)D levels in the treatment group (p = 0.025) and in the placebo group (p =
0.007) compared with non-users. The seasonal summer increase did not differ
significantly between hormonal contraceptive users in the treatment group (p = 0.362) or
in the placebo group (p = 0.090) (Table 21a), or in the overall group (Table 21b). Nor
did the seasonal change differ significantly among doses of estrogen (Table 21b).
Table 21a. Comparison of the September serum 25(OH)D levels and the seasonal
summer increase in serum 25(OH)D levels between treatment and placebo groups in
the 86 subjects who completed the study.
Treatment Group
Placebo Group
p
n
(nmol/L)
n
(nmol/L
Total
55
104.7 ± 33.1
31
100.2 ± 33.7
NS
September
OCP-* 27
94.6 ± 25.0
10
77.2 ± 21.32
0.059
25(OH)D
OCP+* 28
114.4 ± 37.3
21
111.1 ± 33.4
NS
Total
55
42.6 ± 27.9
31
38.3 ± 22.7
NS
OCP-* 27
46.1 ± 25.6
10
28.3 ± 24.7
0.065
OCP+* 28
39.2 ± 30.1
21
43.1 ± 20.6
NS
*OCP- group includes individuals with ≤15 μg daily estrogen (contraceptive patch and
ring users)
Treatment and placebo groups were compared with use of independent samples t-tests.
Seasonal summer
increase
in 25(OH)D
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Table 21b. Seasonal increase in serum 25(OH)D levels among levels of estrogen
dose in the 86 subjects who completed the study.
Summer Increase in Serum 25(OH)D
Estrogen Dose
n
(nmol/L)
p
Non-oral contraceptive users*
37
41.3 ± 26.3
NS
Oral contraceptive users
49
40.9 ± 26.3
Non-oral contraceptive users*
28
40.9 ± 25.5
Low-exogenous estrogen (15
9
42.6 ± 30.1
μg/d)
Medium exogenous estrogen
15
48.8 ± 29.4
(20-25 μg/d)
High exogenous estrogen (>25
34
37.3 ± 24.4
μg/d)
*Non-oral contraceptive users include individuals with ≤15 μg daily estrogen
(contraceptive patch and ring users).
Subject groups were compared with use of independent samples t-tests.
Mean 25(OH)D levels were compared among levels of estrogen dose with use of
ANOVA.

NS

Pearson correlations were performed between the magnitude of seasonal change
in serum 25(OH)D levels and estrogen dose, percent body fat, baseline serum 25(OH)D
levels, skin type, and summer sun exposure. There was a significant inverse relationship
between skin type and seasonal change (r = -0.282, p = 0.009). Individuals with darker
skin pigmentation experienced less seasonal increase in serum 25(OH)D levels than did
those with lighter skin. One-way analysis of variance with Tukey’s post-hoc analysis
identified significant differences between September serum 25(OH)D levels in subjects
with extremely fair skin and those with light brown skin (Table 22). There were no
significant correlations between the seasonal change in serum 25(OH)D levels and
estrogen dose, percent body fat, baseline serum 25(OH)D levels, or summer sun
exposure.
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Table 22. Seasonal change in serum 25(OH)D levels among skin types in the 86
subjects who completed the study.
Skin Type
n Summer Increase in Serum 25(OH)D (nmol/L)
p
I Extremely fair
4
73.9 ± 7.7*
II Fair
23
42.5 ± 32.7
0.028
III Medium
42
41.7 ± 21.6
IV Olive / Light brown 16
30.7 ± 23.6*
V Brown
1
15.3
Mean 25(OH)D levels were compared among skin type with use of ANOVA.
*Tukey’s post-hoc analysis: mean difference is significant (p = 0.015).
Logistic regression analysis was performed to determine which factors influenced
the summer seasonal increase in serum 25(OH)D levels. Logistic regression analysis was
used to predict the probability that the summer increase in serum 25(OH)D levels would
be at least 60 nmol/L. A backward stepwise approach was used for this analysis. Skin
type was the only predictor included in the final model.
A test of the full model versus a model with constant only was statistically
significant, X2 (df = 1) = 15.160, p < 0.0005. Table 23a shows the logistic regression
coefficient, Wald test, and odds ratio for skin type. Table 23b shows the logistic
regression coefficient and Wald test for the variables eliminated from the final model.
The model was able to correctly classify 100% of the subjects with a seasonal
change less than 60 nmol/L and 20% of those with a change greater than 60 nmol/L, with
an overall success rate of 95% (Table 23c). Nagelkerke R2 was 0.244 and -2 Log
likelihood was 78.124. Twenty-four percent of the variation in the seasonal change in
serum 25(OH)D levels was explained by the logistic regression model.
A Hosmer and Lemeshow Test was performed, X2 (df = 1) = 0.237, p < 0.627.
Therefore we did not reject the null hypothesis that the observed and predicted values
were the same and concluded that the model fits the data reasonably well.
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Table 23a. Logistic regression predicting the seasonal increase in serum 25(OH)D
levels from skin type.
Variable
Beta
S.E.
Wald
p
Odds Ratio
Skin type
-1.385 0.406 11.656
0.001
0.250
Constant
2.465
1.048
5.529
0.019
11.761
Table 23b. Variables eliminated from the backward stepwise logistic regression
model predicting the seasonal increase in serum 25(OH)D levels.
Step
Variable Eliminated
Beta coefficient Wald Coefficient P Value
1
Body fat
0.001
0.001
0.977
2
Sun exposure summer 2005
-0.005
0.032
0.859
3
Baseline serum 25(OH)D
0.012
0.705
0.401
4
Estrogen dose
-0.011
0.287
0.592
5
Sunscreen use
0.254
1.222
0.269
Table 23c. Classification table.
Predicted
<75 nmol/L
66
16

<75 nmol/L
≥75 nmol/L
Sensitivity = 66/66 = 100%
Specificity = 4/20 = 20%
Positive Predictive Value = 66/82 = 80%
Negative Predictive Value = 4/4 = 100%
Total Correct = 70/74 = 95%
Observed
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≥75 nmol/L
0
4

One-Year Change
Body mass index, percent body fat, weight, vitamin D intake, and urinary
calcium:creatinine ratio changed significantly between February 2005 and February 2006
(Table 24a). However, these changes were not significantly different between the
placebo and treatment groups (Table 24b).
Table 24a. Comparison of parameters in February 2005 and February 2006 in the
overall group (n=86).
February 2005
February 2006
n
Mean ± SD
Mean ± SD
p
2
BMI (kg/m )
85
25.8 ± 5.0
26.5 ± 5.5
<0.0005
Total body fat (%)
85
30.0 ± 7.5
31.3 ± 7.7
<0.0005
Weight (kg)
85
69.7 ± 14.0
71.8 ± 15.1
<0.0005
Vitamin D from diet (IU/d)
83
137 ± 118
103 ± 96
0.008
Summer sun exposure, 2004
86
16.3 ± 9.2
15.4 ± 9.3
NS
and 2005 (h/wk)
Serum calcium (mg/dL)
86
9.7 ± 0.26
9.8 ± 0.34
NS
Urine calcium:creatinine
86
0.141 ± 0.083
0.168 ± 0.113
0.046
Number of cold days
85
6.47 ± 7.45
5.48 ± 6.19
NS
Subject groups were compared with use of independent samples t-tests.
Table 24b. Comparison of one-year change in parameters between treatment and
placebo groups.
Treatment Group
Placebo Group
p
n
Mean ± SD
n
Mean ± SD
Change in BMI (kg/m2)
55 0.68 ± 1.23
30 0.96 ± 1.65
NS
Change in body fat (%)
55 1.19 ± 2.20
30 1.47 ± 2.26
NS
Change in weight (kg)
55 1.81 ± 3.49
30 2.5 ± 4.50
NS
Change in vitamin D intake (IU/d) 53 -46.3 ± 116.3 30 -13.2 ± 111.7 0.211
Change in sun exposure (h/wk)
55 -0.296 ± 11.5 31 -2.05 ± 7.73
NS
Change in serum calcium (mg/dL) 55 -0.012 ± 0.397 31 0.118 ± 0.398 0.150
Change in urine calcium:creatinine 55 0.010 ± 0.127 31 0.056 ± 0.111 0.095
Change in number of cold days
54 -0.893 ± 8.12 31 -1.17 ± 8.46
NS
Treatment and placebo groups were compared with use of independent samples t-tests.
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Tolerance to Vitamin D Supplementation
Serum calcium and urinary calcium and creatinine levels were measured to
monitor tolerance to the supplementation. Mean serum calcium levels and the urinary
calcium to creatinine ratios were not significantly different between the placebo group
and the treatment group after five months of supplementation with 800 IU vitamin D3
(Table 25a). There was no significant difference in serum calcium levels or the calcium
to creatinine ratio in the treatment group between February 2005 and February 2006
(Table 25b). In the placebo group, however, the urinary calcium to creatinine ratio
increased significantly from February 2005 (0.13 ± 0.09) to February 2006 (0.18 ± 0.14);
serum calcium levels did not change in the placebo group (data not shown). The oneyear change in serum calcium and in the urine calcium to creatinine ratio was not
significantly different between the treatment and placebo groups (Table 24b). After the
supplementation period, three subjects in the treatment group and four subjects in the
placebo group had urinary calcium to creatinine ratios above 0.40, indicating
hypercalciuria. However, all seven subjects had serum calcium levels within normal
limits.
Table 25a. Comparison of serum calcium levels and urinary calcium to creatinine
ratios in treatment and placebo groups after five month supplementation period.
Treatment Group
Placebo Group
p
Serum calcium (mg/dL)

55

9.7 ± 0.33

31

9.8 ± 0.37

NS

Urinary calcium to creatinine ratio
55
0.16 ± 0.10
31 0.18 ± 0.14 NS
Treatment and placebo groups were compared with use of independent samples t-tests.
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Table 25b. Comparison of serum calcium and urinary calcium to creatinine ratios
in the treatment group in February 2005 (before supplementation) and in February
2006, after five months of supplementation.
February 2005
February 2006
n = 55

n = 55

p

9.8 ± 0.27

9.7 ± 0.33

NS

Urinary calcium to creatinine ratio
0.15 ± 0.08
0.16 ± 0.10
Subject groups were compared with use of independent samples t-tests.

NS

Serum calcium (mg/dL)

Response to Supplementation
As seen in Table 26, serum 25(OH)D levels increased by 35.3 ± 23.2 nmol/L in
the treatment group between February 2005 and February 2006. In the placebo group,
serum 25(OH)D levels increased 10.9 ± 16.9 nmol/L. The net treatment effect was a 24.4
nmol/L increase in serum 25(OH)D levels.
Table 26. One-year change in serum 25(OH)D levels.
February
February
One-Year Change in Serum
2006
2005
25(OH)D Levels
25(OH)D
25(OH)D
(nmol/L)
(nmol/L)
(nmol/L)
n
†
†
97.4 ± 31.3*
35.3 ± 23.2*
Treatment 55 62.1 ± 24.0
†
†
31 61.9 ± 22.6
72.7 ± 27.8*
10.9 ± 16.9*
Placebo
*Treatment and placebo groups compared using independent samples t-tests, p < 0.0005.
†
February 2005 and February 2006 serum 25(OH)D levels compared using paired
samples t-tests, p < 0.0005.
The actual vitamin D3 content of the vitamin D capsules was measured by the
manufacturer at the time they were made (February 2005, 869 IU), and by an independent
laboratory at the beginning (September 2005, 956 IU) and end (April 2006, 832 IU) of
the supplementation period. The mean vitamin D3 content of the capsules was 885 IU
(22 μg). The net treatment effect of 24.4 nmol/L in those receiving 885 IU vitamin D3
daily corresponds to an increase of 1.1 nmol/L for every μg of supplemental vitamin D3
intake.
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Examination of Predictor Variables for Response to Supplementation in the
Treatment Group
Baseline Serum 25(OH)D Levels
There was no correlation between baseline (February 2005) serum 25(OH)D
levels and the one-year change in serum 25(OH)D levels, nor was there any significant
difference in the one-year change in serum 25(OH)D levels among categories of baseline
serum 25(OH)D levels in the treatment group (Table 27a). In the placebo group, there
was no significant difference in the one-year change in serum 25(OH)D levels among
categories of baseline serum 25(OH)D levels (Table 27b).
Table 27a. One-year change in serum 25(OH)D levels in the treatment group (n =
55) among categories of baseline serum 25(OH)D levels.
Baseline serum 25(OH)D level
One-Year Change in Serum
(nmol/L)
n
25(OH)D (nmol/L)
p
<50 nmol/L
19
34.6 ± 22.0
NS
50 – 75 nmol/L
21
40.0 ± 22.7
>75 nmol/L
15
29.6 ± 25.4
Mean changes in 25(OH)D levels were compared among categories of baseline serum
25(OH)D levels with use of ANOVA.
Table 27b. One-year change in serum 25(OH)D levels in the placebo group (n = 31)
among categories of baseline serum 25(OH)D levels.
Baseline serum 25(OH)D level
One-Year Change in Serum
(nmol/L)
n
25(OH)D (nmol/L)
p
<50 nmol/L
14
14.0 ± 17.6
NS
50 – 75 nmol/L
7
5.8 ± 16.3
>75 nmol/L
10
10.0 ± 16.9
Mean changes in 25(OH)D levels were compared among categories of baseline serum
25(OH)D levels with use of ANOVA.
Hormonal Contraceptive Use
There was no correlation between exogenous estrogen dose and the one-year
change in serum 25(OH)D levels in the treatment group. Analysis of variance revealed
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no difference in one-year change in serum 25(OH)D levels among levels of exogenous
estrogen dose in the treatment group, or in the placebo group (Table 28).
Table 28. One-year change in serum 25(OH)D levels in the treatment and placebo
groups among levels of exogenous estrogen exposure.
Treatment Group
Placebo Group
One-Year Change
One-Year Change
in Serum 25(OH)D
in Serum 25(OH)D
n
(nmol/L)
p
n
(nmol/L)
p
Non-hormonal
21
31.3 ± 21.2
7
12.1 ± 7.6
contraceptive users
NS
NS
Hormonal
34
37.8 ± 24.4
24
10.5 ± 18.9
contraceptive users
Non-hormonal
21
31.3 ± 21.2
7
12.1 ± 7.6
contraceptive users
Low exogenous
6
34.6 ± 19.3
3
4.8 ± 18.1
estrogen (15 μg/d)
NS
NS
Medium exogenous
9
32.9 ± 23.8
6
18.2 ± 26.3
estrogen
(20-25 μg/d)
High exogenous
19
41.0 ± 26.6
15
8.6 ± 18.0
estrogen (>25 μg/d)
Hormonal contraceptive users and non-users were compared with use of independent
samples t-tests.
Mean changes in 25(OH)D levels were compared among levels of estrogen use with use
of ANOVA.
Mean Body Mass Index
There was no correlation between mean BMI and the one-year change in serum
25(OH)D levels in the treatment group. There was no significant difference in the oneyear change in serum 25(OH)D levels among BMI categories in the treatment group
(Table 29), or in the placebo group (data not shown).
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Table 29. One-year change in serum 25(OH)D levels in the treatment group (n = 55)
among mean BMI categories.
One-Year Change in Serum
Mean BMI
n
25(OH)D (nmol/L)
p
2
<25 kg/m
26
37.7 ± 21.0
2
NS
25 – 30 kg/m
20
34.3 ± 27.6
>30 kg/m2
9
30.5 ± 20.1
Mean changes in 25(OH)D levels were compared among levels of BMI with use of
ANOVA.
Mean Percent Body Fat
There was no correlation between mean percent body fat and the one-year change
in serum 25(OH)D levels in the treatment group. There was not a significant difference
in the one-year change in serum 25(OH)D levels among tertiles of mean percent body fat
in the treatment group (Table 30a), or in the placebo group (Table 30b).
Table 30a. One-year change in serum 25(OH)D levels in the treatment group
among tertiles of mean body fat.
One-Year Change in Serum
Tertile of Mean Body Fat
n
25(OH)D (nmol/L)
p
<26%
19
39.3 ± 26.8
NS
26 – 33%
18
32.9 ± 22.9
>33%
18
33.4 ± 20.0
Mean changes in 25(OH)D levels were compared among tertiles of body fat with use of
ANOVA.
Table 30b. One-year change in serum 25(OH)D levels in the placebo group (n = 31)
among tertiles of mean body fat.
One-Year Change in Serum
Tertile of Mean Body Fat
n
25(OH)D (nmol/L)
p
<27%
10
9.3 ± 19.2
NS
27 – 34.9%
11
15.3 ± 17.2
≥35%
10
7.6 ± 14.7
Mean changes in 25(OH)D levels were compared among tertiles of body fat with use of
ANOVA.
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Mean Body Weight
There was no correlation between mean weight and the one-year change in serum
25(OH)D levels in the treatment group. There was no significant difference in the oneyear change in serum 25(OH)D levels among tertiles of mean weight in the treatment
group (Table 31), or in the placebo group (data not shown).
Table 31. One-year change in serum 25(OH)D levels in the treatment group (n = 55)
among tertiles of mean body weight.
One-Year Change in Serum
Mean Body Weight Tertile
n
25(OH)D (nmol/L)
p
<62 kg
18
36.0 ± 23.9
0.205
62 – 74 kg
19
41.5 ± 21.1
>74 kg
18
27.9 ± 23.8
Mean changes in 25(OH)D levels were compared among tertiles of weight with use of
ANOVA.
Skin Type
There was no correlation between skin type and the one-year change in serum
25(OH)D levels in the treatment group. There was no significant difference in the oneyear change in serum 25(OH)D levels among skin type classifications in the treatment
group (Table 32), or in the placebo group (data not shown).
Table 32. One-year change in serum 25(OH)D levels in the treatment group (n = 55)
among skin types.
Skin Type
n One-Year Change in Serum 25(OH)D (nmol/L)
p
I Extremely fair
2
35.1 ± 17.9
II Fair
13
36.8 ± 22.0
NS
III Medium
29
37.8 ± 25.8
IV Olive or Light brown 10
26.4 ± 19.0
V Brown
1
32.5
Mean changes in 25(OH)D levels were compared among skin type with use of ANOVA.
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Tanning Bed Use
As seen in Table 33, in the treatment group, subjects who only tanned during
winter 2005-2006 had a significantly higher one-year change in serum 25(OH)D levels
than did subjects who only tanned during winter 2004-2005. In the placebo group, there
was no significant difference in the one-year change in serum 25(OH)D levels according
to tanning bed use (data not shown).
Table 33. One-year change in serum 25(OH)D levels in the treatment group (n = 55)
among users and non-users of tanning beds.
One-Year Change in Serum
Tanning Bed Use
n
25(OH)D (nmol/L)
p
No tanning bed use
45
34.9 ± 22.0
Tanning bed use both winters
3
39.2 ± 3.4
Tanning bed use –
0.031
3
6.6 ± 19.0*
winter 2004-2005 only
Tanning bed use –
4
58.0 ± 28.9*
winter 2005-2006 only
Mean changes in 25(OH)D levels were compared among levels of tanning bed use with
use of ANOVA.
*Tukey’s post-hoc analysis: p = 0.017
Dietary Vitamin D Intake
There was no correlation between mean vitamin D intake and the one-year change
in serum 25(OH)D levels in the treatment group. There was no significant difference in
the one-year change in serum 25(OH)D levels among tertiles of mean vitamin D intake in
the treatment group (Table 34), or in the placebo group (data not shown).
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Table 34. One-year change in serum 25(OH)D levels in the treatment group (n = 55)
among tertiles of mean dietary vitamin D intake.
Mean Vitamin D
One-Year Change in Serum 25(OH)D
Intake
n
(nmol/L)
p
<56 IU
18
33.6 ± 16.8
0.199
56 – 125 IU
19
29.5 ± 24.8*
>125 IU
18
42.9 ± 26.0*
Mean changes in 25(OH)D levels were compared among levels of vitamin D intake with
use of ANOVA.
*Tukey’s post-hoc analysis: p = 0.184
Dietary Calcium Intake
There was no correlation between mean calcium intake and the one-year change
in serum 25(OH)D levels in the treatment group. There was no significant difference in
the one-year change in serum 25(OH)D levels among tertiles of mean calcium intake in
the treatment group (Table 35), or in the placebo group (data not shown).
Table 35. One-year change in serum 25(OH)D levels in the treatment group (n = 55)
among tertiles of mean dietary calcium intake.
Mean Calcium Intake n
One-Year Change in Serum 25(OH)D (nmol/L)
p
<725 mg/d
18
31.7 ± 13.9
NS
726 to 981 mg/d
19
35.8 ± 29.6
>981 mg/d
18
38.3 ± 23.7
Mean changes in 25(OH)D levels were compared among levels of calcium intake with
use of ANOVA.
Alcohol Consumption
There was no significant difference in the one-year change in serum 25(OH)D
levels among tertiles of alcohol consumption in the treatment group (Table 36), or in the
placebo group (data not shown).
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Table 36. One-year change in serum 25(OH)D levels in the treatment group (n = 55)
among tertiles of alcohol consumption.
One-Year Change in Serum
Tertile of Alcohol Consumption
n
25(OH)D (nmol/L)
p
0 drinks/wk
18
40.2 ± 18.8
NS
≤3 servings/wk
20
31.7 ± 26.6
>3 servings/wk
17
34.3 ± 23.7
Mean change in 25(OH)D levels were compared among tertiles of alcohol consumption
with use of ANOVA.
Smoking
There was no significant difference in the one-year change in serum 25(OH)D
levels between smokers and non-smokers in the treatment group (Table 37), or in the
placebo group (data not shown).
Table 37. One-year change in serum 25(OH)D levels in the treatment group (n = 55)
among smokers and non-smokers.
One-Year Change in Serum
Tobacco Use
n
25(OH)D (nmol/L)
p
Non-smokers
51
34.8 ± 22.8
NS
Smokers
4
41.0 ± 31.7
Subject groups were compared with use of independent samples t-tests.
Magnitude of Summer Increase in Serum 25(OH)D Levels
The seasonal summer increase in serum 25(OH)D levels was positively correlated
with the one-year change in serum 25(OH)D levels in the treatment group (r = 0.402, p =
0.002). Analysis of variance revealed significant increases in the one-year change in
serum 25(OH)D levels among tertiles of the summer increase in serum levels in the
treatment group (Table 38a), but not in the placebo group (Table 38b).
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Table 38a. One-year change in serum 25(OH)D levels in the treatment group (n =
55) among tertiles of magnitude of seasonal change.
Magnitude of Seasonal
One-Year Change in Serum
Change
n
25(OH)D (nmol/L)
p
<29 nmol/L
18
25.4 ± 21.0*
0.051
29 – 52 nmol/L
19
36.3 ± 21.1
>52 nmol/L
18
44.0 ± 24.7*
Mean changes in 25(OH)D levels were compared among tertiles of seasonal change with
use of ANOVA.
*Tukey’s post-hoc analysis: p = 0.041
Table 38b. One-year change in serum 25(OH)D levels in the placebo group (n = 31)
among tertiles of magnitude of seasonal change.
Magnitude of Seasonal
One-Year Change in Serum
Change
n
25(OH)D (nmol/L)
p
<27 nmol/L
10
4.0 ± 11.6
NS
27 – 42 nmol/L
11
16.0 ± 11.4
>42 nmol/L
10
12.1 ± 16.9
Mean changes in 25(OH)D levels were compared among tertiles of seasonal change with
use of ANOVA.
Serum PTH Concentration
There was no correlation between February 2006 serum PTH levels and the oneyear change in serum 25(OH)D levels. As seen in Table 39, February 2006 PTH levels in
the treatment group were significantly higher in subjects who started out in the lowest
tertile of baseline serum 25(OH)D levels compared to those in the highest tertile.
Furthermore, in the subjects who started out in the highest tertile of serum 25(OH)D
levels, serum PTH levels were significantly lower in February 2006, after the
supplementation period, than in February 2005. In the placebo group, the February 2005
and February 2006 PTH levels were not significantly different among tertiles of baseline
serum 25(OH)D levels, nor was the one-year change in PTH significantly different
among tertiles of baseline serum 25(OH)D levels (data not shown).
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Table 39. February 2006 serum PTH levels and the one-year change in serum PTH levels in the treatment group (n = 55)
among tertiles of baseline serum 25(OH)D levels from the overall group.
Baseline
February 2005
February 2006
February 2006
February 2005
One-year
serum
Mean Serum
Mean Serum
mean serum
mean serum
change in
25(OH)D
25(OH)D Levels
25(OH)D Levels
PTH levels
PTH levels
PTH levels
n
p
p
tertiles
(nmol/L)
(nmol/L)
(pg/mL)
(pg/mL)
p
(nmol/L)
Lowest tertile
A
16
37.4 ± 6.9
71.7 ± 25.7
36.2 ± 10.4*
32.6 ± 7.2
0.183
(< 47 nmol/L)
Middle tertile
0.004
NS
B
20
58.9 ± 8.3
97.6 ± 25.7
30.4 ± 11.3
27.6 ± 10.2
0.346
(47 – 72.4
nmol/L)
Highest tertile
C
19
88.8 ± 13.9
118.7 ± 25.1
23.5 ± 10.3*
29.5 ± 9.1
0.038
(≥ 72.5 nmol/L)
*Tukey’s post-hoc analysis: February 2006 PTH A,C (p = 0.003)
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Variables Affecting One-year Change in Serum 25(OH)D Levels
Linear and logistic regression techniques were used to determine which factors
predict the one-year change in serum 25(OH)D levels. Both methods identified the
treatment group, magnitude of the seasonal summer increase in 25(OH)D levels, estrogen
dose, and baseline serum 25(OH)D levels to be significant predictors of one-year change.
The logistic regression results are described below (Table 40a).
Logisitic regression analysis was used to predict the probability that the one-year
increase in serum 25(OH)D levels would be greater than 40 nmol/L. A backward
stepwise approach was used for this analysis. In the backward stepwise model, all of the
variables start in the model and, in a stepwise fashion, one variable is eliminated at each
step. Estrogen dose, summer increase in 25(OH)D levels, baseline 25(OH)D levels, and
treatment group were the predictors included in the final model.
A test of the full model versus a model with constant only was statistically
significant, X2 (df = 4) = 37.351, p < 0.0005. Table 40a shows the logistic regression
coefficient, Wald test, and odds ratio for estrogen dose, summer increase in 25(OH)D
levels, baseline 25(OH)D levels, and treatment. Table 40b shows the logistic regression
coefficient and Wald test for the variables eliminated from the final model.
The model was able to correctly classify 91% of the subjects with a change in
25(OH)D less than 40 nmol/L and 65% of those with a change in levels greater than 40
nmol/L, with an overall success rate of 83% (Table 40c). Nagelkerke R2 was 0.509 and 2 Log likelihood was 65.847. Fifty-one percent of the variation in one-year change can
be explained by the logistic regression model.
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A Hosmer and Lemeshow Test was performed, X2 (df = 8) = 9.572, p < 0.296.
Therefore we did not reject the null hypothesis that the observed and predicted values are
the same and concluded that the model fits the data reasonably well.
Table 40a. Logistic regression predicting the one-year change in serum 25(OH)D
levels from estrogen dose, summer serum 25(OH)D increase, baseline 25(OH)D
levels, and treatment category.
Variable
Beta
S.E.
Wald
p
Odds Ratio
Estrogen dose
0.073
0.028
6.581
0.010
1.075
Summer increase
0.045
0.014
10.227
0.001
1.046
Baseline 25(OH)D
-0.028
0.015
3.346
0.067
0.973
Treatment
3.338
0.928
12.948
<0.0005
28.170
Constant
-8.394
2.185
14.755
<0.0005
0.000
Table 40b. Variables eliminated from the backward stepwise logistic regression
model predicting one-year change in serum 25(OH)D levels.
Step
Variable Eliminated
Beta coefficient Wald Coefficient
p
1
Mean calcium intake
0.000
0.024
0.877
2
Skin type
-0.087
0.037
0.848
3
Mean body fat
-0.016
0.071
0.789
4
Change in serum calcium
0.374
0.136
0.713
5
Smoking
1.350
0.202
0.653
6
Change in vitamin D intake
0.002
0.224
0.636
7
Alcohol
-0.093
0.431
0.511
8
Change in calcium:creatinine
2.224
0.693
0.405
9
Days with a cold in 2006
0.051
0.859
0.354
10
Change in sun exposure
0.034
1.139
0.286
11
Tanning bed use 2005-2006
1.450
2.374
0.123
Table 40c. Classification table.
Predicted
Observed

<40 nmol/L
52
9

<40 nmol/L
≥40 nmol/L

Sensitivity = 52/57 = 91%
Specificity = 17/26 = 65%
Positive Predictive Value = 52/61 = 85%
Negative Predictive Value = 17/22 = 77%
Total Correct = 69/83 = 83%
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≥40 nmol/L
5
17

One-Year Change in Serum PTH Levels
Serum PTH followed a seasonal pattern, increasing during winter and decreasing
during summer. There were no significant differences in serum PTH levels between the
treatment and placebo groups in February 2005, September 2005, or February 2006.
Mean serum PTH levels did not change significantly from February 2005 to February
2006 in the placebo group or in the group receiving 800 IU vitamin D3 (Table 41);
however, they did change significantly in the treatment group who were in the highest
tertile of baseline serum 25(OH)D levels (Table 39). The one-year change in serum PTH
levels was not significantly different among tertiles of one-year change in serum
25(OH)D levels (Table 42).
Table 41. Change in serum PTH levels from February 2005 to February 2006.
February 2005
September 2005
February
n
PTH (pg/mL)
PTH (pg/mL)
2006
p
PTH (pg/mL)
Treatment group
55
29.7 ± 9.1
28.4 ± 14.5
29.7 ± 11.7
NS
Placebo group
31
32.9 ± 14.4
30.3 ± 17.4
32.3 ± 15.4
NS
Independent samples t-tests revealed no significant differences between treatment and
placebo groups (p > 0.05).
Independent samples t-tests revealed no significant differences between PTH levels in
February 2005 and February 2006 (p > 0.05).
Table 42. One-year change in serum PTH levels in the whole group (n = 86) among
tertiles of one-year change in serum 25(OH)D.
Mean One-Year Change in Serum
Mean One-Year Change in Serum
25(OH)D (nmol/L)
n
PTH (pg/mL)
p
Overall (26.5 ± 24.1)
86
-0.22 ± 13.0
Lowest tertile (<15 nmol/L)
28
3.0 ± 11.7
NS
Middle tertile (15 – 38.74 nmol/L)
29
-2.4 ± 13.7
Highest tertile (≥38.75 nmol/L)
29
-1.1 ± 13.2
Mean change in PTH levels were compared among tertiles of change in 25(OH)D levels
with use of ANOVA.
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Summary of Serum 25(OH)D Levels Over 12 Months
Serum 25(OH)D levels fluctuated seasonally in the placebo group and the winter
decrease was attenuated in the treatment group (Figure 6).
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Figure 6. One-year fluctuation in serum 25(OH)D levels in the treatment and
placebo groups.
Of the 55 subjects receiving daily 800 IU vitamin D3 supplementation, 80% had
optimal serum 25(OH)D levels at the end of winter (Figure 7). As seen in Table 42,
subjects who achieved optimal serum 25(OH)D levels at the end of winter had
significantly higher baseline serum 25(OH)D levels and lower percent body fat. In
addition, the subjects who used oral contraceptives appeared to be more likely to have
optimal serum 25(OH)D levels (Table 43). However, a Pearson Chi-Square revealed this
difference was not significant.
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Table 43. Characteristics of subjects in the treatment group who achieved optimal
serum 25(OH)D levels (≥75 nmol/L) in February 2006.
February 2006 Serum
February 2006 Serum
25(OH)D <75 nmol/L
25(OH)D ≥75 nmol/L
(Suboptimal)
(Optimal)
p
(n = 11)
(n = 44)
Baseline 25(OH)D
40.9 ± 16.4
67.4 ± 22.8
0.001
(nmol/L)
35.4 ± 7.4
29.9 ± 7.1
0.028
Percent Body Fat
Oral Contraceptive
27
57
0.08
Use (%)
Subject groups were compared with use of independent samples t-tests.
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Figure 7. Changes in the prevalence of vitamin D deficiency and insufficiency over
one-year, and in response to 800 IU vitamin D3 supplementation.
Summary of Association Between Serum 25(OH)D Levels
and BMI or Body Composition
There was a significant inverse correlation between serum 25(OH)D levels and BMI and
percent body fat in February 2005, September 2005, and February 2006 (in both
treatment and placebo groups). However, there was no significant correlation between
response to supplementation and BMI or body fat, nor was there a correlation between
the seasonal increase in 25(OH)D levels during summer and BMI or body fat. Percent
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body fat was a significant predictor of baseline serum 25(OH)D levels, but was not a
significant predictor of the one-year change in serum 25(OH)D levels after treatment with
800 IU vitamin D3.
Summary of Association Between Serum 25(OH)D Levels
and Hormonal Contraceptives
There was a significant positive association between serum 25(OH)D levels and
exogenous estrogen dose at all time points. Hormonal contraceptive use was a strong
predictor of both baseline serum 25(OH)D levels and of the one-year change in serum
25(OH)D levels.
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Chapter 5
DISCUSSION
The purpose of this research was to evaluate the serum 25(OH)D response to
supplementation with 800 IU vitamin D3 during winter in premenopausal women living
in Maine. The goals were to achieve optimal serum 25(OH)D levels in the supplemented
group at the end of winter, and to examine the effects of body composition and oral
contraceptive use on baseline serum 25(OH)D levels and response to supplementation.
One hundred twelve women aged 19 to 35 years were recruited to participate in
the study. All subjects received placebo from March 2005 until September 2005, at
which time they were randomized to receive either 800 IU vitamin D3, or matching
placebo until March 2006. Blood samples were collected from each subject for the
analysis of serum 25(OH)D, parathyroid hormone, and calcium levels in March 2005,
September 2005, and March 2006. Every three months from March 2005 until March
2006, the subjects picked up a new supply of supplements and completed a brief
questionnaire about other factors that affect serum 25(OH)D levels, such as sun exposure,
medical conditions, medications, and skin type. In addition, they completed a three-day
food record during the winter to assess dietary vitamin D intake. Body fat was measured
at the beginning and end of the study using a dual energy x-ray absorptiometry (DXA)
scan.
There were high rates of vitamin D insufficiency and deficiency among the
subjects in February 2005. Serum 25(OH)D levels increased greatly over the summer
and there were no cases of vitamin D deficiency at the end of summer. Eighty percent of
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the treatment group had optimal serum 25(OH)D levels at the end of February 2006, after
receiving 800 IU vitamin D3 daily during winter.
Vitamin D Status in Maine
Vitamin D insufficiency is common in Maine. At the end of winter, 29% of
subjects in this study of white premenopausal women had optimal serum 25(OH)D levels
(≥75 nmol/L). In Maine, due to the tilt of the earth, there is insufficient ultraviolet-B
radiation from November until March for cutaneous vitamin D synthesis5 resulting in
high levels of vitamin D insufficiency at the end of winter. The vitamin D synthesized
during the summer, and the vitamin D consumed from the diet are not able to sustain
optimal serum 25(OH)D levels through winter. If vitamin D insufficiency is common in
this group of active young women, it is likely indicative of vitamin D insufficiency in all
age groups in Maine.
The rates of deficiency in the current study were similar to those seen in other
studies in the United States.8,121 Analysis of NHANES III data found 40% of
premenopausal women (20 to 39 years) had levels less than 50 nmol/L during winter in
the southern US (latitude range 25o to 41oN; median 32oN).121 In the southern US, at
latitudes below 35oN, there is sufficient sun for cutaneous synthesis of vitamin D yearround,121 and, therefore, a lower prevalence of vitamin D deficiency would be expected at
the end of the winter. However, the higher prevalence of vitamin D deficiency seen in
the NHANES III data is most likely due to the lower serum 25(OH)D levels present in
the non-Hispanic Black and Mexican American women who made up 38% and 47% of
the sample, respectively.121 In the 12 to 29 year old female age group in the south, 15%
of non-Hispanic white females had serum 25(OH)D levels less than 50 nmol/L during
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winter compared to 70% of non-Hispanic black, and 41% of Mexican American
females.121 Thirty-six percent of 18 to 29 year old healthy men and women in Boston
(42oN) had serum 25(OH)D levels less than 50 nmol/L in March.8
Few other studies have examined optimal serum 25(OH)D levels at the end of
summer. In the current study, there was a large increase in serum 25(OH)D levels during
the summer due to increased cutaneous synthesis of vitamin D. Rates of vitamin D
insufficiency were much lower at the end of the summer, and there was no occurrence of
vitamin D deficiency (25(OH)D <50 nmol/L). Other studies, on the other hand, showed
higher rates of vitamin D deficiency during summer in the US than the current study.4,121
NHANES III data showed that, in the northern US, 18% of 20 to 39 year old women had
serum 25(OH)D levels less than 50 nmol/L, and only 70% of women in the north had
serum 25(OH)D levels greater than 62.5 nmol/L during summer.121 The higher
prevalence of vitamin D deficiency seen in the NHANES data is again most likely due to
the lower levels of serum 25(OH)D seen in non-Hispanic blacks and Mexican Americans.
People with dark skin experience a smaller seasonal summer increase in serum 25(OH)D
levels than do people with light skin.129,141 In addition, the NHANES data includes all
serum 25(OH)D levels measured during summer (between April and October) rather than
at the end of the summer. Therefore, it includes many serum levels that had not yet
peaked, as well as some that had peaked and started to decrease due to declining sun
exposure. However, 17% of white adolescent girls in Maine had serum 25(OH)D levels
below 50 nmol/L at the end of summer.4 Unlike the NHANES data, this higher incidence
of deficiency cannot be explained by race or time of measurement, but may be due to the
use of a different assay.
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In areas far from the equator, such as Maine, serum 25(OH)D levels increase
during summer and decrease during winter when there is insufficient sunlight for
cutaneous vitamin D synthesis. Over time, the suboptimal serum 25(OH)D levels seen at
the end of winter in many people, and even year-round in some people, may result in
lower bone mineral densities, increased risk of osteoporosis and fractures, increased risk
of autoimmune disease, increased risk of certain cancers, and decreased immune
function.30 During winter, individuals living in Maine and other sun-deprived areas need
supplemental vitamin D to maintain optimal serum 25(OH)D levels.
Estrogen
Serum 25(OH)D levels are significantly higher in women who use hormonal
contraceptives.139,152,153 In addition, although there was no correlation between
exogenous estrogen dose and response to supplementation, logistic regression revealed
that exogenous estrogen appeared to be one of the forces causing a better response to oral
vitamin D supplementation in premenopausal women, independent of estrogen’s effects
on baseline serum 25(OH)D levels.
The elevation in serum 25(OH)D levels due to oral contraceptive use in the
current study was similar to that seen in other studies.139,152,153 At the end of winter,
serum 25(OH)D levels were 20.3 nmol/L higher in hormonal contraceptive users. Both
Nesby-O’Dell and colleagues,139 and Harris and Dawson-Hughes153 saw similar
differences of 24.8 nmol/L and 24.0 nmol/L, respectively, in white women at the end of
winter. Sowers and colleagues152 saw a 15.0 nmol/L difference in summertime serum
25(OH)D levels between oral contraceptive users and non-users, which is similar to the
21 nmol/L difference in the current study.
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The current study was the only study to look at the effect of the dose of estrogen
on serum 25(OH)D levels. Serum 25(OH)D levels increased as the estrogen dose within
the contraceptives increased above 15 μg. The lack of an effect at doses of 15 μg could
be because 15 μg estradiol was too low to cause an increase in 25(OH)D levels, or it
could be because the 15 μg contraceptives were not taken orally, but are in the form of a
skin patch, or vaginal ring.
No other studies have examined the effect of estrogen on response to
supplementation. The two theories offering explanations for the increased levels of
serum 25(OH)D levels in subjects receiving estrogen can also be used as possible
explanations for the improved response to supplementation. If estrogen increases
hydroxylation activity in the liver, a higher percentage of vitamin D intake would be
hydroxylated,154,155 increasing serum 25(OH)D levels more in women receiving
exogenous estrogen. On the other hand, if estrogen increases serum 25(OH)D levels by
increasing vitamin D-binding protein concentration, then more DBP is present in
circulation, and more 25(OH)D could be bound to DBP in women receiving estrogen,
resulting in more serum 25(OH)D being measured.25 Similarly, increased DBP could
result in more vitamin D3 being picked up in circulation and transported to the liver for
hydroxylation, causing an increase in serum 25(OH)D levels.
It is not known whether there is a physiological benefit to the increased serum
25(OH)D levels in oral contraceptive users, or if oral contraceptive use simply raises the
measurable 25(OH)D. PTH is the only measure available in this study to evaluate the
functional effect of serum 25(OH)D levels, and there was no significant difference in
mean PTH levels between oral contraceptive users and non-users at baseline (Table 17c)
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despite significantly higher serum 25(OH) levels. However, other researchers suggest
that oral contraceptives may impact PTH levels independently of vitamin D,234 so PTH is
of limited use in examining the effect of oral contraceptive use on vitamin D status.
Furthermore, due to the large amount of individual variation in serum PTH levels, a
larger number of subjects would be needed to use PTH to evaluate the functional effect of
serum 25(OH)D levels. Further research is needed to determine whether oral
contraceptive use provides a beneficial effect on vitamin D status.
Oral contraceptive use must be considered in any research involving
premenopausal women and adolescents looking at a change in serum 25(OH)D levels,
and all contraceptives do not affect vitamin D status equally.
Body Composition
Increased body fat, BMI, and weight were associated with lower serum 25(OH)D
levels in the current study. However, as also reported by Arunabh,129 body fat percentage
had the strongest correlation with serum 25(OH)D levels, indicating that it is adiposity,
and not simply body mass, that affects serum 25(OH)D levels. Therefore, body fat was
the variable included in the regression analyses and was found to be a significant
predictor of baseline serum 25(OH)D levels, while controlling for other variables known
to affect serum 25(OH)D levels such as, season, vitamin D intake, exogenous estrogen,
and age. The change in serum 25(OH)D levels due to supplementation, however, was not
affected by body fat content.
The impact on baseline serum 25(OH)D levels was greatest in those with the
highest tertile of body fat (>33% body fat). This difference in serum 25(OH)D levels
based on body fat is consistent with the findings of Arunabh and colleagues,129 who

119

found significantly lower serum 25(OH)D levels in the highest quartile (>44% body fat)
compared with the lowest quartile (<31% body fat) of body fat in women, and with
Nesby-O’Dell and colleagues139 who found significantly lower serum 25(OH)D levels in
white women with BMI greater than 30 compared to those with normal BMI (18.5 to
24.9).
As vitamin D is transported by DBP to the liver for hydroxylation, some is
deposited in adipose tissue for storage along the way.146 Obese people have larger
amounts of adipose tissue, and therefore pick up more vitamin D from circulation,
resulting in lower serum 25(OH)D levels.146
The change in serum 25(OH)D levels due to supplementation was not affected by
body fat content. This lack of relationship is consistent with the findings of Wortsman
and colleagues146 who found that obese individuals experienced an attenuated increase in
vitamin D3 upon exposure to sunlight compared to non-obese peers, but the response to
supplementation with oral vitamin D2 was not different between the two groups.
Likewise, Brazilian nursing home residents responded similarly to a weekly dose of 7000
IU vitamin D3 regardless of body fat category.200 In contrast, Barger-Lux and
colleagues145 saw BMI, but not body weight, contribute significantly to the variance in
25(OH)D response to supplementation with vitamin D3. It is not clear why BMI
influenced response to supplementation in the study by Barger-Lux and colleagues, but
not in others. Barger-Lux and colleagues145 used much larger doses of vitamin D3 (1000,
10,000, 50,000 IU), so more of it may have been transferred from the chylomicrons to
vitamin D-binding protein in circulation,31 some of which is then deposited in adipose
tissue for storage.22-24
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Body composition affects baseline serum 25(OH)D levels and, therefore,
indirectly affects response to supplementation. Because obese women have lower
baseline serum 25(OH)D levels than non-obese women, obese women require a higher
dose of vitamin D3 to optimize their vitamin D status. However, overweight and obese
individuals do not need a higher dose of vitamin D3 to produce the same incremental
serum 25(OH)D response to supplementation as normal weight individuals.
Sun Exposure
Cutaneous synthesis of vitamin D following exposure to UVB radiation provides
80% to 90% of the vitamin D input for people who spend time in sunlight.3 The increase
in serum 25(OH)D levels provided by one MED (minimal erythemal dose) of sunlight
(the amount that causes a slight pinkness to the skin) while wearing a bathing suit is
equivalent to the consumption of 10,000 to 25,000 IU oral vitamin D2.115 However, the
exact amount of vitamin D produced in response to sunlight varies by age and skin
type.116 Comparatively, consumption of eight ounces of fortified milk provides only
about 100 IU vitamin D, and three ounces of salmon provides 245 to 988 IU vitamin
D3.235
Summer sun exposure, as measured in this study, was not a significant predictor
of serum 25(OH)D levels, or of the summer increase in serum 25(OH)D levels. Sun
exposure not being predictive of serum 25(OH)D levels is not likely due to a lack of
effect, but is more likely a result of the difficulty in estimating sun exposure. Sun
exposure and, therefore, cutaneous synthesis of vitamin D, vary on a daily basis
depending on the weather and cloud cover, the type of clothing worn, the amount of
sunscreen used and frequency of application of sunscreen, and the length of time spent
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outside, which makes cutaneous vitamin D synthesis a very difficult variable to quantify
with validity. To truly ascertain the impact of sun exposure on serum 25(OH)D levels, a
valid and reliable measurement tool must be developed. To further complicate matters,
however, cutaneous vitamin D production is highly variable between individuals, with
some individuals having low serum 25(OH)D levels despite abundant sun exposure.117
Alcohol Consumption
The current study, like others169-171 showed higher levels of serum 25(OH)D
levels with consumption of moderate amounts of alcohol, compared to no alcohol
consumption. The likely mechanism for alcohol’s effect on serum 25(OH)D levels is due
to an increase in estrogen levels with alcohol consumption.167 It is not clear whether this
increase in serum 25(OH)D levels due to estrogen provides any physiological benefit, or
simply increases the amount of measurable 25(OH)D.
Number of Days with a Cold
The number of days with a cold was used as a rough indicator of immune status.
The subjects were simply asked how many times they had a cold in the previous three
months, and the approximate number of days the cold lasted (see Lifestyle
Questionnaires in Appendix B). Surprisingly, this simple retrospective measure was a
significant variable in the logistic regression looking at determinants of baseline serum
25(OH)D levels. Women with higher serum 25(OH)D levels may have improved
immunity over women with lower 25(OH)D levels, which may be associated with fewer
days with a cold. Researchers believe 1,25(OH)2D stimulates the innate immune
response.83-85 It is possible that raising serum 25(OH)D levels during winter provides
more substrate for production of 1,25(OH)2D, which may protect against colds and the
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flu.90 Further research in this area would be beneficial, especially to children, the elderly,
and the immunosuppressed during cold and flu season.
Tanning Bed Use
Although serum 25(OH)D levels were much higher in the 11 subjects who used a
tanning bed during winter than in subjects who did not tan, this difference was not
significant due to the small number of tanners in this study. At the end of winter in
Boston, Tangpricha and colleagues142 saw serum 25(OH)D levels 90% higher in subjects
who used tanning beds in the previous six months compared with adults who did not tan.
Artificial UVB radiation promotes cutaneous vitamin D synthesis and may provide an
alternative to oral supplementation for increasing serum 25(OH)D levels during winter.
However, due to the increased risk of melanoma and squamous cell carcinoma in tanning
bed users,236 artificial UVB radiation for tanning is not an acceptable public health
approach to improving vitamin D status.
Seasonal Increase in Serum 25(OH)D Levels
The 66% summer increase in serum 25(OH)D levels was much greater than that
seen in other studies.4,6,215 Serum levels in adolescents living in the Bangor area (44oN)
increased 14 nmol/L or 28% during the summer.4 In 24 to 70 year old women living in
London (51oN), serum 25(OH)D levels were 36% higher in summer than in winter.215 In
white 18 to 35 year old women living in Toronto (43oN), serum 25(OH)D levels
measured in summer were 31% higher than in winter.6
There are many factors that affect cutaneous synthesis of vitamin D, and
therefore, affect the seasonal summer increase in serum 25(OH)D levels. London has a
reputation for cloudiness and more air pollution than Maine, which could explain the
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lower seasonal increase in serum 25(OH)D levels seen in London. In all of the studies,
cloud cover and temperature could affect the amount of clothing worn, which affects
vitamin D synthesis. The blood samples in the current study were specifically drawn
when serum 25(OH)D levels are at their lowest (end of February) and highest
(September),122 whereas in the Toronto and London studies, blood samples were
measured during winter and during summer, so not all levels had reached their nadir and
peak. It is also possible that the subjects in the current study exhibited more sun-seeking
behavior than those in the other studies.
Skin type was the only variable determined to predict the seasonal change in
serum 25(OH)D levels. As expected, subjects with darker skin experienced a smaller rise
in serum 25(OH)D levels than did subjects with lighter skin, which is consistent with the
findings of other researchers.5,138 Melanin acts as a natural sunscreen, so individuals with
darker skin require more ultraviolet exposure to effect the same increase in serum
25(OH)D levels as individuals with lighter skin.138 Using artificial UVB radiation,
Armas and colleagues116 found that together, skin type and the UVB dose explained 80%
of the variation in the serum 25(OH)D response to UVB radiation. Age, gender, BMI,
body surface area, and baseline 25(OH)D levels did not significantly contribute to the
variation in serum 25(OH)D response.
The seasonal summer 2005 increase in serum 25(OH)D levels was unexpectedly a
significant predictor of the one-year change (February 2005 to February 2006) in serum
25(OH)D levels. Since serum 25(OH)D levels increase every summer, and individual
sun exposure behavior is presumed to be consistent from year to year, the affect on
February serum 25(OH)D levels was expected to be similar from year to year, and,
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therefore, was not expected to affect the overall one-year change in serum 25(OH)D
levels. Indeed, in a three-year study by Sullivan and colleagues,4 the summer serum
25(OH)D levels increased to approximately the same levels every September and
decreased to approximately the same levels every March. The difference found in the
current study suggests greater cutaneous synthesis in summer 2005 than in summer 2004,
resulting in higher serum 25(OH)D values in February 2006. The one-year increase in
serum 25(OH)D levels in the placebo group also suggests a bigger influence of summer
on February levels during the second February. Analysis of climatological data from the
National Oceanic and Atmospheric Administration revealed that summer 2004 was
cooler than summer 2005,237,238 so the subjects may have spent less time outside, or may
have worn more clothing while outside in 2004 than in summer 2005, both of which
would decrease vitamin D production. Temperatures in summer 2004 (May through
August) were 6.4oF below normal compared to 1.1oF below normal in summer
2005.237,238 During May through August 2004, Bangor had 236 cooling degree days237
compared to 405 cooling degree days during the same period in summer 2005.238 One
cooling degree day is accumulated for each whole degree that the daily mean temperature
is above 65oF.237
Researchers cannot assume that the summer increase in serum 25(OH)D levels
will have a consistent impact on serum 25(OH)D levels the following February from year
to year. Therefore, it is important to control for this change with a placebo group when
looking at the one-year change in serum 25(OH)D levels.
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Baseline Serum 25(OH)D Levels
Although there was no correlation between baseline serum 25(OH)D levels and
response to supplementation, logistic regression analysis identified baseline serum
25(OH)D levels as having an independent effect on response to supplementation.
Subjects with lower baseline serum 25(OH)D levels had a stronger serum 25(OH)D
response to supplementation, which is consistent with other research studies.197-200
The hydroxylation of vitamin D3 to 25(OH)D is likely a saturable process,145 causing a
weaker response to supplementation in individuals with higher baseline serum 25(OH)D
levels.
Rather than adjusting vitamin D supplementation dosages depending on baseline
serum 25(OH)D, a single dose could be used for everyone since people with lower
baseline serum 25(OH)D levels have a greater response to supplementation, and people
with higher baseline levels have a weaker response. Because vitamin D toxicity has only
occurred after exceptionally high intakes of vitamin D, one dose can be used safely for
everyone.
Magnitude of Response to Supplementation
On average, serum 25(OH)D levels increased 1.1 nmol/L for every microgram of
supplemental vitamin D3 input, which is within the range (0.59 to 2.1 nmol/L) found by
other researchers.145,198,209,210,219 In fact, Barger-Lux and colleagues145 estimated that in a
70 kg person (the mean weight of subjects in the current study), serum 25(OH)D levels
would increase by 22 nmol/L on 800 IU supplemental vitamin D3 daily, which would be
a 1.1 nmol/L increase for each mcg of input.
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The current study confirms the findings of other researchers that serum 25(OH)D
levels increase approximately 1.0 nmol/L for every microgram of oral vitamin D3 input.
However, these numbers (0.7, 1.0, 1,1, and so on) are just average responses to one
microgram of vitamin D3. Some individuals may have a stronger or lesser response
depending on baseline vitamin D status, and estrogen use.
Adequacy of Dose
Eighty percent of the premenopausal women receiving 800 IU vitamin D3 daily
achieved optimal vitamin D status at the end of the second winter, compared to 29% of
the subjects at baseline. The women for whom 800 IU was inadequate had lower mean
baseline serum 25(OH)D levels, had a higher mean body fat content, and were less likely
to be taking oral contraceptives; 73% of women with suboptimal serum 25(OH)D levels
after supplementation were not on oral contraceptives. Thirty percent of the women
receiving 800 IU vitamin D3 daily who were not using oral contraceptives had suboptimal
serum 25(OH)D levels after five months of supplementation.
An adequate dose of vitamin D3 would increase serum 25(OH)D levels
sufficiently to suppress PTH secretion during winter. Other researchers have seen a
suppression of PTH secretion with serum 25(OH)D levels of at least 75 nmol/L.13 As
seen in Table 39, in the treatment group, the one-year change (decrease) in serum PTH
levels was significant in the highest tertile of baseline serum 25(OH)D levels. The
February 2006 serum PTH levels were also significantly lower in those with the highest
baseline serum 25(OH)D levels compared to those in the lowest serum 25(OH)D tertile.
It appears that 800 IU vitamin D3 increased serum 25(OH)D levels in the highest tertile
of baseline serum 25(OH)D levels enough to result in significant suppression of PTH.
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The women in the treatment group were consuming approximately 1000 IU
vitamin D daily from supplementation and diet. The current Adequate Intake (200 IU)
set for this age group by the Food and Nutrition Board21 is only one-fifth of the amount
consumed in this study. An AI is set when the Board feels there is not enough evidence
available to establish a Recommended Daily Allowance (RDA). By definition, the RDA
is the average daily intake required to meet the needs of 97% to 98% of healthy
individuals in a specific age and gender group.21
In the current study, 97.5% of subjects had baseline serum 25(OH)D levels
greater than 28.0 nmol/L. Therefore, in order to ensure that 97% to 98% of subjects have
optimal serum 25(OH)D levels of at least 75 nmol/L, the individuals with baseline serum
25(OH)D levels as low as 28.0 nmol/L would need to be optimized. Evidence suggests a
linear relationship between vitamin D3 intake and the increase in serum 25(OH)D
levels.209 Therefore, based on the 1.1 nmol/L increase in serum 25(OH)D levels per
microgram of vitamin D3 input seen in the current study, approximately 1700 IU vitamin
D3 would be required daily to optimize the vitamin D status of 97.5% of the population.
Doing the same calculation, but using a 0.7 nmol/L increase per microgram as
determined by Heaney and colleagues,209 2700 IU would be required for 97.5% of the
population to achieve serum 25(OH)D levels above 75 nmol/L. Similarly, using
NHANES III data and a 0.7 nmol/L increase per microgram of vitamin D3 input,
Heaney134 determined that approximately 2600 IU vitamin D3 would be needed to meet
the needs of 97.5% of a population of 60 to 79 year old white women. There are many
factors that affect baseline serum 25(OH)D levels and response to oral supplementation,
therefore 0.7 and 1.1 nmol/L per microgram of vitamin D3 intake are just estimates.
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Nevertheless, many studies145,198,209,210,219 have found values in the same range and
Heaney believes these estimations are very close to the amount needed.134
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Chapter 6
CONCLUSIONS
Researchers speculate that approximately 800 to 1000 IU vitamin D3 is required
to achieve optimal serum 25(OH)D levels of at least 75 nmol/L in the absence of
sunlight.1 However, further research is needed to determine how much vitamin D3 is
required to optimize serum 25(OH)D levels for different age groups.
The purpose of this study was to measure the serum 25(OH)D response to daily
supplementation with 800 IU vitamin D3 during winter in premenopausal women living
in Maine, and to examine the effects of body composition and hormonal contraceptive
use on baseline serum 25(OH)D levels and on the response to supplementation. From the
sample of white premenopausal women in the current study, many conclusions can be
extrapolated into the entire population.
There is a high rate of vitamin D insufficiency in the northeastern United States
and serum 25(OH)D levels fluctuate seasonally. In February 2005, less than one-third of
young women in Maine had optimal serum 25(OH)D levels (≥75 nmol/L). Serum
25(OH)D concentrations increased 66% during the summer, and 77% of young women
had optimal levels at the end of the summer. For 80% of this relatively homogeneous
sample, 800 IU supplemental vitamin D3 daily was sufficient to achieve serum 25(OH)D
levels of at least 75 nmol/L at the end of winter.
Exogenous estrogen from hormonal contraceptive use increases serum 25(OH)D
levels, and, in the current study, also increased the serum 25(OH)D response to
supplementation. Further research is needed to determine whether or not these higher
serum 25(OH)D levels are merely a result of an increase in the amount of 25(OH)D that
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is measured or actually represent a functional improvement in vitamin D status. Percent
body fat, on the other hand, is negatively associated with serum 25(OH)D levels.
Women with higher percent body fat, have lower serum 25(OH)D levels. Body fat did
not, however, affect serum 25(OH)D response to supplementation in the current study.
Women who started with lower serum 25(OH)D levels had a greater increase in serum
25(OH)D levels during supplementation than women who started with higher serum
25(OH)D levels.
Because of the large variation in vitamin D requirements due to factors such as
body composition, oral contraceptive use, and initial serum 25(OH)D levels, as well as
the many factors affecting vitamin D synthesis, including skin color, sun exposure, and
geographic location, it is very difficult to develop a strategy to optimize vitamin D status
for everyone. For the health of the nation, the Food and Nutrition Board must review the
abundant research that has been conducted since the current Adequate Intake for vitamin
D was established in 1997 and revise their recommendations.2 Ideally, everyone should
have their serum 25(OH)D levels measured at the end of winter to determine
supplementation needs. However, screening everyone for vitamin D deficiency would be
expensive. Therefore, people who do not receive adequate sunlight, which includes
everyone who resides at latitudes above 35oN, may need 800 IU vitamin D3 or more daily
during winter. Given the low risk of toxicity, vitamin D supplementation
recommendations should be high enough to optimize serum 25(OH)D levels in the
population regardless of body composition, baseline serum 25(OH)D levels, or skin
color.
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In the current study, 800 IU vitamin D3 was only adequate to optimize vitamin D
status in 80% of this sample of white, young adult women. Therefore, supplementation
with 800 IU vitamin D3 is not likely to optimize vitamin D status in the population as a
whole. Further research is needed to determine the dose of vitamin D3 required to
optimize vitamin D status in the US population as a whole.
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VITAMIN D CONTENT OF FOODS
Table A1. Vitamin D content of fish.
Food
Cod liver oil, 1 Tablespoon
Salmon, wild-caught, 3½ ounces
Salmon, farm raised, raw, 3½ ounces
Salmon, farm raised, baked, 3½ ounces
Salmon, farm raised, fried in vegetable oil, 3½ ounces
Blue fish, 3½ ounces
Cod, 3½ ounces
Trout, farm raised, 3½ ounces
Tuna, Ahi-yt, 3½ ounces
Mackerel, cooked, 3½ ounces
Tuna fish, canned in oil, 3 ounces
Sardines, canned in oil, drained, 1¾ ounces
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International Units (IU)
Per Serving
(mean ± SEM when available)
1,360a
988 ± 524b
240 ± 108b
240b
123b
280 ± 68b
104 ± 24b
388 ± 212b
404 ± 440b
24b – 345a
200a
250a

Table A2. Vitamin D content of foods fortified with vitamin D.
Food
International Units (IU)
Per Serving
MILK
Milk, nonfat, reduced fat, and whole fat, vitamin D
100a
fortified, 1 cup
Soy Milk Silk® regular, lowfat and fat free, 8 oz
120c
Soy Milk, 8th Continent®, regular, lowfat, and fat free,
100c
8 oz
YOGURT
Colombo Classic and Light Yogurt, 6 oz
Colombo® Lowfat Yogurt, 8 oz
Dannon® Light & Fit®, 6 oz
Dannon® Activia®, 4 oz
Dannon®, Fruit on the Bottom and Fruit Blends, 6 oz
Dannon®, Danimals®, 4 oz
Stonyfield Farm®, Organic Whole Milk and Lowfat,
and All Natural Fat Free, 6 oz
Stonyfield Farm®, 2-a-Day Yogurt, 6 oz
Yoplait® Original Fruit Flavors, Custard Style, and
Light Flavors, 6 oz
Yoplait® Trix® Yogurt, 4 oz
Yoplait® Whips®, Fruit Flavors 4 oz
Yoplait® Go-Gurt®, 2.25 oz tube
®

®

CEREAL
General Mills: Cheerios®, Chex®, Wheaties®, Total®,
Trix®, Lucky Charms®, Kix®, 1 oz
Kellogg’s Special K®, Frosted Mini Wheats®, 1 oz
Kellogg’s Rice Krispies®, All Bran®, Corn Flakes®,
Froot Loops®, Corn Pops®, Frosted Flakes®, Smart
Start®, 1 oz
Quaker Cap’n Crunch®, Life®, Oatmeal Squares®, 1 oz
Post Honey Bunches of Oats®, Golden Crisp®, Grape
Nuts®, 1 oz
Post Shredded Wheat®, 1 oz
Kashi Heart to Heart®, Go Lean®, Go Lean Crunch®, 1
oz
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0c
100c
60 – 80c
0c
0c
60c
0c
80
80c
40c
40c
24c

40c
0c
40c
0c
40c
0c
0c

Food

International Units (IU)
Per Serving
(mean ± SEM when available)

MARGARINE
Margarine, fortified, 1 tablespoon
Land O’Lakes®, 1 Tbsp
Fleischman’s® Original (stick), 1 Tbsp
Fleischman’s® made with olive oil, 1 Tbsp
Promise® Regular, Light, 1 Tbsp
Smart Balance®, 1 Tbsp
Smart Balance®, Light, 1 Tbsp
Shedd’s Spread® Country Crock® with calcium and
vitamins, 1 Tbsp
ORANGE JUICE
Orange Juice, fortified, 8 oz
(such as, Tropicana Pure Premium® Healthy Kids,
Tropicana Pure Premium® Calcium + Vitamin D,
Minute Maid Kids+®, Minute Maid® Calcium and
Vitamin D)
Orange Juice, not fortified with vitamin D, 8 oz

60a
0c
60c
0c
60c
60c
0c
60c

100c

0c

OTHER
Egg yolk, 1 whole
20a
Liver, beef, cooked, 3½ ounces
15a
Cheese, Swiss, 1 ounce
12a
a
Office of Dietary Supplements, Dietary Supplement Fact Sheet: Vitamin D [Internet].
Bethesda (MD): National Institutes of Health; [modified 2007 Aug 30, cited 2007 Sep
17]. Available from: http://ods.od.nih.gov/factsheets/vitamind.asp#h2.
b
Lu Z, Chen TC, Zhang A, Persons KS, Kohn N, Berkowitz R, Martinello S, Holick MF.
An evaluation of the vitamin D3 content in fish: is the vitamin D content adequate to
satisfy the dietary requirement for vitamin D? J Steroid Biochem Molec Biol
2007;103:642-4.
c
According to package label 2007 Sep 18
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And
Lifestyle Questionnaires
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Date of Visit:

Subject Number:

Health History Screening Form
(January 2005)
We are asking these health history questions because certain conditions and
medications affect vitamin D metabolism. A positive response may or may
not disqualify you from participation in the study. Please answer as
accurately as possible.
Date of Birth
Do you have, or have you ever had:
Diabetes
Cystic Fibrosis
Crohn’s Disease
Ulcerative Colitis
Chronic Diarrhea
Whipple’s Disease

Y
Y
Y
Y
Y
Y

N
N
N
N
N
N

Celiac Disease / Sprue
Gluten Intolerance
Liver Disease
Kidney Disease
Pacemaker

Y
Y
Y
Y
Y

N
N
N
N
N

Do you have any other medical conditions? If so, please explain:

Weight?

What is your current height ?

Please do not write
in this box.
BMI = _________

Are you pregnant?

Yes

No

Maybe

Are you planning to become pregnant in the next 12 months? Yes

No

Do you have a regular menstrual cycle (occurring every 23-35 days)? If not,
how often do you menstruate?
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Health History Screening Questionnaire, continued
(January 2005)
Are you currently taking:
Steroids, including inhalers (i.e. prednisone)
Anti-seizure medication (i.e. phenytoin, valproic acid, and others)
Thyroid medication (i.e. synthroid)
Cholesterol-lowering medication (i.e. Questran, Colestid)
Depo-Provera
Mineral Oil
Do you take any vitamins or minerals? If so, which ones, how much, and
how often?

What other medications or herbal supplements do you take, and how often?

Will you be able to be available on a weekday between 8:00 am and 5:00 pm
to have your blood drawn in March 2005, September 2005, and March 2006,
and to have your body composition measured in March 2005 and 2006?
Y
N

Due to the nature of this study, we ask that all participants refrain from
taking supplemental multivitamins, calcium, or vitamin D other than those
on an approved list. You must also have no plans to travel south of Southern
California, Southern Texas, Louisiana, New Mexico, Georgia, Alabama, or
Florida over winter 2004/2005 and 2005/2006. (Spring Break will be okay)
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Lifestyle Questionnaire – Sun Exposure
(March 2005)

Please help us estimate the amount of time you typically spent outdoors last
summer between the hours of 10 :00 am and 3 :00 pm between the beginning of
May and the end of August 2004.
Work Day : On a typical workday last summer, how much time did you spend
outdoors between the hours of 10 am and 3 pm ?
On average, how many days per week did you work last summer ?
Day Off : On a typical day off last summer, how much time did you spend
outdoors between the hours of 10 am and 3 pm ?
On average, how many days off per week did you have last summer ?
Vacation Time : While you were on vacation last summer, how many hours per
day did you spend outdoors between the hours of 10 am and 3 pm ?
How many days were you on vacation last summer ?

When you were outside, did you wear sunscreen on your face ?
Never

Rarely

Sometimes

Often

Always

When you were outside did you wear sunscreen on the rest of your body ?
Never

Rarely

Sometimes

Often

Always

To which part(s) of your body did you typically apply sunscreen?
□ Arms

□ Back and Shoulders

□ Hands

□ Legs

□ All Bare Skin

What number SPF sunscreen did you typically wear?
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Lifestyle Questionnaire, continued
(March 2005)

Did you use a tanning bed in the past 5 months? If so, how many times?

Have you traveled to a southern climate since October? If so, where and for what
dates?

Are you allergic to any of the following ingredients that are in the vitamin D or
placebo capsules? Placebo: Gelatin, maltrin, magnesium stearate. Vitamin D3:
gelatin and synthetic vitamin D3.
Yes No

When was the first day of your last period?

Are you pregnant?

Yes

No

Maybe

Do you use a birth control pill, patch, shot, or ring? If so, which brand?

If yes, have you been on this birth control for at least 4 months?

Y

N

Please list any new medications that you took during the past 2 months:

Did you take any vitamins, minerals, or herbal supplements during the past 2
months? If so, which ones, how much, and how often did you take them?
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Lifestyle Questionnaire, continued
(March 2005)

Do you have any chronic medical condition? If so, please explain.

How many times did you have a cold or the flu in the past 3 months?
How many days did it usually last?

Do you smoke?

Y

N

If yes, how many packs/day?

Which of the following best describes how often you take an antacid such as Tums
or Rolaids?
At least once a day

At least once a week

At least once a month

Less than once a month

Never

Which antacid do you take?

Which of the following best describes how often you eat fat-free snacks that
contain the fat substitute, olestra (i.e. WOW Chips)?
At least once a day

At least once a week

At least once a month

Less than once a month
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Never

Contact Information

Do you have a new address or phone number since we last saw you? If so, please
provide below:

Your next visit for the Vitamin D Study is in June. You will need to pick up a
new supply of capsules and return the unused ones. Please provide your summer
address and phone number so that we can get in contact with you.

June Address:

June Phone Number:

If you are not going to be near Orono this summer, are you planning to be on
campus or in the Bangor area anytime during June? If so, when could we
connect?
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Lifestyle Questionnaire
(June 2005)
Please let us know if your contact information will change this fall.
Over the past 3 months:
Did you experience any side effects that you think are related to the capsules given
to you in this study? If yes, please describe

Approximately how many capsules did you forget to take during the past 3
months?

Did you use a tanning bed? If so, how many times?

Have you traveled to a southern climate since March? If so, where and for what
dates?

Are you pregnant?

Yes

No

Maybe

Do you use a birth control pill, patch, shot, or ring? If so, has your prescription
changed in the past 3 months (what brand do you use now)? What month did this
change occur?

Have you quit using a birth control pill, patch, shot, or ring in the past 3 months?
If so, what month did you stop taking it?
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Lifestyle Questionnaire, continued
(June 2005)
Please list any new medications that you took during the past 3 months:

Did you take any vitamins, minerals, or herbal supplements during the past 3
months? If so, which ones, how much, and how often did you take them? (Not
including the capsule for this study)
How often do you take an antacid such as Tums or Rolaids?
At least once a day
At least once a week
Never
At least once a month
Less than once a month
Which antacid did you typically take?
Do you smoke?

Y

N

If yes, how many packs/day?

Were you diagnosed with any chronic medical condition in the past 3 months?

How many times did you have a cold or the flu in the past 3 months?
How many days did it usually last?

Which of the following best describes how often you eat snacks that contain the
fat substitute Olestra (i.e. WOW Chips or Light Chips)?
At least once a day
At least once a week
Never
At least once a month
Less than once a month

How do you remember to take your daily capsule? I would like to compile these
responses (without names attached) to give the other participants some
suggestions.
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The Vitamin D Study
Lifestyle Questionnaire
(September 2005)
Please change the above address label to reflect your current address. This is the
address to which your October check will be sent.
Do you receive a paycheck from the University of Maine? Y N
(When I submit the information for your check, payroll needs to know this.)
Please help us estimate the amount of time you typically spent outdoors between
the hours of 10:00 am and 3:00 pm between the beginning of May and the end of
August 2005.
Work Day: If you worked or went to school, on a typical work or school day,
how much time did you spend outdoors between the hours of 10 am and 3 pm?
On average, how many days per week did you work or go to school?
Day Off: On a typical day off, how much time did you spend outdoors between
the hours of 10 am and 3 pm?
On average, how many days off did you have per week?
Vacation Time: If you went on vacation, while you were on vacation, how many
hours per day did you spend outdoors between the hours of 10 am and 3 pm?
How many days were you on vacation?
Over the past 3 months:
When you were outside, did you wear sunscreen on your face?
Never Rarely Sometimes Often Always
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Lifestyle Questionnaire, continued
(September 2005)
When you were outside, did you wear sunscreen on the rest of your body?
Never Rarely Sometimes Often Always
To which part(s) of your body did you typically apply sunscreen?
□ Arms
□ Back and Shoulders
□ Hands
□ Legs
□ All Bare Skin
What number SPF sunscreen did you typically wear?
Did you use a tanning bed? If so, how many times?
When was the first day of your last period?
Are you pregnant?

Yes

No

Maybe

Did you experience any side effects from the capsules given to you in this study?
If yes, please describe:
Approximately how many capsules did you forget to take in the past 3 months?

Do you use a birth control pill, patch, shot, or ring? If so, has your prescription
changed in the past 3 months (what brand do you use now)? What month did this
change occur?

Have you quit using a birth control pill, patch, shot, or ring in the past 3 months?
If so, what month did you stop taking it?

168

Lifestyle Questionnaire, continued
(September 2005)
Please list any medications that you took over the past 3 months:

Did you take any vitamins, minerals, or herbal supplements over the past 3
months? If so, which ones, how much, and how often did you take them? Please
include brand names if possible. (Do not include the capsule for this study)

How often do you take an antacid such as Tums or Rolaids?
At least once a day
At least once a week
At least once a month
Less than once a month
Which antacid do you typically take?

Do you smoke?

Y

N

If yes, how many packs/day?

Were you diagnosed with any chronic medical condition in the past 3 months?

How many times did you have a cold or the flu in the past 3 months?
How many days did it usually last?

How often do you eat fat-free snacks that contain the fat substitute, olestra (i.e.
WOW Chips or Light Potato Chips)?
At least once a day
At least once a week
Never
At least once a month
Less than once a month
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Skin Type Questionnaire
(September 2005)
Skin color affects the amount of vitamin D your skin is able to make. Skin type is
often categorized by the Fitzpatrick skin type scale which ranges from very fair
(skin type I) to very dark (skin type VI). This classification is based on a person’s
complexion and response to sun exposure. Please check the description which
best fits your skin type:
□ Skin Type I: Persons with this skin type have blond or red hair and very

fair skin or ivory white skin. They often have freckles and blue eyes. They
easily burn, never tan, and are extremely sensitive to sunlight.

□ Skin Type II: Persons with this skin type usually have blue or hazel eyes,

and red or blonde hair. Their skin color is white or fair and they may have
freckles. They typically burn easily and tan slightly or slowly.

□ Skin Type III: Persons with this skin type have fair skin and are blond or

brunette. Their skin is white to slightly beige or olive. They tan slowly and
moderately, gradually turning to a light brown color. They sometimes
burn.

□ Skin Type IV: Persons with this skin type usually have beige, light brown,

or olive-colored skin, dark eyes, and dark hair. They tan easily and
moderately, and rarely burn.

□ Skin Type V: Persons with this skin type are similar to those with skin

type IV, but they never burn. They tan profusely to a deep brown or black
color.

□ Skin Type VI: Persons with this skin type have dark eyes and hair and

dark brown or black skin. They never burn.

To further help us understand the ability of your skin to make vitamin D, how
would you describe (the largest portion of) your ethnicity?
□ White
□ Asian
□ Black or African American
□ Indian or Alaska Native
□ Hispanic or Latino
□ Native Hawaiian or Other Pacific Islander
□ Some other race
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The Vitamin D Study
Lifestyle Questionnaire
(December 2005)
Phone Number:
If you are a student, in what semester did you start (year and month) at UM
or UCB?
Over the past 3 months:
Did you experience any side effects from the capsules given to you in this
study?
If yes, please describe:
Approximately how many capsules did you forget to take in the past 3
months?
Are you pregnant?

Yes

No

Maybe

Do you use a birth control pill, patch, shot, or ring? (circle one) Yes

No

If so, as your prescription changed in the past 3 months? (circle one) Yes No
In what month did this change occur?
Which brand do you use now?
Have you quit using a birth control pill, patch, shot, or ring in the past 3
months? If so, what month did you stop taking it?
How often do you take an antacid such as Tums or Rolaids?
At least once a day
At least once a week
At least once a month
Less than once a month
Which antacid do you typically take?
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Never

Lifestyle Questionnaire, continued
(December 2005)
Please list any medications that you took during the past 3 months:

Did you take any vitamins, minerals, or herbal supplements during the past 3
months? If so, which ones, how much, and how often did you take them?
(Not including the capsule for this study)

Did you use a tanning bed in the past 3 months? If so, how many times?
Did you travel to a southern climate in the past 3 months? If so, where, and
for what dates?
Did you ski in the past 3 months? If so, how many hours do you spend
skiing each week during the day (don’t count night skiing)?
Do you smoke?

Y

N

If yes, how many packs/day?

Have you been diagnosed with any chronic medical condition in the past 3
months?
How many times did you have a cold or the flu in the past 3 months?
How many days did it usually last?
How often do you eat fat-free snacks that contain the fat substitute, olestra
(i.e. WOW Chips)?
At least once a day
At least once a week
Never
At least once a month
Less than once a month
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The Vitamin D Study
Lifestyle Questionnaire
(March 2006)
Please change the above address label to reflect your current address.
Are you currently a UM student (I need to know this for billing purposes)? Y N
Over the past 3 months:
Did you experience any side effects from the capsules given to you in this study? Y

N

If yes, please describe
Approximately how many capsules did you forget to take in the past 3 months?

Did you use a tanning bed in the past three months?
If so, where and how many times?
Did you travel to a southern climate in the past three months? If so, where, and for what
dates?
Did you ski? If so, how many hours do you spend skiing each week during the day
(don’t count night skiing)?
Please list any medications that you took over the past 3 months:

Did you take any vitamins, minerals, or herbal supplements over the past 3 months? If
so, which ones, how much, and how often did you take them? (Not including the capsule
for this study)
When was the first day of your last period?
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Do you use a birth control pill, patch, shot, or ring?
Y
N
If so, has your prescription changed in the past 3 months (what brand do you use now)?
What month did this change occur?
Have you quit using a birth control pill, patch, shot, or ring in the past 3 months? If so,
what month did you stop taking it?
If you have ever used a birth control pill:
Approximately how many years did you /have you used it?
Which years did you use a birth control pill?
Do you smoke?

Y

N

If yes, how many packs/day?

On average, how many days a week do you consume alcohol?
Using the serving information below, on average, how many servings of alcohol do you
drink in a week?
1 serving of alcohol:
1 can or bottle (12 oz) or ½ of a “big red” or Solo cup of beer / 1 bottle (12 oz) of wine coolers / 5 oz wine / 1 shot of liquor (1 ½ oz)
/ 1 Dixie cup of jello shots

Have you been diagnosed with any chronic medical condition in the past 3 months?
How many times did you have a cold or the flu in the past 3 months?
How many days did it usually last?
How often do you eat fat-free snacks that contain the fat substitute, olestra (i.e. WOW
Chips)?
At least once a day
At least once a week
Never
At least once a month Less than once a month
How often do you take an antacid such as Tums or Rolaids?
At least once a day
At least once a week
At least once a month
Less than once a month
What brand of antacid do you most often use?
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Never

Appendix C
Recruitment Letter
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November 16, 2004
Dear Student:
Did you know that almost half of the women living in Maine have low levels of vitamin
D in their blood, putting them at increased risk of developing weak bones or other health
problems? These low levels occur because the sun is not strong enough in winter in
Maine for the skin to make vitamin D. However, researchers are not sure how much
extra vitamin D women need during winter.
We plan to do a study to find out how much vitamin D is needed to maintain normal
blood levels in winter in Maine. We are looking for women between the ages of 19 and
35 to participate in “The Vitamin D Study”, a 12-month supplementation study. For a
relatively small effort on your part, you can help make a difference in vitamin D research.
What the study involves:
 Three blood tests (March 2005, September 2005, and March 2006)
 Filling out short questionnaires every 3 months
 Taking a vitamin D or placebo capsule daily (A placebo is a capsule that
looks like the vitamin D capsule, but contains an inactive, harmless
substance instead)
 Body composition measurement at the beginning and end of the study
We are looking for women to sign up for the study this fall. The first testing will take
place in March 2005. Compensation will be $200 for completion of the study.
Please consider participating in our study and encourage your friends to do the same. If
you are interested in participating or would like more information, please call 581-1622.
Thank you,

Monica Nelson, MPH, RD
Graduate Student
Food Science and Human Nutrition
University of Maine

Susan Sullivan, DSc, RD
Director Didactic Program
Food Science and Human Nutrition
University of Maine
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Appendix D
Recruitment Flyer
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DO YOU GET ENOUGH SUN?

Skin makes vitamin D when it is exposed to sunlight.
During winter in Maine, the sun is not strong enough for skin
to make vitamin D. Researchers at the University of Maine are
looking for women between the ages of 19 and 35 to
participate in a 12-month study to find out how much extra
vitamin D young women need to keep blood levels high
enough during winter in Maine.
What the study involves:
o Blood tests every 6 months (3 tests - less than two
tablespoons of blood will be drawn each time.)
o Filling out short questionnaires every 3 months
o Taking a vitamin D capsule or a sugar pill daily
o Body composition measurement in Bangor in March
2005 & 2006
We are looking for women to sign up for the study this fall.
The first testing will take place in March 2005. Compensation
will be $200 for completion of the study.
For more information, please call Susan Sullivan, D.Sc., R.D.
of the Department of Food Science and Human Nutrition at the
University of Maine or Monica Nelson, graduate student, at
581-1622.
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PATIENT INFORMATION AND INFORMED CONSENT STATEMENT
TITLE:

Serum 25-Hydroxyvitamin D Response to Customized Doses of
Vitamin D3 in Premenopausal Women

DATE:

June 1, 2005

You have been asked to take part in a research study being conducted by Dr.
Susan Sullivan, faculty member, and Monica Nelson, graduate student, in the
Department of Food Science and Human Nutrition at the University of Maine.
Funding for this study is being provided by the United States Department of
Agriculture (USDA).
You have initially qualified to take part in this study because you are a 19-35 year
old healthy woman. You cannot have any serious medical conditions such as
diabetes, celiac disease or Crohn’s disease or take any prescription medications
such as steroids that affect vitamin D and calcium metabolism. If you are
pregnant or become pregnant, you will not be allowed to continue in this research
study. Your body mass index (BMI) must be between 18.5 and 40 to participate.
BMI is the product of 705 times your weight in pounds divided by your height in
inches, squared (BMI = lbs/inches2 x 705). These conditions and medications
will be discussed with you in detail prior to your enrolling in the study. In addition,
you must agree to avoid taking most vitamin, mineral, and herbal supplements,
other than those on an approved list. You must avoid tanning booths during the
study period, and you must try to avoid traveling south of 35o north latitude
(southern California, southern Texas, New Mexico, Louisiana, Alabama, Georgia,
and Florida) from October through February (see attached map).

WHY IS THIS STUDY BEING DONE?
Vitamin D is important for building and maintaining healthy bones. Vitamin D
may also reduce a person’s risk for some cancers, immune disorders, high blood
pressure and type I diabetes. In Maine, it is common to have low blood levels of
vitamin D because there is not enough sunlight in the winter for the skin to make
vitamin D. Exposure to strong sunlight during winter can ruin the results of this
study, therefore you must try to avoid traveling south from October through
February. If southern travel becomes necessary please wear sunscreen
(minimum SPF 8) and avoid the sunlight as much as possible.
The main purpose of this study is to help identify how much extra vitamin D
young women in Maine need to keep blood levels normal during winter. This
study will also look at how body fatness affects vitamin D levels in the blood.
There will be about 120 women in this study.
Initial here to confirm page has been read ________
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WHAT IS INVOLVED IN THE STUDY?
In this study you will either be in the treatment group where you will receive a
vitamin D capsule containing 800 International Units (IU) of vitamin D, or in the
control group where you will receive a placebo (we call it a sugar pill even though
it does not contain any sugar). The sugar pill looks exactly like the vitamin D
capsule, but does not contain any vitamin D. A computer will randomly decide if
you will be in the treatment or control group. You will not be told which group you
are in. You will have a 2 in 3 chance of receiving vitamin D and a 1 in 3 chance
of receiving a sugar pill.
If you meet the requirements for the study and agree to take part in it, you will
need to take one vitamin D capsule or sugar pill every day. Taking the capsules
every day is very important for this study to be successful. If you forget to take a
capsule one day, you can take two pills the following day.
You will need to report to Cutler Health Center at the University of Maine three
times over the next 12 months for testing (March 2005, September 2005, and
March 2006). You will also report to the research office at the University of
Maine to pick up a new supply of capsules every three months. In March 2005
and March 2006 you will visit the Maine Center for Osteoporosis Research and
Education (MECORE) in Bangor for body composition measurement.
In January 2005 there will be an informational meeting at the University of Maine.
The estimated time for this meeting is 1-2 hours. During this time you will:
• Be given time to ask questions about the study
• Be asked to read and sign this informed consent
• Be asked questions about your health and medications to make sure you
qualify for the study. You will be asked questions such as:
o Do you have, or have you ever had diabetes, celiac disease, cystic
fibrosis, gluten intolerance, Crohn’s disease, ulcerative colitis…
The first visit to Cutler Health Center will be in March 2005. The estimated time
for this visit is 30-45 minutes. During this time you will:
• Have your weight and height measured
• Have less than 2 tablespoons of blood drawn
• Provide a urine sample
Blood will be drawn to measure calcium, parathyroid hormone, and vitamin D.
Urine will be collected to measure calcium.
After the first blood draw, if your blood vitamin D is very low (<22.5 nmol/L) or
high (>175 nmol/L), you will not be allowed to continue in the study, and you will
be advised to speak with your doctor for evaluation at your own expense.
Initial here to confirm page has been read ________
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If you meet the requirements and want to be in the study, the computer will
choose which one of the treatments you will receive (vitamin D or sugar pill).
During the 12 months of the study, you will be on sugar pill for six of the months
and either vitamin D or sugar pill for the other six months. Neither you nor the
researchers will know whether you are taking vitamin D or the sugar pill. No one
at the clinic will be able to tell you which pill you are taking. This information will
be available at Cutler Health Center in case of emergency.
You will return to Cutler Health Center for two more visits over the next 12
months. These visits will be in September 2005, and March 2006. At each of
these visits, the testing will be the same as described above. The estimated time
for each of these visits is 30 minutes.
Starting in March 2005 you will visit the research office at the University of Maine
every three months to return any unused capsules and receive a new supply.
You will be asked to stop taking all other multivitamins, vitamin D, or calcium
supplements during the study. You will be given a list of vitamins such as vitamin
C and folate that you will be allowed to take. The estimated time for this visit is
15 minutes. At this time you will be asked brief questions about your health,
such as:
• Did you take any vitamins, minerals, or herbal supplements over the past
3 months? If so, which ones, how much, and how often did you take
them?
Between January and March 2005 and 2006 you will be asked to keep a threeday record of what you eat and drink. The day after you finish this record, the
researcher will call you to find out what you ate and drank. This information will
be used to estimate how much vitamin D, calcium, phosphorus, protein, and
calories you ate. The estimated time for this phone call is 30 minutes. In
addition, during your visits to the research office, you will be asked some
questions about the foods that you typically eat and drink.
In March 2005 and 2006 you will visit the Maine Center for Osteoporosis
Research and Education (MECORE) in Bangor to have your body fat and bone
density measured by dual energy x-ray absorptiometry (DXA). The DXA scanner
is similar to an x-ray. During the exam you will lie on a padded table and the arm
of the machine will pass over your body. You will not be enclosed in any way
during this exam.
The estimated time for this MECORE visit is ½ hour. During this time you will:
• Have your weight and height measured
• Take a urine pregnancy test before your body fat is measured because an
embryo should not be exposed to the small amount of radiation used to
measure body fat.
• Have a total body DXA scan to measure your body fat and bone density
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POSSIBLE BENEFITS OF THE STUDY:
This study is being done to find out more about vitamin D needs during winter. It
may not provide any direct benefit to you. If you would like, at the end of the
study, you and your doctor will be given your body fat and vitamin D results along
with information on how to optimize vitamin D levels and body composition.
Based on this information, decisions can be made to help decrease your future
risk of osteoporosis and other health concerns.
If you complete all of the requirements you will be compensated a total of $200
for your mileage, time, and effort. You will be paid in April 2005 ($25), October
2005 ($50), and March 2006 ($125). If you choose to discontinue the study
before March 2006, you may keep any money you have received.

POSSIBLE RISKS OR DISCOMFORTS OF THE STUDY:
You will have blood drawn three times during the study. When you have blood
drawn you may have some pain, bleeding, or a black and blue spot at the site of
the blood draw. The total blood volume drawn will be less than two tablespoons.
During the bone density scan (DXA) you will be exposed to less radiation than
you would get during a chest x-ray or a long flight in an airplane. The radiation
may be harmful to an embryo, therefore you will be withdrawn from the study if
you become pregnant.
There are no known side effects of 800 IU of vitamin D which is in the safe dose
range set by the Food and Nutrition Board. In comparison, a light-skinned
person wearing a swimsuit in the summer will absorb about 20,000 IU of vitamin
D in the amount of time it takes her skin to get lightly pink. If you have any
concerns about this vitamin D supplementation, please contact the researchers
at 581-1622.

CONFIDENTIALITY:
The results of all testing and questionnaires will be recorded on special forms.
These forms will have no name on them, but will use a code number to protect
your privacy. All records will be kept for no more than five years following
completion of the study. Your name will not be used in any publication
describing this research. Medical information from the study will be made
available to your physician upon your request after you have signed a written
release.
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VOLUNTARY PARTICIPATION:
Taking part in this study is voluntary. You can choose not to answer any
questions on the forms. You are free to leave the study at any time. If you fail to
meet the requirements of the study, the researchers can remove you from the
study at any time. There will be no charge to you or to your insurance company
for tests or services that are required by this study. You will receive
compensation for your time, travel and general inconvenience. St. Joseph
Hospital and the University of Maine do not provide financial payment for any
injury resulting from this study.

ADDITIONAL INFORMATION:
To become a part of this study, you must sign this consent. By signing this
consent, you are confirming the following:
1) You have had time to consider if you want to take part in this study. You have
read or had read to you this consent and had it explained to you in language you
are able to understand.
2) You have had a chance to ask questions, and you have received answers that
fully satisfy your questions.
3) You understand the information in this consent form. You willingly agree to
take part in this study.
4) You understand the study has been reviewed and approved by an ethical
research review committee to protect your legal rights.
5) You have been given a copy of this informed consent.
6) If you have any further questions about this study, you may contact Susan
Sullivan at (207) 581-3130 or Monica Nelson at (207) 581-1622. If you have any
questions about your rights as a research subject you may contact Gayle
Anderson, Assistant to the University of Maine’s Protection of Human Subjects
Review Board, at (207) 581-1498.

Subject Signature / Date
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Appendix F
Calculation of Sun Exposure
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CALCULATION FOR DETERMINING SUN EXPOSURE
Example:
Work days – 6 days per week; 1 hour sun per day
Days off – 1 day per week; 3 hours sun per day
Vacation days – 2 weeks; 5 hours sun per day
Table F1. Calculation used for determining sun exposure.
Step

Instructions

Example

1

Multiply days worked per week x 16 weeks = Work
Days

6x16=96 work days

2

Multiply days off per week x 16 weeks = Days Off.

1x16=16 days off

3

Determine how many days of vacation would have
been days worked versus days off based on typical
week from Steps 1 and 2.

2 weeks vacation = would
have been 12 work days, 2
days off

4

Subtract vacation days from Work Days or Days Off
as appropriate

96 - 12 = 84 days worked;
16 - 2 = 14 days off

5

Multiply new Work Days (from Step 4) by number
of hours in sun per work day = Total Work Sun

84 days worked x 1 hour
sun = 84 hours work sun

6

Multiply new Days Off (from Step 4) by number of
hours in sun per day off = Total Day-Off Sun

14 days off x 3 hours sun =
42 hours day-off sun

7

Multiply vacation days x hours of sun per vacation
day = Total Vacation Sun

14 vacation days x 5 hours
sun = 70 hours vacation
sun

8

Add up Total Work Sun + Total Day-Off Sun +
Total Vacation Sun = Total Sun

84 + 42 + 70 = 196 hours
sun

9

Divide Total Sun by 16 to determine number of
hours of sun per week.

196 / 16 = 12.25 hours sun
/ week
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